Genetic predisposition to genomic instability in cancer. by Vessey, Carina Jayne
Open Research Online
The Open University’s repository of research publications
and other research outputs
Genetic predisposition to genomic instability in cancer.
Thesis
How to cite:
Vessey, Carina Jayne (1998). Genetic predisposition to genomic instability in cancer. PhD thesis. The Open
University.
For guidance on citations see FAQs.
c© 1998 Carina Jayne Vessey
Version: Version of Record
Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright
owners. For more information on Open Research Online’s data policy on reuse of materials please consult the policies
page.
oro.open.ac.uk
Genetic Predisposition to Genomic 
" Instability in Cancer
Volume 1 of 2
A thesis subm itted for the degree of 
Doctor of Philosophy
(Pertaining to the D iscip line of M olecular Oncology)
Dr Carina Jayne V essey  
MA, MSc, BM BCh, D ip  RCPath
Institute of Molecular Medicine, 
Oxford,
Sponsoring Establishment for 
The Open University.
I
Submission date 24/8/98
W cwa/>< 3-0^
ProQuest Number: 27696810
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27696810
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
ABSTRACT
Ataxia telangiectasia and Bloom's syndrome are cancer prone genomic 
instability disorders for which the causative genes ATM  and BLM have only 
recently been identified. The cellular localisation and biochemical roles of 
these proteins are currently being defined. ATM shares sequence homology 
with several lipid and protein kinases but at the outset of this work a kinase 
function for ATM itself was not established and the extent to which the kinase 
domain contributed to the cellular phenotype of A-T was unknown. In 
addition the role of ATM heterozygosity and genomic instability in breast 
cancer had been suggested but not elucidated.
During the course of this work, the anti-ATM antibody (CN-12) and 
anti-BLM antibody (IHIC-27), were developed and affinity purified. Antibody 
CN-12 successfully demonstrated the presence of the 350 kDa ATM protein 
by immunoblotting and immunoprécipitation in HeLa cells. The protein was 
largely nuclear in localisation with a minor microsomal fraction but was 
found to be absent in AT2RO cells which contain a homozygous truncating 
mutation of ATM. Tumour cell lines provided by the NCI showed varying 
expression of ATM except for the promyelocytic leukaemia cell line HL60 in 
which no ATM was detected. Antibody IHIC-27 demonstrated the presence 
of a 180 kDa protein in HeLa cells which was absent in the Bloom's cell line 
GM8505. Studies using antibodies directed to the C and N-termini showed 
BLM instability and cell fractionation studies demonstrated that the protein 
was nuclear in localisation. Anti-BLM monoclonal antibodies 185a and 32e 
were able to identify the fusion protein to which they were raised and BLM 
immunoprecipitated by IHIC-27 but could not identify BLM in whole cell 
lysates. N either ATM nor BLM antibodies were usefu l for 
immunohistochemical studies with the protocols tested despite successful 
immunostaining of the positive control.
Studies of immunoprecipitated ATM using a variety of assay 
\ conditions* with p53 peptides and PHAS-I as substrates did not reveal any 
serine / threonine protein kinase activity, although low  levels of 
autophosphorylation were identified. H1299 cells transfected with a mutant 
ATM  kinase domain did not exhibit a dominant negative phenotype, which 
curtailed further studies of the cellular function of the domain.
DNA repair in peripheral blood lymphocytes from breast cancer 
patients and controls was assessed by the comet assay. Although the patients 
generally showed less DNA repair than the controls at 30 min and 120 min, 
the difference was not found to be statistically significant.
AIMS
The general purpose of this work was to elucidate the mechanisms 
underlying the genomic instability seen in a taxi a-telangiectasia. Bloom's 
syndrome and breast cancer by studying the gene products of ATM  and BLM 
and by investigating the DNA repair capacity in breast cancer patients.
The specific goals are listed below:
1) To raise and characterise polyclonal antibodies versus ATM and BLM 
proteins which are abnormal in the genetic instability disorders ataxia- 
telangiectasia and Bloom's syndrome respectively.
2) To determine the levels of expression of these proteins in normal and 
tumour cell lines and in the tissue from a variety of human tumours.
3) To investigate the putative protein kinase activity of ATM protein with a 
view to developing an ATM kinase assay for use in determining the integrity 
of ATM signalling in the lymphocytes of normal women and women with 
breast cancer. It was hoped that this would enable the development of a test 
to determine an individuals risk of breast cancer.
4) To investigate the role of the ATM kinase domain in the cellular phenotype 
of ATM using a dominant negative strategy.
5) To examine the constitutional ability of DNA repair in lymphocytes from 
normal women and women with breast cancer using the comet assay. The 
intention was to assess the importance of DNA repair defects as a cause of 
genomic instability in the aetiology of this disease and to identify differences 
between the two populations which would be useful as a test of an 
individuals potential risk of developing breast cancer.
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T hesis Plan
This thesis comprises four results chapters which are broadly related to 
the theme of genomic instability in cancer but which are quite different in their 
individual content. The overall plan of the thesis reflects this by the provision of 
a general introduction concerning genetic predisposition to genome instability 
in cancer and a general materials and methods section, followed by results 
chapters with their own specific shorter introductions, additional methods and 
individual discussions. It is hoped that this format will make the thesis content 
easier to digest and scrutinise as information specific to each chapter is 
presented within the chapter itself.
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Chapter 1
General Introduction
Genetic predisposition to genome instability in cancer
The studies presented in this thesis are related by the common theme of 
genomic instability and cancer. This introduction aims to provide an overview 
of the subject and its involvement in the development of breast cancer in 
particular. A brief summary of the importance of genomic stability is given 
followed by a description of the classical cancer prone genomic instability 
disorders. Specific attention is paid to ataxia telangiectasia. Bloom's syndrome 
and the molecular biology of breast cancer including genomic instability and 
DNA repair, as these are the subject of the investigations performed.
The importance o f genom ic integrity
The stability of an organism's genome is an absolute necessity for 
faithful transmission of genetic information. This is of prime importance both 
in mitosis during the lifetime of an organism, so that daughter cells behave and 
function appropriately, and in meiosis for maintenance of the species as a 
distinct genetic entity.
The term genomic instability has been used in several different contexts 
in the literature to describe genetic, cytogenetic and phenotypic changes in 
the cell. Therefore the endpoints of the studies which have been performed to 
analyse genomic instability include DNA sequence changes (deletions, 
insertions, point mutations etc), chromosomal aberrations ( gaps, breaks, 
translocations, chromosomal rearrangements) and cellular transformation 
respectively. Although ultimately it will be best to consider genomic 
instability at the genetic level (as chromosomal and cell behavioural 
abnormalities are ultimately due to genetic change), instability at the
chromosomal level is not necessarily accompanied by sequence instability and 
vice versa. Therefore cells may be subject to different types of genetic 
instability, achieved by different molecular pathways.
It has been established over the past few decades that cancer is a genetic 
disease at the cellular level, and the transformation of a normal cell into a 
cancer cell is known to be a multistep process. This is well illustrated in 
sporadic colon cancer which follows the accumulation of mutations in at least 7 
different genes (Kinzler and Vogelstein, 1996). This may take some time to 
occur, in part explaining the emergence of tumours late in life. In view of the 
requirement for multiple genetic changes, it has been suggested that genetic 
instability is the driving force behind the acquisition of the multiple mutations 
required for tumorigenesis (Nowell, 1976), (Loeb, 1991). It would therefore be 
of considerable interest to discover how common genetic instability is in 
tumours and whether its presence is essential. This thesis is primarily 
concerned with the inherited cancer prone disorders which are associated with 
such gross instability at the DNA and chromosomal level that the instability 
itself is a defining feature of the syndrome. Such syndromes include ataxia- 
telangiectasia (A-T), Bloom's syndrome (BS), Nijmegen breakage syndrome 
(NBS), Fanconi anaemia (FA), hereditary non-polyposis colon cancer (HNPCC) 
and its variants and finally xeroderma pigmentosum (XP) and its variants. 
Xeroderma pigmentosum is included because genetic instability is a 
recognised feature of this syndrome and the defective genes are better 
characterised in terms of function than the genes involved in the other 
syndromes. Patients with genomic instability disorders are of great interest to 
the molecular biologist and oncologist alike because they offer an opportunity
to investigate the molecular mechanisms which are fundamental to the 
maintenance of genomic integrity and the prevention of cancer.
Likely candidate genes involved in the maintenance of genomic 
integrity include those required for 1) the fidelity of DNA replication, 2) the 
detection of and the coordination of the response to DNA damage (this 
damage may be caused by internally or externally generated agents eg 
products of oxidative metabolism, irradiation and genotoxic chemicals), 3) 
pathways of DNA repair, 4) cell cycle checkpoint integrity and 5) appropriate 
apoptotic responses to deal with cells which are irredeemably damaged.
These processes will be discussed in as far as they relate to known 
defects in the cancer prone disorders mentioned. There has been considerable 
interest in this field in recent years and different aspects of the subject have 
been reviewed previously (Honchel et al., 1995), (Tlsty et al., 1995), (ap Rhys 
and Bohr, 1996), (Lindahl, 1996), (Sarasin and Stary, 1997), (Miyagawa, 1998).
Ataxia telangiectasia (A-T)
C linical m anifestations
Ataxia telangiectasia is a rare autosomal recessive syndrome with an 
birth incidence of about 1: 300,000 (Swift et al., 1986), (Woods et al., 1990). It is 
a pleiotropic disorder affecting many organ systems. The ataxia is cerebellar in 
nature and is due to death of Purkinje cells in the cerebellum, causing 
incoordination of eye, head, trunk and limb movement which generally 
renders the sufferer wheelchair bound by the teenage years. The telangiectasia 
develops in childhood and tortuous, dilated thin walled blood vessels appear
on the conjunctivae of the eyes and on other sun-exposed areas, a-feto-protein
levels are elevated which, along with the ataxia and telangiectasia support the 
diagnosis.
Infections of the respiratory tract (eg pneumonia) are the most common 
cause of mortality in A-T patients; These are due to defects in both cell 
mediated and humoral immunity. There are deficiencies of IgA and IgE 
together with abnormal T and B cell responses due to problems with 
lymphocyte maturation and compromised intracellular signal transduction 
(Lavin and Shiloh, 1996). Approximately 10 % of A-T patients develop 
malignancy and there is a 250-fold excess risk for lymphomas and a 70-fold 
excess risk for leukaemias (Morrell et al., 1986). The commonest lymphoid 
malignancies are mature T-cell leukaemias (Taylor, 1992), although there is 
also an increased predisposition to B cell tumours. Other tumour types arising 
in this syndrome include gastric, liver, pancreatic, ovarian, breast and salivary 
gland cancers (Swift et al., 1987), and malignancy constitutes another major 
cause of death. Another haUmark.of the condition noted when patients first 
received radiotherapy as treatment for tumours is the dramatic tissue 
radiosensitivity seen after standard radiotherapy doses (Cunliffe et al., 1975). 
This can result in severe tissue necrosis with life threatening consequences and 
has necessitated a reduction in the given dose. This radiosensitivity is also 
reflected in the reduced clonogenic survival of A-T cells in culture post 
irradiation. A-T heterozygotes (-1% of the general population) are believed to 
a have a 3-4 times increased risk of developing cancer. The risk of breast cancer 
in heterozygote women may be up to five fold greater than that for normal 
women and this is discussed in more detail later.
Cytogenetic features and predisposition to leukaem ias
The dramatically increased cancer risk in homozygotes is at least in part 
due to genomic instability. Cells from hom ozygotes show striking 
chromosomal instability with increased rates of chromosomal aberrations 
including chromosome losses, gaps, breaks, inversions, translocations, 
telomere-telomere fusions and increased rates of intrachromosomal 
recombination. This genetic instability is seen spontaneously presumably as a 
result of intracellular genotoxic insults, and is exacerbated after treatment of 
the cells with ionising radiation, radiomimetic chemicals (eg bleomycin, 
streptonigrin and some restriction enzymes. Cytogenetic studies have shown a 
significant increase in the number of chromosome breaks in A-T cells post 
irradiation (Taylor, 1978), (Comforth and Bedford, 1985). About 10% of all T 
lymphocytes in A-T patients show translocations and inversions at specific 
breakpoints involving chromosomes 7 and 14. These include inv(7)(pl3q35), 
t(7;7)(pl3;q35), t(7 ;14)(p l3 ;q ll), t(7;14)(q35;qll), t(14;14)(qll;q32), 
inv(14)(qll;q32) and t(X;14)(q28;qll). Apart from 14q32 and Xq28 these 
breakpoints are the locations of the T cell receptor (TCR) genes, 14q ll
(TCRo/0), 7q35 (TCRP) and 7pl4 (TCRy) and in some cases translocations have
been proven to occur within them. A-T patients are estimated to have about a 
40-fold increase in translocations involving chromosomes 7 and 14 compared 
with non-A-T individuals but the increase for inv(7) is even greater. Cells with 
these translocations can proliferate to produce large clones of cells and 
subsequent clonal selection is associated with the development of leukaemia in 
young adults. The presence of breakpoints in the TCR genes suggests that
there is a defect in some form of recombination or some aspect of regulation of 
recombination (Taylor et al., 1996); however the process of V(D)J 
recombination appears to be qualitatively normal in A-T cells. The presence of 
cytogenetic abnormalities involving TCR loci is also reflected by the fact that, T 
cell tumours including T-cell acute lymphocytic leukaemia (T-ALL) and T cell 
prolymphocytic leukaemia (T-PLL), are seen at a greatly elevated frequency in 
A-T children when compared with non-A-T children, although B-cell tumours 
and occasional myeloid leukaemias do occur (Stankovic et al., 1998), (Taylor, 
1998). Young adults with A-T are especially susceptible to a mature T-cell 
leukaemia similar to T-PLL. The latter is a rare leukaemia which is seen 
sporadically in elderly people from the normal population and which usually 
shows structural anomalies in ATM (Yuille et al., 1998). In T-PLL the most 
common site involved in the aberrant rejoining during translocation is the TCL- 
1 (T-cell leukaemia) locus at 14q32. Two clusters of breakpoints are seen at this 
locus, between which the TCL-1 gene has been identified (Virgilio et al., 1994). 
Activation of TCL-1 by T cell regulatory elements located upstream or 
downsteam of TCL-1 may then occur. Breakpoints in T-PLL are also seen in the 
Xq28 region within one of two genes c6.1A or c6.1B (MTCP-1). The latter has 
four transcripts and one of the protein products shows marked sequence 
similarity to the TCL-1 protein (Stem et al., 1993). These translocations 
involving 14q32 and Xq28 are however insufficient for tumorigenesis because 
large clones can survive for many years before leukaemic transformation. 
The influence of other genetic changes is presumably required to complete the 
transformation process.
Cell cycle checkpoint abnormalities
Cell cycle checkpoints activated in response to DNA double strand 
breaks are also abnormal in A-T. Instead of arresting in G1 post irradiation, A- 
T cells continue to progress into S-phase therefore allowing replication of 
DNA on a damaged template. Cells then accumulate at G2/M  where most then 
die. In addition, A-T cells irradiated in S-phase fail to undergo the transient 
arrest of replication characteristic of normal cells. This phenomenon, termed 
radioresistant DNA synthesis (RDS), is a defining cellular characteristic of A-T. 
A-T cells irradiated in G2 also fail to arrest cell cycle progression and initially 
continue rapidly into the next G1 phase; only at later times after irradiation do 
the cells become significantly delayed at the G2 boundary. The G l /S  DNA  
damage checkpoint in normal cells is dependent on induction of the tumour 
suppressor p53 which in turn is a transcriptional activator of the CDK inhibitor 
p21 . p21 inhibits the action of cyclin dependent kinases (CDKs), which are 
necessary for phosphorylation of the retinoblastoma protein RB. If 
hyperphosphorylation of RB does not occur, release of E2F, a transcription 
factor which is required for S-phase progression is prevented and the cells 
arrest in Gl-phase. A-T cells show both delayed and reduced induction of p53 
post- irradiation (Lu and Lane, 1993) and reduced p21 responses. The cells 
cannot perform an adequate G1 arrest post irradiation and continue into S- 
phase unchecked.
Initially it was thought that the RDS phenotype was responsible for the 
radiosensitivity of A-T cells, however A-T cell lines exist in which these 
features are separable. Non-cycling A-T cells are also radiosensitive as shown 
by the absence of recovery after 'liquid holding' (when the cells are held in a
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non-proliferating state after irradiation (Cox, 1982)). Therefore any potential 
explanation for the radiosensitivity ought to be applicable to cells in the GO 
phase.
The A IM  gene
The gene defective in ataxia telangiectasia ATM (ataxia telangiectasia mutated) 
is found on llq22-23 and was positionally cloned in 1995 (Savitsky et al., 1995). 
It is 150 kb in size, consists of 66 exons (Uziel et al., 1996) and codes for a major 
13 kb transcript which is ubiquitously expressed (there may also be several 
other transcripts of smaller size resulting from alternative splicing). Binding 
sites for several factors including E4F1 and E4F2, SPl and a cAMP and insulin 
responsive elements have been predicted in the putative promoter region. The 
promoter is bi-directional and also serves the adjacent E l4 (NPAT/CAND3) 
gene (Byrd et al., 1996). The ATM protein comprises 3056 amino acids with 
molecular weight of 350 kDa (Fig. 1.1). The mutations currently known (-250 
in total) are scattered throughout the gene and there are no recognised 
mutational hotspots (Taylor, 1998). Most mutations create null alleles (ie they 
lead to premature truncation with destabilisation of the protein product) and 
the majority of patients are compound heterozygotes carrying different 
mutations of each allele (Gilad et al., 1996), (Byrd et al., 1996).
ATM is ubiquitously expressed with the highest levels seen in the ovary, 
testis and spleen (Chen and Lee, 1996). Immunohistochemical studies have 
shown homogenous nuclear localisation of ATM (Lakin et al., 1996), although 
some is seen in the cytoplasm associated with unidentified membranous
10
organelles. The subcellular distribution is different in the ovary where ATM is 
predominantly seen in the cytoplasm rather than in the nucleus.
Variant A-T phenotypes
Clinically these are patients who show milder features including a later 
onset of ataxia and cerebellar deterioration with reduced or absent cancer 
predisposition (McConville et al., 1996), (Gilad et al., 1998). Cells from these 
patients exhibit levels of radiosensitivity which are intermediate between 
normals and patients with classical A-T (Taylor, 1998). In contrast to classical 
A-T patients with truncating mutations which destabilise the protein such that 
no ATM is detected on Western blotting, in patients with a variant A-T 
phenotype ATM protein can be found in varying levels. This may represent 
low amounts of normal protein (formed for example by a degree of normal 
splicing from a mutation in an intronic sequence resembling a splice donor 
site), or higher amounts of mutant ATM produced from non-destabilising 
mutations (eg missense mutations) with some residual function (McConville et 
al., 1996).
ATM hom ologues
ATM is related by sequence to several known proteins from organisms 
as diverse as yeast and mammals (Savitsky et al., 1995), (Zakian, 1995), (Lavin 
et al., 1995) (Table 1.1 and Fig. 1.2 ) and these can be classified by their degree 
of similarity and protein size into two broad groups (Jackson, 1996). The first 
group comprises large proteins (>270 kDa), of similar size to ATM, which have
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ATM protein 
Homologue
Species Function
PI 3-kinase 
p i  10 catalytic 
subimit
mammals Lipid and protein kinase. 
Signal transduction
DNA-PK
catalytic
subunit
human Serine/  threonine protein 
kinase activated by DNA 
ends. DNA repair, V(D)J 
recombination
Vps34 S. cerevisiae Vesicular trafficking
Rad3 S. pombe Cell cycle checkpoint roles in 
G2 and S in response to 
damaged or unreplicated 
DNA
Tor proteins S. cerevisiae Targets of the 
immunosuppressant drug 
rapamycin. Bind the 
rapamycin/FKB12 complex
FRAP mammals
RAFT-1 mammals
M ecl/E srl S. cerevisiae Cell cycle checkpoint role in 
G2 and S phase in response 
to damaged or unreplicated 
DNA
Tell S. cerevisiae Telomere length regulation, 
mitotic recombination and 
chromosomal stability
MEI-41 D. melanogaster Cell cycle checkpoint role in 
S phase and G2/M; DNA 
repair and meiotic 
recombination
Table 1.1
ATM homologues in different species and their cellular functions.
a carboxy-terminal phosphatidyl inositol 3-kinase like (PI 3-K) domain. Some 
of these also feature two other regions of homology, a central Rad-3 like area 
and PIK-related kinase region (phosphatidyl kinase related kinase region) 
located at the extreme carboxy-terminus of the protein. This group includes S. 
pombe Rad3 itself, its S. cerevisiae homologue M ed , hum an DNA dependent 
protein kinase (DNA-PK), D. melanogaster Mei-41, the S. cerevisiae proteins 
Tori and Tor2 with their mammalian equivalents Frap-1 and Raft-1 and S. 
cerevisiae Tell which is the closest relative of ATM in yeast. The second group 
of ATM related proteins are much smaller proteins (< 110 kDa) and show less 
similarity. These include the prototypic p i 10 protein which is the catalytic sub­
unit of PI3-K, S. cerevisiae Vps34 and PI4-kinases. The ATM-related proteins 
with established lipid and protein kinases activity are discussed in greater 
detail in Chapter 4. Members of the first group seem to show the most 
functional similarity to ATM at present. Broadly speaking members of this 
group appear to be important in cell cycle regulation after DNA damage, the 
maintenance of genomic integrity, and in DNA repair although only M ECl is 
an essential gene.
Schizosaccharomyces pombe radS mutants are checkpoint defective in that
they fail to arrest in G2 after DNA damage induced by y-irradiation, ultraviolet
light (Seaton et al., 1992) and methanemethylsulphonate (A-T cells are only
sensitive to y-irradiation). They also lose the safeguard which prevents the
initiation of mitosis when DNA replication is incomplete (Jimenez et al., 1992). 
mecl m utants also show these two checkpoint losses in addition to defective 
G l /S  and intra-S checkpoints post DNA damage. These m utants also
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demonstrate genomic instability and abnormal meiotic recombination as MEC- 
1 is required to prevent progress through meiosis w hen recom bination- 
induced double strand breaks are not rejoined (Lydall 1995). The hum an 
protein most closely related to Rad-3/Mec-1 is ATR, which has been shown to 
be present w ith ATM along meiotic chromosomes (although ATM is found 
along synapsing areas and ATR is present along unpaired chromosomal axes), 
(Keegan et al., 1996).
tell m utants were named because they have very short telomeres 
(Greenwell et al., 1995). tell/m ecl double mutants suggest that there may be 
some functional overlap between A T M  homologues due to the fact that tell 
m utations can enhance the radiosensitivity of mecl m utants even though tell 
m utations alone do not confer hypersensitivity to DNA damaging agents. In 
addition overexpression of Tell can complement the phenotype produced by 
truncated M ecl protein (Morrow et al., 1995). It is interesting to note that 
m utants of tell which shows the most marked degree of homology to A T M  
apart from sharing short telomeres and genomic instability otherwise have a 
quite different phenotype from cells from individuals with A-T. In particular 
unlike A-T cells, tell mutants have no checkpoint defects, do not show elevated 
levels of mitotic recombination and as described, are not hypersensitive to 
DNA damaging agents. It is possible that the amino-terminal region of ATM, 
which shows no similarity to any other known protein at present but which 
may allow ATM to interact with other molecules, is responsible for these 
differences.
The Mei-41 protein is involved in checkpoint control and in the 
maintenance of genomic stability in D. melanogaster (Hari et al., 1995). Mei-41
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m utants show defects in the G l/S , S phase and G 2/M  checkpoints together 
with abnormalities in meiosis, including reduced meiotic recombination with 
altered frequency and morphology of late recombination nodules. The genomic 
instability in these mutants is manifest as chromatid and isochromatid breaks.
The yeast Tor (target of rapamycin) proteins (Helliwell et al., 1994) and 
their mammalian counterparts FRAP and RAFT are targets for the macrolide 
antibiotic rapamycin which has immunosuppressive properties (Brown et al.,
1994). When rapamycin binds to its intracellular receptor FKBP12 and the Tor 
proteins, or FRAP and RAFT, the target proteins are inhibited and G1 arrest 
results. The mechanism of cell cycle arrest is believed to be via inactivation of 
p70 ribosomal protein S6 kinase which is needed for translation of certain 
mRNAs into proteins required for G l/S  progression (Brown et al., 1995). In 
addition inhibition of cyclin dependent kinases (cyclin D-cdk4 and cyclin E- 
cdk2) may be important, (Albers et al., 1993). A substantial body of information 
is now available concerning DNA dependent protein kinase (DNA-PK) which 
is a further hum an relative of ATM  (Jeggo, 1997), (Hartley et al., 1995). DNA- 
PK is often used as a paradigm  for A TM  although it is known that DNA-PK 
m utants are not checkpoint defective, unlike A-T cells. Moreover DNA-PK is 
normal in A-T patients. Therefore these proteins, whilst related, do not have 
identical roles. However, cells deficient in DNA-PK are similar to A-T cells in 
that they are radiosensitive. In addition, animals with DNA-PK deficiency (eg 
mice w ith severe combined immunodeficiency), are immunodeficient as are 
individuals with A-T. These observations are common to DNA double strand 
break (dsb), repair disorders. DNA-PK is a heterotrimeric enzyme.
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consisting of a 460 kD catalytic sub-unit and the regulatory subunit Ku 
(comprising two subunits Ku 70 and Ku 86), which requires DNA ends for its 
activity (Gottlieb and Jackson, 1993). An extended form of Ku86 called KARP-1 
which has potential leucine zipper for protein-protein interactions and a 
possible basic DNA binding dom ain may also be im portant in DNA-PK 
activity (Myung et al., 1997). Recently KARP-1 induction post irradiation has 
been shown to be dependent upon ATM and p53 proteins (Myung et al., 1998). 
Ku binds to DNA ends and when complexed with the catalytic subunit the 
DNA-PK enzyme is able to perform DNA dsb repair and probably to also 
inhibit local transcription by phosphorylation of RNA pol II. A ttenuation of 
enzymatic function is regulated by a negative feedback mechanism. DNA-PK 
phosphorylation of c-Abl results in deactivation of DNA-PK after c-Abl 
reciprocally phosphorylates it, and DNA-PK is capable of autophosphorylation 
which causes inhibition of enzyme activity and dissociation of the catalytic 
subunit from Ku (Kharbanda et al., 1997). DNA dsbs are formed as part of the 
process of site-specific V(D)J rejoining to generate antibody and T-cell receptor 
diversity in the immune system. DNA-PK is required for proper repair of the 
coding joins. If the enzyme is absent coding regions rejoin but deletions are 
seen, with adverse consequences for immune function. Seeking a parallel with 
A T M  , it has been proposed that Ku homologs may be required for A TM  
function but this remains unproven.
The second group of smaller ATM related proteins are involved in 
signal transduction cascades (eg the PI 3-kinases) (Kappeller and Kantley,
1994). Vps34 also shows PI 3-kinase activity and is im portant in directing 
proteins to the vacuole in S. cerevisiae. (Schu et al., 1993), (Stack et al., 1995).
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W hether ATM in the microsomal fraction of hum an cells shares related 
functions remains to be seen. The possibility of defective signal transduction in 
A-T has been discussed previously (Lavin and Shiloh, 1996). At present the 
reasons for the association of diabetes mellitus with A-T or for the death of 
Purkinje cells and granular cells in the cerebellum are unknown but failure to 
respond to insulin or nerve growth factor may be due to compromised signal 
transduction. Faulty signal transduction might also underlie the defective 
mitogenic responses in T and B cells in A-T (O'Connor and Linthicum, 1980), 
(Khanna et al., 1997). M ultiple defects in intracellular signalling post­
irradiation have been noted in A-T cells and have been reviewed recently 
(Rotman and Shiloh, 1997). These include reduced p53 dependent responses, 
reduced phosphorylation of replication protein A (RPA), failure of activation 
of poly (ADP-ribose) polymerase (PARP), defective activation of the stress 
activated protein kinases (SAPK), diminished activation of c-Abl, failure of
increased tyrosine phosphorylation of p34^^c2 and inhibition of cyclinB/cdc2 
kinase activity.
A T M  fu n ctio n
The exact role of the A T M  gene product has not yet been elucidated but 
cellular A-T phenotypes such as radiosensitivity and genomic instability 
suggest that a deficiency in the repair of DNA double strand breaks (dsbs) may 
be responsible. Therefore it has been postulated that ATM protein is involved 
in either the detection or signalling of DNA damage or in the process of DNA 
repair itself. For m any years DNA repair in A-T cells was thought to be
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relatively normal. Reports of increased numbers of residual DNA dsbs post 
irradiation and deficiency of the fast phase of DNA repair have been made as 
time has gone on. Many of these studies have only looked at DNA repair in A- 
T cells in the first couple of hours after treatment with ionising radiation and 
this may be a highly relevant oversight in the light of new evidence. Recently it 
has been demonstrated in non- transformed human fibroblast cell lines that the 
initial phase of DNA dsb repair in A-T cells is better than that seen in normal 
cells (upto 6 hours). After this the repair curve crosses that of the control cells 
such that the residual damage at 24 hours is greater in the A-T cells (Foray et 
al., 1997). Moreover, the number of residual DNA dsbs correlated with the 
radiosensitivity of A-T cells. This supports the idea that the hypersensitivity in 
A-T to ionizing radiation is due to the defective repair of dsbs. It has also been 
shown that a particular type of DNA repair is specifically deficient in A-T cells. 
Using the shuttle vector pZ189, containing an oxidatively induced dsb, the 
integrity of DNA repair was studied in one normal and two A-T fibroblast cell 
lines. Mutation frequencies were twice as high in the A-T fibroblasts and the 
mutational spectrum was different. The majority of the mutations in all the cell 
lines were deletions (44-63%). DNA sequence analysis showed that in the 
normal cells 17 of 17 plasmids with deletion mutations occurred between short 
direct sequences (removing one of the repeats plus the intervening sequences), 
suggesting that illegitimate recombination was important in dsb rejoining. Of 
the 23 deletions in the A-T cells only 3 involved direct repeat sequences and 
the average deletion size was much shorter than for normals (14 bp versus 71 
bp), implicating a defect in the illegitimate recombination pathway (Dar et al., 
1997). Such a defect might be in regulation of the process of illegitimate
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recombination or within the pathway itself. The relationship between the lethal 
and the m utagenic sequelae of DNA dsbs is poorly understood but the 
existence of such an error prone repair mechanism within hum an cells would 
suggest that maintenance of cellular viability is likely to be the prim ary role of 
this type of repair rather than maintenance of genetic integrity per se.
R ole  o f  A T M  in  m e io s is
As previously m entioned A-T is a pleiotropic d isorder and other 
functions of ATM are suggested by the clinical manifestations. A-T sufferers 
are infertile and a role for ATM is now emerging in meiosis. H igh levels of 
ATM are found in normal testis and ovary, and immunohistochemical studies 
have shown that the molecule is found at the areas of synapsis between 
homologous chromosomes. Exchange of genetic material takes place at these 
junctions by a process of homologous recombination which is facilitated by 
the synaptonemal complex and early and late recombination nodules (RNs). 
Early RNs are protein complexes involved in homology searches occuring 
before or at the time of synapsis. Some of these early RNs are converted into 
late RNs which are the structures involved in the recombination process itself. 
ATM is a com ponent of the early RNs. In A T M  knockout mice the 
synaptonem al complexes fragment at sites of some of the early RNs (Plug et 
al., 1997) and the infertility that occurs in these animals appears to be due to 
chrom osome fragm entation which leads to meiotic arrest and apoptosis 
(Keegan et al., 1996). It is possible that in meiosis ATM may m onitor strand 
disruptions that occur during the process of synapsis and recombination. This
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could be seen as a germ cell-specific adaptation of a more generalised role for 
ATM in the processing of dsbs generated by a variety of means.
A T M  and te lom ere  m eta b o lism
A-T cells have defects in telomere metabolism and show gross structural 
abnormalities such as telomere-telomere fusions. These are particularly seen in 
T-lymphocytes in A-T patients. In these patients a predisposition to accelerated 
telomere shortening is also seen in T cells at the rate of about 95 + /-  23 base 
pairs per year. Telomere fusions are not seen in leukaemic cells in A-T patients 
and there is no evidence that the telomere loss or the telomere fusions per se 
are involved in the tumorigenesis. However, maintenance of telomere length 
is thought to be an im portant factor in cell imm ortalisation, and indeed 
im m ortalised A-T cell lines regain the ability to m aintain their telomeres 
(Sprung et al., 1997). Telomere loss in non-leukaemic A-T lymphocytes is not 
due to an absence of telomerase as telomerase levels have been shown to be 
normal in these cells. One of the clinical consequences of accelerated telomere 
loss may be features of premature aging seen in A-T such as skin atrophy and 
hyperpigmentation, loss of sub-cutaneous fat and greying of the hair even in 
children (Metcalfe et al., 1996). As mentioned above, TELl, is also involved in 
the control of telomere length in S. cerevisiae (Greenwell et al., 1995) and  
mutations in TELl also lead to abnormally shortened telomeres.
In sum m ary, from our present understanding of A-T the cancer- 
proneness of the disorder at least w ith respect to the lym phoreticular 
malignancies is likely to be due to general genomic instability caused by
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defective illegitimate recombinational repair. This instability is implicated in 
the generation of rearrangements in the vicinity of the TCR and Ig genes which 
activate genes like TCL-1 to cause leukaemic transformation. These changes 
may be m odulated by other factors as -90% of A-T patients do not develop 
leukaemia. For other cancers in A-T sufferers or heterozygotes, other tissue 
specific mechanisms may be operating but as yet these are poorly elucidated.
Bloom’s Syndrome (BS)
C lin ica l m a n ife sta tio n s
Bloom's syndrome (BS) is a rare autosomal recessive disorder w ith less 
than 200 cases recognised world wide. It is characterised by a combination of a 
small but properly proportioned body size, bird-like facies, sun sensitivity 
with facial erythema, immunodeficiency, prem ature ageing, male infertility, 
female subfertility and an increased cancer susceptibility (German and 
Passarge, 1989), (German, 1993), (German, 1995). The cancer susceptibility is 
seen for a wide range of hum an cancers, not just for lymphoma and leukaemia 
which predom inate in ataxia-telangiectasia. Death in BS individuals usually 
occurs in the mid twenties.
P h en o ty p e  o f  BS ce lls
BS cells in culture show genomic instability  w ith  cytogenetic 
abnormalities including an increased number of chromatid gaps and breaks in 
untreated  cells. There is also an increased num ber of sister chrom atid 
exchanges (SCEs), w ith an elevation in the num ber of recom binational
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exchanges seen between homologous chromosomes which can be visualised 
after bromodeoxyuridine (BrdU) treatment, indicating an increase in somatic 
recombination in BS cells. The high number of SCEs seen is pathognomonic of 
the syndrom e and is of use diagnostically. The exchange of genetic material 
between the two sister chromatids post-BrdU is revealed as a harlequin pattern 
of staining. Hypermutability is seen at the genetic level at all loci examined and 
BS is a m utator syndrom e, explaining in part the reason for the cancer 
susceptibility.
T h e BLM  g e n e
BLM  , the gene defective in BS, was first assigned to chromosome 15 
after it was discovered that hum an chromosome 15 could complement the 
elevated SCE num ber in BS cells (McDaniel and Schultz, 1992). BLM  was then 
regionally m apped by analyzing consanguineous BS kindreds and was found 
to be closely linked to the oncogene FES found at 15q26.1 (German et al.,
1994). An ingenious approach called somatic crossover point m apping (SCP) 
was then used to locate the gene. This relies on the fact that in some BS 
sufferers a small proportion of their peripheral blood lymphocytes show a low 
SCE frequency instead of a high SCE frequency suggesting that these cells are 
functionally wild type. This can be explained if the two BLM  alleles carry 
different m utations (ie the patient is a compound heterozygote) and somatic 
recombination between these within the BLM  gene results in the generation of 
a wild type allele. Polymorphic markers were used to assess where the site of 
recombination had occurred allowing localisation of the BLM  gene to a 1.3 cM 
interval on chrom osome 15 (Ellis et al., 1995). Identification of further
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polymorphic loci enabled mapping of BLM to a 250kb region and elimination 
of FLS and the adjacent FUR as candidate BS genes. A 4437bp cDNA derived 
from this 250kb region encoded a 1417 aa protein in which were found chain 
term inating m utations in BS sufferers identifying the corresponding gene as 
BLM  (Straughen et al., 1996), (Ellis et al., 1995). Two RNA species at around 
4.5kb in size are seen in unaffected individuals. These two bands are either 
absent or p resen t at reduced intensities in BS sufferers suggesting a 
destabilizing effect of BLM  mutations on the RNA species (Ellis et al., 1995).
BLM  h o m o lo g u e s
BLASTP comparisons of BLM with amino acid sequence databases 
identified significant similarity from amino acids 649-1041 (which contains 
seven conserved helicase domains) to the RecQ subfam ily of DEXH-box 
containing helicases, including L. coli RecQ, hum an RECQL, hum an WRN, S. 
cerevisiae SCSI and S. pombe Rqhl (Ellis et al., 1995). Helicases are enzymes 
which can unwind DNA, a process important in both DNA replication and in 
recombination between DNA molecules. For example, RecQ is a 3'-5' helicase 
w hich is a com ponent of the RecF recom bination pathw ay in E. coli 
(Dunderdale and West, 1994). SCSI ,  WRN, Rqhl and BLM are much larger 
proteins than RecQ and RecQL because they have extra domains surrounding 
the region of helicase activity. Between amino acids 588-661 of BLM three short 
motifs showing some identity to RNA polymerase II are also found and the 
extreme amino and carboxy-termini of BLM are highly charged and serine- 
rich. The functions of these terminal regions are as yet unknown but they may
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be the site of interaction with other cellular proteins. This may explain why 
Werner's syndrome, which causes dramatic and premature ageing, has a 
different clinical phenotype to BS. The causative gene of Werner's syndrome 
WRN contains a similar RecQ helicase domain to BLM but it is dissimilar at the 
N  and C-termini.
BLM function
The product of BLM has recently been shown to be an ATP dependent 
3'-5' DNA-helicase with a requirement for magnesium (Karow et a l, 1997). The 
exact mechanism by which loss of the helicase function results in the observed 
cellular and clinical phenotypes is not understood, but it has been 
hypothesized that perturbation of replication or recombinational processes 
may explain the increased recombination and genomic instability seen in this 
disorder. Indeed there is some evidence that BLM is involved in replication; a 
retarded rate of DNA chain elongation is seen in BS cells (Hand and German, 
1975), (Giannelli et al., 1977) and the size distribution of DNA replicational 
intermediates has also been found to be abnormal in BS cells (Lonn et al., 1990). 
The S. cerevisiae homologue of BLM, SGSl when mutated is also associated 
with an elevated recombination frequency (Gangloff et al., 1994), (Watt et al.,
1996), and it has been suggested that because many of the mutations seen in BS 
patients are predicted to inactivate the helicase activity of the molecule (Ellis et 
al., 1995), the helicase activity itself is required to suppress inappropriate 
recombination. The S. cerevisiae homolog SGSl may yield several clues to the 
function and potential partners of human BLM, as it is likely that the 
evolutionary conservation in structure is accompanied by conservation of
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cellular roles. Sgsl protein is known to interact physically with two of the 
topoisomerase enzymes expressed by budding yeast, Top2p (Watt et al., 1995) 
and Top3p (Gangloff et al., 1994). It is therefore possible that the 
corresponding human topoisomerases might cooperate with BLM in the 
execution of its cellular duties. It is clear from the above discussion that much 
work remains to be done to finally elucidate the exact molecular pathway 
causing genetic instability in Bloom's syndrome and to relate this to the 
increased tumour burden that is characteristic of this disease.
Nijmegen Breakage Syndrome (NBS)
Nijmegen breakage syndrome is an autosomal recessive disorder, much 
rarer than A-T, which is also associated with chromosomal instability. Affected 
individuals show microcephaly with mental retardation, bird-like facies, 
developmental delay, short stature, deficiencies in both cellular and humoral 
immunity and primary ovarian failure. There is also a dramatic 75- fold 
increase in lymphoreticular malignancies most commonly manifest as B- cell 
lymphoma which presents at an unusually young age (Wegner et al., 1998), 
Although the clinical phenotype is dissimilar from A-T, the cellular phenotype 
shares several key features leading to descriptions of NBS as an A-T variant 
syndrome'. Similarities to A-T include the cytogenetic characteristics of 
cultured NBS lymphocytes, which show rearrangements most frequently 
affecting chromosomes 7 and 14 in clusters around the immunoglobulin and T- 
cell receptor loci. There is also sensitivity to ionising radiation and several 
groups report that NBS cells are similar in their failure to suppress DNA ’ 
synthesis post irradiation (radioresistant DNA synthesis or RDS) (Taalman et
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al., 1983), (Young and Painter, 1989), (Perez-Vera et al., 1997), (Jongmans et al.,
1997), (Sullivan et al., 1997), although the latter observation is contested 
(Antoccia et al., 1995). This similarity to A-T at the cellular level might suggests 
either that NBS regulates p53 independently independently of ATM. 
Alternatively, the NBS and ATM gene products may interact within the same 
complex or within the same pathway. One study examining NBS primary 
fibroblasts and EBV transformed NBS lymphoblastoid cell lines from the same 
patient treated with 5 Gy of irradiation showed levels of fibroblast 
radiosensitivity in NBS which was intermediate between normals and A-T 
fibroblasts. In addition in the NBS lymphoblastoid cells p53 and p21 induction 
was reduced but there was no significant delay in the p53 response, in contrast 
to the delayed kinetics of induction seen in A-T cells (Matsuura et al., 1998).The 
existence of a variant of A-T called A - T p r e s n o  in which the clinical phenotype of 
both NBS and classical A-T merges (Curry et al., 1989), lends further support to 
this latter hypothesis. All cases of A - T p r e s n o  examined to date have shown 
mutations in ATM  (Gilad et al., 1998) and it is speculated that these may 
critically alter a putative NBS-ATM interaction domain.
The gene defective in NBS has recently been positionally cloned (Varon 
et al., 1998). It was initially mapped to 8q21-24 by complementation of 
radiosensitivity using microcell-mediated chromosome transfer (Matsuura et 
al., 1997). Linkage analysis of 7 NBS pedigrees in the UK, USA and the 
Netherlands was used to further localise the NBS gene to chromosome 8q21. 
The NBS consortium conducted a whole genome screen in NBS families 
mostly of Czech and Polish origin which demonstrated that 30 patients shared 
a common founder haplotype arising from a mutation in 16th century
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Bohemia, which then transferred to Germany and the Netherlands with 
migration of the Slavic people. This approach lead to localisation of the NBS 
gene to a 1 cM interval on 8q21 (Saar et al., 1997). Linkage disequilibrium 
associated with this common founder mutation allowed narrowing of the 
region of interest to less than 300kb. A gene in this area was discovered to have 
truncating mutations in all NBS patients and was designated NBS-1 (Varon et 
al., 1998). NBS-1 spans over 50 kb of genomic DNA and the cDNA of 4386 bp 
includes an open reading frame of 2277 bp containing 16 exons. The gene 
product of the Nijmegen breakage syndrome encodes a protein of 754 amino 
acids which was called nibrin. Sequence analysis showed that it featured an 
amino-terminal fork-head associated (FHA) domain (Hoffman and Bucher,
1995), which may mediate interactions w ith phosphoserine and 
phosphothreonine. This domain is present in several yeast protein kinases 
including S. cerevisiae Dunl, Rad53 and S. pombe Cdsl which are all involved 
in regulation of the S phase checkpoint. Nibrin also contains a breast cancer 
carboxy-terminal domain (BRCT) found in a wide variety of proteins which 
participate in DNA damage checkpoints (Bork et al., 1997). Nibrin was found 
to be identical to a protein called p95 which was already being studied by 
another group as a component of the hM rell/hRad50 double strand break 
repair complex (Carney et al., 1998). In the presence of p95, cells treated with 
ionizing irradiation show relocalisation of immunologicaUy detected hM rell 
and hRad50 into spotty nuclear foci within 30 minutes. This relocalisation does 
not occur in NBS cells, hence p95/nibrin may be the DNA damage sensor or 
the transducer of the DNA damage signal from the DNA lesions to the repair 
complex and to the cell cycle machinery for appropriate checkpoint function.
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The mutations described in NBS-1 so far include the founder mutation 657del5 
which results in truncation of the protein beyond both the FHA and BRCT 
domain and 4 smaller deletions between 1-4 bp and a 1 bp insertion mutation, 
all of which also result in protein truncation. It remains to be seen whether 
milder NBS phenotypes share mutations in NBS-1 or are genetically distinct. 
.Whether the molecular causes of genomic instability in NBS and A-T are 
related is obviously a key question at present and will be the subject of future 
research. However, although the final pathway leading to the similar 
chromosomal rearrangements may be shared, it is likely that the outcome of 
this genomic instability will be different, because in A-T, T-cell malignancies 
predominate whereas in NBS, B-cell malignancies are most common.
Fanconi Anaemia (FA)
Fanconi anaemia (FA) is an autosomal recessive disorder with 
pleiotropic and variable clinical effects. The disease is rare with a prevalence of 
about 1:200,000. Affected individuals suffer growth retardation and 
progressive bone marrow failure (pancytopoenia) with onset within the first 
few years of life. 75% of patients also have other abnormalities including 
aplasia of the radius and the thumbs, renal and urinary malformations, 
microcephaly and skin pigmentation. The increased cancer risk is manifest 
most commonly as an acute myeloid leukaemia (Liu et al., 1994), (Buchwald et 
al., 1997). FA cells show marked chromosomal instability after exposure to 
genotoxic agents causing DNA cross-links. These agents include 
diepoxybutane, cisplatinum and mitomycin C. Somatic cell fusion studies in 
transformed lymphoblastoid FA cell lines analysed for their cross-linker
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sensitivity have identified 8 complementation groups to date: FA groups A-H 
(Duckworth-Rysiecki et al., 1985), (Strathdee et al., 1992), (Joenje et al., 1997). 
The clinical diagnosis of FA relies on the characteristic induction by cross 
linking chemicals of chromosomal aberrations, namely chromatid breaks and 
chromosome recombination figures. Spontaneous chromosomal damage is also 
seen in untreated FA cells. This may be due to lesions caused by oxidative 
damage as several products of oxidative metabolism (eg singlet oxygen, the 
hydroxyl anion, hydrogen peroxide and the superoxide anion) are known to be 
able to crosslink DNA and proteins. Indeed, FA cells grown at a low oxygen 
tension of 5% show suppression of several aspects of the FA cell phenotype 
(Schindler and Hoehn, 1988), (Joenje and Oostra, 1983). FA cells in culture 
show poor growth and reduced plating efficiency. FACS analysis demonstrates 
a greater proportion of cells in the G2 phase of the cell cycle. This may be due 
to an inherent increase in the length of G2 in FA cells or because of DNA  
damage of cells in S phase leading to cell cycle checkpoint activation and G2 
arrest. The latter may be related to unresolved crosslinks or stalled replication 
forks preventing completion of DNA replication. Sensitivity to DNA  
interstrand crosslinks is a consistent hallmark of FA cells, although studies to 
investigate whether FA cells are deficient in the ability to remove DNA  
crosslinks have given conflicting results with different complementation 
groups and different methodologies used p igw eed  and Sperling, 1996). Partial 
removal of interstrand crosslinks to leave adducts on only one strand of the 
DNA, thus restoring denaturability of the molecule, may explain why in some 
studies FA cells appear to be proficient at crosslink repair. Persistent 
interstrand crosslinks might impede the progress of replication forks, reducing
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the rate of DNA synthesis in S phase. This has been found for FA-A cells after 
treatment with crosslinking agents (Moustacchi et al., 1987), (Digweed et al., 
1988). It is likely that DNA with interstrand cross-links would be repaired by 
recombination using a separate undamaged DNA molecule as the template. 
This would explain the cytogenetic observations in FA cells, as failure of repair 
of crosslinked damage might lead to chromatid breaks and chromosomal 
recombination figures as a result of failure to complete the repair process. 
Defective recombinational repair has been reported in normal and FA-D cells 
after crosslinking treatment. In FA cells, defective recombination resulted in 
mutations which were mainly deletions whereas normal cells suffered point 
mutations (Papadopoulo et al., 1990). Presumably in normal cells, the point 
mutations are offset by the repair of large tracts of crosslinked unreplicatable 
DNA. The genes for FA-A and FA-C complementation groups have been 
cloned and mapped to chromosomes 16q24.3 and 9q3.22 respectively. 
(Strathdee et al., 1992), (Strathdee et al., 1992), (Pronk et al., 1995), (Lo Ten Foe 
et al., 1996), (F. A. B. C. Consortium, 1996). FA-A and FA-C encode distinct and 
novel proteins which interact with each other and form a complex, the 
biochemical function of which remains elusive. Unbound FA-A and FA-C are 
found predominantly in the cytoplasm, but the complex is seen in similar 
quantities in the nucleus and cytoplasm. It is possible that the complex plays a 
role in repair of DNA with interstrand crosslinks, but this is not yet 
established (Kupfer et al., 1997). Experiments examining the ability of nuclear 
extracts to bind crosslinked DNA (Lambert et al., 1992) suggested that a 
crosslink recognition protein is absent or defective in FA-A cells (Hang et al., 
1993). FA-D has been mapped to chromosome 3p22-26 (Whitney et al., 1995).
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This multitude of complementation groups indicates the molecular 
heterogeneity of FA. It is likely that different gene defects giving rise to this 
disorder act within the same biochemical pathway or within the same 
multiprotein complex dealing with cross-linker associated DNA damage. 
Failure of recognition or resolution of crosslink lesions would cause multiple 
genetic abnormalites which could in turn give rise to leukaemic 
transformation. Genetic heterogeneity within the disorder may also account for 
variability of the clinical phenotype and will make the molecular screening for 
FA more difficult, although it is known that certain complementation groups 
are commoner in some populations eg FA-A in Ashkenazi Jews (Whitney et 
al., 1993), (Verlander et al., 1994), and FA-C in Afrikaaners (Pronk et al., 1995) 
and Italians (Savoia et al., 1996). Epidemiological evidence suggesting that FA 
heterozygotes may have a higher cancer risk than the general population 
(Swift, 1971), may mean that identification of all the FA genes and their 
functions has more relevance than was first appreciated.
Xeroderma Pigmentosum (XP)
Xeroderma pigmentosum is a rare genetic disorder. It is characterised 
by acute photosensitivity upon sunlight exposure leading to extreme sunburn 
reactions and later to atrophy and telangiectasia of the affected skin. Affected 
individuals also have more than a 2000-fold increase in all forms of skin cancer 
(Kraemer et al., 1987). Tumours appear on sun exposed sites in childhood with 
a median age of presentation of 8 years. A range of neurological defects 
including neurodegeneration are seen in up to 40% of cases and a small
number show more severe abnormalities with microcephaly and dwarfism
/
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The syndrome therefore affects multiple systems and is somewhat variable in 
its phenotype. At the cellular level there is hypersensitivity to ultraviolet light 
(UVL) and UV-mimicking chemicals with defective DNA repair (Cleaver, 
1968). Cell lines derived from XP individuals also show chromosomal 
instability after exposure to UVL (Parshad et al., 1993), and some have 
considered XP to be a classical chromosome breakage disorder (Weemaes et al., 
1981). XP is now known to comprise two subgroups: classical XP and variant 
XP. In classical XP, seven different complementation groups have been 
discovered: XP-A-G. Variant XP is made up of only one additional 
complementation group, XP-V. In classical XP (80% of cases), the molecular 
defect lies within the nucleotide excision repair (NER) pathway (Kraemer ef al., 
1987).
Two overlapping pathways of NER have been identified: transcription 
coupled repair, which is rapid and which targets the transcribed strand of 
expressed genes, and the more tardy global genome repair serving the rest of 
the DNA. Most groups are deficient in both pathways of NER but XP-C 
apparently only shows a defect in global genome repair. In variant XP the 
defect is not well characterised but is believed to affect post-replication repair 
mechanisms which are themselves poorly understood. The gene products 
corresponding to the XP complementation groups are now being characterised 
(Table 1.2) and reviewed (Sarasin and Stary, 1997).
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Protein Function
XP-A DNA damage recognition (Jones and 
Wood, 1993)
XP-B/ERCC3 ATP-dependent DNA Helicase 3'->5'. 
Subunit of RNA pol II basal transcription 
factor BTFn(TFilH)
XP-C Role uncertain. May bind damaged DNA  
and recruit repair machinery
XP-D/ERCC2 ATP-dependent DNA Helicase 5 ->3'. p80 
subunit of RNA pol II basal transcription 
factor BTFll (T'FuH), (Schaeffer et al., 1993), 
(Schaeffer et al., 1994), (Sung et al., 1993).
XP-E DNA damage recognition (Jones and 
Wood, 1993).
W-F/ERCC4 Component of the 5' endonuclease 
complex
XP-G 3' endonuclease
XP-V Post replication repair abnormal
Table 1.2
Proteins abnormal in xeroderma pigmentosum and dieir cellular functions.
TFHH is probably involved in the local unwinding of the DNA duplex 
at the site of DNA damage in NER and at the site of the promoter in
34
transcription initiation, which relies on the DNA-dependent ATPase and DNA  
helicase activities associated with XPB and XPD.
Interestingly two syndromes, Cockayne's syndrom e (CS) and 
Trichothiodystrophy ( IT U) showing overlap with XP are known and also 
feature UVL sensitivity and defects in NER, although curiously neither CS nor 
I I D show an elevated cancer risk. CS is characterised by sun sensitivity, 
severe mental retardation due to dysmyelination, skeletal abnormalities and a 
wizened facial appearance (Lehmann et al., 1993). The features of TTD include 
sulphur-deficient brittle hair and nails, and icthyosis (thickened scaling skin) 
(Itin and Pittelkow, 1990). Growth is also impaired and dysmyelination is seen, 
as in CS. Classical CS (complementation groups A and B) are defective in 
transcription coupled repair whereas CS/XP-B, CS/XP-D and CS/XP-G fall 
into XP complementation groups and are defective in both paths of NER. In 
TTD 90% of patients are assigned to the same complementation group as XP-D 
ie TTD/XP-D. Classical TTD ( group TTD-A) and TTD/XP-B are in the 
minority. Although XP-D and TTD/XP-D mutations reside in the same gene, 
the phenotypic consequences of these mutations are different and the cancer 
risk is only seen with XP. Analysis of the mutations in the XPD and XPB genes 
in the different NER syndromes suggests certain mutations are syndrome 
specific (Broughton et al., 1994), (Broughton et al., 1995), (Takayama et al.,
1995), (Takayama et al., 1996). It has been hypothesized that particular 
mutations may render the transcription role of the complex TFIIH abnormal 
perhaps affecting expression of a variety of genes leading to TTD (transcription 
syndrome) whereas others may abolish the NER function leading to genetic 
instability and tumorigenesis after exposure to UVL.
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Hereditary Non-Polyposîs Colorectal Cancer (HNPCC)
HNPCC, also known as Lynch syndrome ( types I and II), is a major 
cause of genetic instability-related cancer. It shows autosomal dominant 
inheritance, affects ~ 1/200 of the population, and poses a considerable health 
burden as it accounts for 4-13% of all colorectal cancer in industrialised 
nations (Lynch et al., 1993). The syndrome is defined clinically by the 
occurence of tumours in at least 3 family members in 2 generations or more, at 
least one of whom should have been diagnosed below the age of 50 years 
(Vasen et al., 1991). Affected individuals develop intestinal tumours, usually of 
the colon (Lynch type I). In Lynch type II, there is also a predisposition to 
extraintestinal cancers including transitional cell tumours of the urinary tract 
and gynaecological malignancies eg endometrial carcinoma. A clue to the 
mechanism underlying HNPCC was found several years ago when it was 
demonstrated that some colonic tumours from HNPCC patients showed 
dramatic changes in microsatellite sequences termed microsatellite instability 
(MIN) (Aaltonen et al., 1993) (Peltomaki et al., 1993). Microsatellites are 
sequences consisting of 10-50 repeats of 1-6 bp elements. The length of a given 
sequence is often polymorphic and heritable. Whilst they have no definite 
attributed function they have been implicated in recombination, as promoter 
sequences, as possible binding sites for DNA topoisomerases (Honchel et al.,
1995) and they have been used to demonstrate the presence of loss of 
heterozygosity (LOH) in human tumours, ht addition to LOH, some tumours 
studied were shown to have expansion or contraction of the repetitive element 
within microsatellites when compared to DNA from non-tumorous tissue. 
MEN is now known to be a feature of some sporadic cancers and it is present
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in about 80% of colonic and extracolonic HNPCC tumours. Intriguingly when 
MIN occurs in tumours it tends to be associated with tumour diploidy, 
indolent clinical behaviour and improved patient survival. In contrast tumours 
which lack MIN but which show high degrees of LOH tend to be aneuploid, 
suggesting that there may be different overall genetic mechanisms which may 
both encourage tumorigenesis. At the molecular level there seem to be three 
different types of MEN. One type where there is a single repeat difference with 
a slightly higher than normal new mutation rate, a second type which again 
shows a single repeat difference but this time with a higher mutation rate and a 
third type which features marked expansion or contraction in multiple 
microsatellites (Honchel et al., 1995). Mapping of the genes involved in 
HNPCC was begun when linkage of HNPCC to chromosome 2p was found in 
2 large kindreds (PeltomaJd et al., 1993) although no LOH was demonstrated 
on chromosome 2 suggesting that the observed MIN was caused by something 
other than loss of tumour suppressor gene activity. The elucidation of the 
molecular defects underlying HNPCC was largely guided by earlier work on 
mutants of E. coli which showed elevated frequencies of instability in regions 
of simple repeat sequences, reminiscent of MIN in humans. These bacterial 
strains bore mutations in the genes mutS and mutL, which are involved in 
DNA mismatch repair (Levinson and Gutman, 1987). Investigation of similar 
instability in repeat tracts in the yeast S. cerevisiae was shown to be due to 
mutations in yeast homologues of the bacterial genes of mismatch repair 
named MLHl {MutL homologue 1), MSH2 {MutS homologue 2) and PMSl 
(Post meiotic segregant 1). Two groups quickly identified a human gene 
hMSH2 (human mutS homolog 2) on chromosome 2p, which was mutated in
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some patients with HNPCC (Fishel et al., 1993)(Leach et al., 1993). However 
some kindreds of HNPCC showed linkage to chromosome 3p and also 
exhibited MIN. This led to the identification of hMLHl, which is a human 
homologue of bacterial mutL and yeast M LHl genes. Whilst hMSH2 and 
hMLHl mutations are thought to account for most of the cases of HNPCC, two 
other susceptibility genes on chromosomes 2q and 7 have now been discovered 
and are called hPMS l  and HPMS2 after their S. cerevisiae counterparts. 
Interactions between these mismatch repair proteins are now being described 
and their functions are being further elucidated. The gene product of HMSH2 
associates with hMSH3 or hMSH6 as a heterodimer. No mutations have been 
found in hMSHS or HMSH6 in HNPCC so far, perhaps because these complexes 
overlap in function (Acharya et al., 1996), (Risinger et al., 1996). Recently it has 
been shown that the hMSH2-hMSH6 complex is an ATPase which binds 
mismatched nucleotides in the ADP-bound form whilst ADP->ATP exchange 
results in dissociation of the complex. ATP hydrolysis then allows recovery of 
mismatch binding (Gradia et al., 1997). This recognition step may serve to 
initiate further downstream events in the repair pathway. The importance of 
mismatch recognition may also explain why the most conserved region of the 
mutS homologues contain a helix-tum helix domain associated with a "Walker- 
A"-type adenine nucleotide and magnesium binding motif. Mutation of 
conserved amino-acid residues within the adenine nucleotide binding domain 
results in a dominant mutator phenotype in bacteria and yeast. Defective 
mismatch repair may cause cancer by causing mutations in oncogenes and 
tumour suppressor genes. Alternatively, the resulting MIN near or within 
certain genes may alter their function is such a way as to promote more
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generalised genomic instability, or other aspects of the transformed phenotype. 
There is no clear explanation yet of the differences at the genetic level that 
explain the distinction between the Lynch type I and type II phenotypes. It is 
possible that other genes modify expression of the phenotype or perhaps 
different mutations give rise to different clinical entities. This may be the case 
for the Muir-Torre Syndrome, in which affected patients present with at least 
one sebaceous gland tumour and a minimum of one internal malignancy 
(usually colorectal carcinoma). MTS patients also show MIN, and genetic 
linkage to DNA markers on Chromosome 2 linked to HNPCC kindreds has 
been demonstrated (Hall et al., 1994). It is tempting to speculate therefore that 
MTS is another phenotypic variant of HNPCC, although this requires further 
elucidation.
Breast cancer
Breast cancer is a major cause of death in females in the UK with a 
provisional incidence rate for England and Wales in 1997 of 109.6/100,000 
wom en and a mortality rate (1996) of 45.3/100,000 women (personal 
communication from the Office for National Statistics). About 80% of breast 
cancer cases are sporadic due to acquired mutations, with a peak incidence in 
the peri-menopausal years, whereas in 20% there is a family history of the 
disease. Some of the familial cases are clusters which have occurred by chance 
because breast cancer is so common. In others the clusters are related to 
exposure to common environmental agents or shared lifestyle patterns and the 
rest are due to inherited genetic causes. In hereditary breast cancer (5% of the 
total), the age of onset is younger and bilaterality is more common.
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Prediposing factors for breast cancer include sex (only 1% of cases occur 
in males), age (99% of cases occur over the age of 30), prolonged exposure to 
hormones causing proliferation of breast tissue (early age of menarche, late 
maternal age at the birth of the first child, late menopause, use of the oral 
contraceptive pill or of hormonal replacement therapy, breast feeding), obesity, 
high dietary fat intake, smoking, exposure to ionising irradiation, country of 
residence and a previous history of breast disease or a family history of breast 
cancer. The latter may be seen in patients with a family history of a breast and 
ovarian cancer or as breast cancer alone. Certain syndromes also carry an 
increased risk eg Li-Fraumeni syndrome. Lynch syndrome (type II), Cowdens 
disease, Peutz-Jegher syndrome, Ruvalcaba-Myresmith and Klinefelters 
syndrome (Hodgson and Maher, 1993).
Studies of the cytogenetics of breast cancer may reveal chromosomal 
regions which are important in the pathogenesis of this disorder. Some have 
commented that there are no consistent karyotypic abnormalities in breast 
cancer (Bodmer, 1988), although there have been many reports of allelic losses 
or rearrangements most notably of chromosomes 11, 13 and 17 (Bieche and 
Lidereau, 1995). These have been associated with mutations in Tp53 (17pl3.1), 
BRCA-1 (17q21), BRCA-2 (13ql2.13), ERB-B2 (17ql2), NM23 (17q22) and ATM  
(Hq22-23) (Kerangueven et al., 1997), (Plummer et al., 1997) and allele losses 
are even seen in pre-invasive disease and good prognosis grade I tubular 
carcinomas (Man et al., 1996).
At the molecular level, breast cancer may be due to mutations in rare 
but highly penetrant genes, mutations in more common but low penetrance 
genes, and/or polygenic effects which perhaps modulate the expression of
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either of the former. Overall, defects in low penetrance genes may account for 
more cases of breast cancer in the population than those due to the highly 
penetrant genes (Ponder, 1990).
Several genes have been implicated in the development of hereditary 
breast cancer including BRCAl, BRCA2, Tp53, ATM and the aiidrogen receptor 
and oestrogen receptor genes. The latter have an obvious role in hormonal 
signal transduction within the nucleus and p53 is important in checkpoint 
integrity after DNA damage and the induction of apoptosis. It is likely that 
BRCAl and 2 and ATM are involved in the cell response to DNA damage and 
in DNA repair mechanisms but their exact functions are not fully elucidated.
BRCA-1
The human BRCAl gene was identified by positional cloning in 1994 
(Miki et al., 1994). The gene is thought to function as a tumour suppressor and 
mutations in it confer a marked predisposition to breast and ovarian cancer. 
Women who inherit a mutant BRCAl allele have a 90% lifetime risk of 
developing breast cancer (Ford et al., 1994), indicating high penetrance. The 
mutated gene is found in 45 % of families with inherited breast cancer and 80- 
90 % of families with an inherited susceptibility to breast and ovarian cancer. 
Hie gene is composed of 24 exons, 22 of which code for a protein of 1863 amino 
acids. Most of the exons are small but exon 11 is very large making up -60% of 
the coding region. The function of BRCAl is unknown but database searches 
reveal an amino terminal C3H4C4 motif, characteristic of RING finger zinc- 
binding domains which interact with DNA or proteins. Other regions of 
interest include a bipartite nuclear localisation signal (NLS) encoded by exon
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11 and two BRCT domains in the carboxy terminus which may function as 
transactivators of transcription (Chapman and Verma, 1996). The latter may 
have a role in the regulation of gene expression as the ability of artificial and 
genomic reporter constructs to activate p53-responsive elements is reduced if 
the second BRCT element is mutated (Ouichi et al., 1998). A role in activation 
of the WAF-1 promoter has also been reported independent of p53 activation 
(Somasundaram et al., 1997). The BRCT domain has also been identified in the 
cell cycle checkpoint proteins p53-binding protein-1 and S. pombe Rad4 , the 
DNA repair protein XRCCl and the retinoblastoma protein pRb. Involvement 
of BRCAl in the regulation of gene transcription is also suggested by its 
association with RNA polymerase II (Scully et al., 1997). In terms of molecular 
partners, BRCAl has been found in a multiprotein complex with hRadSl 
(Scully et al., 1997), a protein which catalyzes ATP-dependent DNA strand 
exchange reactions and is a homologue of E. coli recombination and DNA  
repair protein RecA. Additional support for the hypothesis that BRCAl is 
involved in the response to DNA damage is suggested by the fact that DNA  
damage is associated with BRCAl hyperphosphorylation and altered nuclear 
co-localisation of BRCAl with hRadSl (Scully et al., 1997).
BRCA2
The BRCAl gene was mapped to chromosome 13ql2-13 in 1994 and was 
recently identified (Wooster et al., 1995), (Tavtigian et al., 1996). In contrast to 
BRCAl, both female and male BRCAl heterozygotes are susceptible to breast 
cancer with a lifetime risk of -80-90% for women and -  6% for men (Stratton,
1996). In addition, BRCAl confers susceptibility to other tumours including
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carcinomas of the ovary, colon, pancreas, larynx and prostate. Genetic 
inactivation of both alleles appears to be associated with tumorigenesis and 
BRCAl therefore seems to behave as a tumour suppressor gene (Stratton,
1996), (Collins et al., 1995), (Gudmundsson et al., 1995).
The BRCAl gene is composed of 27 exons, 26 of which code for a large 
protein of 3814 amino acids (Tavtigian et al., 1996), with no strong resemblance 
to any other known proteins. It is a nuclear protein and in vitro transactivation 
assays suggest that its amino terminus is involved in the transcriptional 
regulation of genes, the identities of which are unknown at present (Milner et 
al., 1997). BRCA2 has been found to associate with hRAD51 via direct binding 
through at least two binding sites, one at the amino-terminal end of the region 
encoded by exon 11 and one at the carboxy-terminus (Scully et al., 1997), 
(Sharan et al., 1997), (Wong et al., 1997). It is thought to exist in a multiprotein 
complex with BRCAl on the basis that BRCAl has also been shown to 
colocalize with hRAD51 (although BRCAl does not bind to hRAD51 directly) 
(Sharan et al., 1997), (Wong et al., 1997), (Mizuta et al., 1997). This suggests that 
BRCA2 may have a role in RAD51 mediated recombination or DNA dsb repair, 
a hypothesis which is supported by a number of other lines of evidence: 
BRCA2 is found in ovary and testis where recombination occurs in meiosis, 
BRCA2 knock-out blastocysts are sensitive to X-irradiation (Sharan et al., 1997) 
but show embryonic lethality as seen with hRAD51 and BRCA-l-knock outs. 
Mice with alleles coding for a truncated BRCA2 molecule (encoding the amino- 
terminus alone with its putative transactivation domain) survive but show  
marked growth retardation and their cells suffer a progressive failure of 
cellular proliferation associated with increased p53 and p21 levels. The cells are
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markedly sensitive to UVL and the alkylating agent methylmethanesulphonate 
and moderately sensitive to y irradiation, but apoptosis and checkpoint 
function seem to be intact. In addition there is spontaneous genetic instability 
with increased numbers of chromatid breaks, quadriradials and triradials 
together with polyploidy. DNA dsb repair in V(D)J recombination, which 
occurs predominantly in G1 phase, is grossly intact. The authors suggest a role 
for BRCA2 in recombination or recombinational repair rather than in DNA dsb 
repair (Patel et al., 1998), although they comment that due to lack of a suitable 
antibody they cannot confirm the presence of truncated BRCA2 in their 
mutants. The animals develop thymic lymphomas (as described for ATM  
mutant mice) but no mammary gland carcinomas are reported.
Mice homozygous for BRCAl truncations which retain the amino- 
terminal putative transactivation domain and the amino-terminal RAD51 
interaction domain have also been generated (Connor et al., 1997). They 
possess a similar overall phenotype to those described by Patel et al, but 
homozygous mutant mouse embryonic fibroblasts (MEFs) showed reduced 
DNA dsb repair after 40Gy of X-irradiation compared with wild type and 
heterozygous MEFs assessed by the neutral comet assay. These authors 
therefore concluded that BRCA2 is required for DNA dsb repair, although, as 
in the other study, they could not verify the expression of truncated BRCA2 
due to lack of suitable reagents.
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p53
p53, encoded by the Tp53 gene is now a well established tumour 
suppressor, mutation of which is the commonest alteration seen in human 
cancer. Women with the rare Li-Fraumeni syndrome who carry a germline 
mutation in p53 are highly predisposed to breast cancer although many other 
tumour types are also seen including soft tissue sarcomas, osteosarcomas, 
leukaemias, brain tumours and adrenocortical carcinomas. p53 is known to be 
important in the maintenance of genomic integrity and is involved in gene 
regulation, cell cycle checkpoint control, DNA repair, cellular senescence and 
apoptosis all of which have an impact on tumorigenesis (Harris, 1996). p53 
germ-line mutations have also been identified in patients with sporadic breast 
cancer (Andersen, 1996), (Prosser et al., 1992), (Sideransky et al., 1992). A p53 
splice site mutation has also been identified in a family with hereditary breast 
and ovarian cancer (JoUy et al., 1994).
The sex horm one receptors
A mutation of the androgen receptor gene which affects the DNA  
binding portion of the receptor has been found in a several cases of male breast 
cancer, a subset of which are characterised by partial androgen insensitivity 
(Andersen, 1996). It is also possible that mutations at the oestrogen receptor 
(ESR) locus are associated with breast cancer susceptibility and there is a report 
of cosegregation of an ESR haplotype and breast cancer in a late-onset family 
(Andersen, 1996), (Zuppan et al., 1991).
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Other genes
A variety of other genes including c-myc, which encodes a nuclear 
transcription factor, c-erb-B2 (HER2/neu) and NM-23 have been implicated in 
breast cancer and show amplification and correlation with poor prognosis 
(Callahan and Campbell, 1989).
ATM
The reported association of an increased risk of cancer in A-T 
heterozygotes (Swift et al., 1976), has resulted in a surge of interest in this area 
although no overall increase in deaths from breast cancer was seen in this non- 
molecular study of 27 families of patients with A-T comparing blood relatives 
to spouse controls. Subsequent studies also suggested that A-T heterozygotes 
were predisposed to breast cancer (Swift et al., 1987), (Swift et al., 1991), 
(Pippard et al., 1988), (Borresen et al., 1990). The lack of an over-representation 
of breast cancer amongst A-T sufferers appears puzzling if the heterozygotes 
are at increased risk and has been explained on the basis that death in A-T 
usually occurs prior to the age of susceptibility to breast cancer. In support of 
this hypothesis, there are reports of breast cancer in A-T patients who reach an 
older age than usual in this condition, but it is also of note that only one ATM  
mutation (7271T->G) has been statistically proven to confer an increased risk of 
breast cancer (Stankovic et al., 1998) which may complicate the picture. If 
heterozygotes really are at increased risk of the disease then knowledge of a 
woman's genetic status with respect to the ATM  gene becomes important in 
terms of breast cancer screening. This is doubly relevant as X-ray exposure for 
mammography is part of the current breast cancer screening programme, yet
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ATM  heterozygotes are theoretically more sensitive to the harmful effects of 
ionising irradiation. These include early and late radiation reactions and 
possible genetic effects leading to oncogenesis. Several investigators have now  
addressed the question of breast cancer risk and ATM status using different 
study designs. Those in association and agreement with Swift include (Athma 
et al., 1996) who have traced ATM  in 99 A-T families using the closely linked 
markers D11S1778 and D11S1819 which flank ATM  . They found 33 women 
with invasive breast cancer; 25 were A-T heterozygotes compared with the 
expected number of 14.9. For all breast cancers in the sample the odds ratio, 
estimating the relative risk of carriers compared to non-carriers, was 3.8 (95% 
confidence limits 1.7-8.4). This risk is similar to that of 3.9 for all ages found by 
an analysis of previously mentioned studies of breast cancer risk in mothers 
and other close relatives of A-T cases (Easton, 1994). For the 21 women under 
the age of 60 the odds ratio was 2.9 (95% Cl: 1.1-7.6) and for the 12 women 
over the age of 60 it was 6.4 ( 95% Cl: 1.4-28.8), suggesting that A-T 
heterozygotes are predisposed to breast cancer. Based on an estimated 
heterozygote frequency in the USA of 1.4% and the estimated relative risks 
before and after age 60, 6 .6% and 8.3% of all breast cancers in the USA were 
estimated to occur in A-T heterozygotes in the younger and older age groups 
respectively. It is notable that the risk in this study appeared greater in older 
rather than younger women. This is in direct contrast to results of previous 
studies (Easton, 1994) and observations in other cancer predisposition  
syndromes. The incidence of bilaterality was not increased in the heterozygotes 
either, although this is increased in other familial breast cancer cases. Other 
investigators have criticised Swift's earlier studies (Swift et al., 1987) and (Swift
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et al., 1991), on the basis that there was an unexpectedly low incidence of 
breast cancer in the controls used (Fitzgerald et al., 1997). This team conducted 
a germ-line mutational study of the ATM  gene in a group of 401 women with 
early onset breast cancer (aged 40 or below), compared with 202 healthy 
individuals with no history of cancer. A cDNA-based protein truncation test 
was used to detect chain terminating mutations (these account for 90% of 
mutations in cases of A-T). Chain terminating mutations were detected in 
2/401 (0.5%) of women with breast cancer and 2/202 (1% ) of controls. 
Although this screening method cannot identify missense or regulatory region 
mutations, whilst identifying pre-mRNA splicing variants, it suggests that 
there is no significant correlation between ATM  heterozygosity and the 
development of early onset breast cancer (Fitzgerald et al., 1997). It is 
conceivable that if the risk of breast cancer in carriers of ATM  gene does 
increase with age then they might have failed to detect the effect in a younger 
age group. An independent statistical analysis (Bishop and Hopper, 1997) of 
(Athma et al., 1996) and (Fitzgerald et al., 1997) has commented that the higher 
estimate of the 95% confidence interval of the Fitzgerald study allows for up to 
a 7-fold increased risk to be consistent with the observed data, therefore 
allowing the results to be consistent with those of (Athma et al., 1996).
The role of A-T heterozygosity in familial breast cancer has been 
examined in 100 Swedish families (two or more cases of breast cancer in the 
family regardless of age of onset) not suffering from germ-line mutations in 
BRCA-1 or BRCA-2 (Chen et al., 1998), using the protein truncation test to look 
for germ-hne ATM  mutations in peripheral blood lymphocytes. One germ-line 
mutation was found, consistent with the expected carrier frequency for A-T of
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1%. They also studied 4 paraffin embedded breast tumours together with non­
tumour tissue from patients with familial breast cancer harbouring known 
germline mutations of ATM. None showed a Knudson double hit' of the ATM  
gene in the tumour tissue; indeed the mutated allele rather than the wild type 
allele had been lost in one case. Although this is only a small sample size it 
suggests that the ATM  gene is not responsible for the tumour development and 
is not acting as a classical tumour suppressor in these cases. Two other studies 
have also shown an absence of linkage to the A-T locus in familial breast 
cancer (Wooster et al., 1993), (Cortessis et al., 1993).
As can be seen from the preceding discussion, the conflict in the 
literature is as yet unresolved, largely due to the relatively small study sizes in 
relation to the assumed frequency of heterozygosity within the general 
population, and the lack of exact information regarding this frequency. It is 
doubtful that ATM  plays a major role in sporadic breast cancer in the general 
population, although it may be relevant in a proportion of women with 
familial breast cancer. This is given further weight by the fact that recently, a 
particular ATM  mutation 7271T->G has been shown to be significantly 
associated with an increased risk of breast cancer in both homozygote and 
heterozygotic carriers (Stankovic et al., 1998). This mutation allows production 
of a full length ATM protein which may have residual activity as it is 
associated with a milder clinical A-T phenotype. This mutation may provide a 
tool which in the future may be used to investigate the molecular mechanism 
of breast cancer association with A-T.
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DNA repair and breast cancer
The repair of DNA damage suffered by a cell is of critical importance to 
survival and several DNA repair systems exist to deal with different DNA 
lesions. Damage on a single strand can be repaired by base excision repair, 
nucleotide excision repair and mismatch repair pathways already mentioned. 
DNA double strand breaks can be repaired by several different pathways 
including homologous recombinational repair (where extensive homology is 
required between the region with the double strand break and the sister 
chromatid or homologous chromosome being used as the template), and non- 
homologous recombinational repair which requires very little or no homology 
on the ends of the strands being rejoined. A more detailed review of these 
repair pathways is beyond the scope of this thesis and for further information 
the reader may refer to the following articles (ap Rhys and Bohr, 1996), 
(Barzilay and Hickson, 1995), (Camerini-Otero and Hsieh, 1995), (Hendrickson,
1997), (Belmaaza and Chartrand, 1994).
One of the risk factors for the development of breast cancer is radiation 
exposure (Goss and Sierra, 1998). DNA damage if left unrepaired can cause 
mutations directly, and unrepaired breaks may be converted into chromosomal 
breaks allowing translocations with abnormal gene position and regulation 
effects and the creation of gene fusions, all of which may be oncogenic.
Constitutional DNA repair has been studied in breast cancer patients by 
analysing the frequency of chromatid breaks after G2 phase X-irradiation in 
phytohaemaglutinin (PHA)- stimulated lymphocytes (Scott et al., 1994). These 
authors found that 21 of an unselected series of 50 women with sporadic breast 
cancer showed an abnormally high frequency of breaks and suggest that these
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women have defects in the processing of DNA damage. In a similar study 
chromatid breaks were quantified in PHA stimulated lymphocytes after either 
X-irradiation or UV-C exposure, with or without post-treatment with a DNA- 
repair inhibitor, 1-b-arabinofuranosylcytosine (ara-C), to examine the 
contribution of DNA repair to the results. 6 out of 7 cases of women with 
breast cancer and a family history of breast cancer and 6 out of 11 cases of 
sporadic breast cancer were found to be deficient in the repair of radiation 
induced DNA damage; these showed greater numbers of chromatid breaks per 
100 metaphases compared with normal controls with no personal or family 
history of breast cancer (Parshad et al., 1996). Scott's group have since
published another study using high dose or low dose rate y-irradiation and a
micronucleus assay on GO lymphocytes from breast cancer cases and normal 
volunteers including some spouses of breast cancer patients. With the high 
dose rate protocol they found 31% (12 out of 39) of breast cancer patients 
compared with only 5% (2 out of 42) controls showed elevated micronucleus 
induction (Scott et al., 1998). A variety of different mechanisms may be 
responsible for the elevated chromosomal radiosensitivity described. These 
include defective DNA repair (Parshad et al., 1983), perturbations in cell cycle 
checkpoint control (Little and Nagasawa, 1985), (Wang et al., 1996), failure of 
the apoptotic elimination of cells with damaged chromosomes (Schwartz et al., 
1995), (Wang et al., 1996) or defects related to those which lead to the classical 
chromosome fragility disorders (ataxia-telangiectasia, Bloom's syndrome, 
Fanconi's anaemia and Nijmegen breakage syndrome) already discussed. 
Consideration of the molecular defects underlying rare disorders, therefore.
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may help to elucidate the mechanisms of genomic instability which are 
important in the evolution of common human malignancies.
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Chapter 2
Materials and Methods
2.1 Chem icals
Unless otherwise stated, all chemicals used were purchased from Sigma 
Chemical Company. All tissue culture media, PBS, EDTA, trypsin and L- 
glutamine were supplied by Tissue Culture Services, Clare Hall, UK. Bacterial 
media were supplied by ICRF Central Stores, Clare Hall. All radioisotopes 
were supplied by Amersham, UK Ltd. Protease inhibitors and Polyacrylamide 
mixes were purchased from Boehringer Mannheim.
2.2 Enzym es
Unless otherwise stated, all enzymes used were purchased from 
Boehringer Mannheim. DNA-dependent Protein Kinase was purchased from 
Promega.
2.3 Plasm ids
The bacterial expression vector pET-14b was purchased from Novagen 
and plasmid pQE-32 (Qiagen) strains 1 and 2 containing histidine sequence- 
tagged-5' inserts of ATM cDNA were received as a gift from Dr Andrew  
Sutcliffe in the form of M15 stab cultures (CRC Laboratories, Birmingham , 
UK). pET-14b with histidine sequence tagged PHAS-I insert was received as a 
gift from Professor John Lawrence (University of Virginia). The mammalian 
expression vector pCD2-CMV was described previously (O'Connell et al., 
1994). pCR-Script was purchased from Stratagene.
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2.4 Bacteriophages
Lambda phage X CEV-29 containing the AT7.9 clone was received as a 
gift from Professor Yosef Shiloh (Tel Aviv University).
2.5 £ . c o li  strains
BL21 (P'ompT W Sg (rg-mg") gal dan (DE3)pLysS (cam^), an E. coli B strain with
DE3, X prophage carrying the T7 RNA polymerase gene was used for
expression of recombinant proteins cloned into pET-14b. The bacteriophage 
DE3 transferred chromosomal copy of the T7 RNA polymerase gene is under
lacUVS prom oter control. A ddition  of IPTG (isopropyl-P  -D-
thiogalactopyranoside) stimulates expression of the polymerase which allows 
expression of recombinant His-tagged protein downstream of the T7 promoter 
of pET-14b. A small amount of T7 lysozyme encoded by a plasmid in BL21
pLysS binds T7 polymerase and inhibits it ensuring very low  levels of
>
expression from the T7 promoter in the absence of IPTG (which might be 
useful if the target product is mildy toxic).
DHiop (P'ara D139 A(ara, leu )7697Alac X74 gal U gal X mcr A  A (mrr-hsd RMS-
mcr BC) rps Ldor fSOd/ac ZDM15 end A1 nup G rec A l) was used as an 
electrocompetent strain for transformations.
LE392 (el4"(McrA“)/zsdR524 supE44 supF58 lacYl) was used as a host for the 
lambda phage X CEV-29 containing the AT7.9 clone.
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\M15 (F- lac Z DM15 ara' gai' mtT recA+ uvr+lorf^ (Km^StiS)), (Hoffmann-La 
Roche Ltd.), was used as the host for pQE-32.
2.6 Preparation of com petent E. co li
To prepare supercompetent DHlOp 3ml of Luria Broth (LB) was
innoculated with a single bacterial colony and grown overnight at 370C in a 
shaking incubator. 2ml of this overnight culture was then innoculated into
200ml of LB and incubated at 37°C until the OD^ OO was (0.5-0.8). The culture 
was then allowed to shake on ice for 30 minutes before centrifugation at 4,200
rpm for 10 mmutes at 40C (Beckman J-6B). The bacterial pellet was then 
washed twice in 200ml of ice cold sterile water, prior to repeat centrifugation 
and resuspension of the bacterial pellet in 20ml of 10% glycerol. After this, a 
final centrifugation was performed as described above and the bacteria were
resuspended in 2ml of 10% glycerol and aliquoted into 50|il samples for
storage at -70°C. A transformation efficiency of at least 10  ^ colonies/|ig  
plasmid was aimed for.
2.7 I'ransformation o f com petent E. co li
Aliquots of competent cells were thawed at room temperature. 0.7|il of 
plasmid DNA was taken directly from the ligation reaction and was added to 
50|l i 1 of electrocompetent DHlOP and mixed gently. The bacteria were then 
transferred to a cuvette and electroporated at 2.5kV, 25|iF, 400D using a
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BIORAD electroporator. ISOjti of SOC medium containing 2% Bacto Tryptone, 
lOmM NaCl, 2.5mM KCl, lOmM MgCl2 , 0.5% Bacto yeast extract, lOmM 
MgS04 and 20mM glucose was then added to the cuvette and the sample was
divided into two aliquots for spreading onto duplicate agar plates (made with 
LB and 100 p,g/ml Ampicillin).
2.8 Agarose gel electrophoresis
DNA samples were electrophoresed through 0.7% agarose gels 
containing 0.25 M-g/ml ethidium bromide in TBE buffer (90mM Tris, 90mM 
boric add, 2.5mM EDTA), using a horizontal gel apparatus (Pharmada). DNA  
samples containing 1 /5  volume of DNA sample buffer (30% (w /v ) sucrose, 
lOOmM EDTA, 0.01% (w /v ) Bromophenol Blue), were electrophoresed at 
100mA until the dye had reached the desired distance. DNA was visualised by 
exposure to UV light from a high intensity, long range wavelength transmitter 
(Fotodyne). A photograph of the gel was taken using by an MP-4 Polaroid 
camera following the manufacturer's instructions.
2.9 Restriction digests
Closed circular plasmid DNA was digested with the appropriate 
restriction enzyme(s) according to the manufacturers instructions assuming
that lp.g of DNA is digested by 1 unit of enzyme in 1 hour at 37°C. The 
mixture was normally made up to a volume of 30|il, induding the appropriate 
buffer and incubated at 37^C for 90 minutes.
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2.10 Small scale preparation of plasm id D N A  from E. co li
A  single bacterial colony containing the plasmid of interest was 
resuspended in 3 ml of medium (LB/100|ig/m l Ampicillin) and incubated
overnight in a shaking incubator at 37°C.
The following morning the cells were collected from 1.5 ml of the 
culture by centrifugation at 14,000 rpm for 30s in a benchtop centrifuge. Most 
of ihe medium was then poured off and the bacteria were resuspended in the 
remaining 50-100 pi. 300 pi of TENS (10 mM Tris pH 8,1  mM EDTA, 0.5% SDS 
and O.IM NaOH), was added to this to lyse the bacteria, and the mixture was 
vortexed for 2-3 s prior to the addition of 150 p.1 of 3M Na acetate (pH 5.2) 
which precipitates the protein and the denatured chromosomal DNA. The 
mixture was vortexed again briefly and centrifuged for 2 min as before. The 
pellet contains most of the chromosomal DNA, SDS-protein complexes and 
cellular debris. The supernatant which contains the plasmid DNA was 
removed to a fresh tube and precipitated with 0.9 ml of absolute ethanol. This 
was then centrifuged again for 2 min to pellet the plasmid DNA, washed in 
70% ethanol and allowed to dry before being resuspended in 30 p.1 of TE (10 
mM Tris.Cl pH 8.0, 1 mM EDTA, pH 8.0), containing 20p,g/ml of RNAase A. 
3p,l of the resulting solution was cut with the appropriate restriction enzymes 
to release the cloned insert from the plasmid. The sizes of the cut vector and 
insert were then verified by agarose gel electrophoresis.
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2.11 Large scale preparation of plasm id D N A  from E. co li
A 2 1 flask with 400ml of LB medium containing 100|ig/ml Ampicillin 
was inoculated with 1 ml of a fresh overnight culture of E.coli containing the 
plasmid of interest. The culture was incubated overnight at 37°C with 
vigorous shaking (250 rpm). The cells were harvested by centrifugation for 10 
minutes at 9Krpm in a JAIO rotor in a J2-21 centrifuge. The pellet was 
resuspended in 10 ml of DISH-1 (50 mM glucose, 25 mM Tris pH 8 and 10 mM 
EDTA). To this 30 ml of freshly prepared TENS (10 mM Tris pH 8, 1 mM 
EDTA, 0.5% SDS and O.IM NaOH),was added and mixed in by swirling. 15 ml 
of 3M Na acetate pH 5.2 was then added to the above mixture to precipitate the 
denatured protein and chromosomal DNA. The mixture was centrifuged again 
as previously and the supernatant containing the plasmid was poured off 
carefully through a sterile gauze into a clean 250 ml centrifuge tube and 
precipitated with 90 ml of absolute ethanol. The precipitated plasmid was then 
pelleted by centrifugation at 9Krpm for 10 min in the JA-10 rotor. The 
supemateint was discarded and the pellet was drained by inverting the bottle 
on tissues for 10 min. After this exactly 8 ml of TE (10 mM Tris.Cl pH 8.0,1  
mM EDTA, pH 8.0), was added to dissolve the pellet. CsCl/ethidium bromide 
density gradient purification allows separation of the plasmid DNA from the 
contaminant chromosomal DNA due to their different capacities to bind the 
interclating agent ethidium bromide which reduces the density of the DNA. 
Plasmid DNA binds less and is therefore more dense, appearing as the lower 
band after CsCl gradient centrifugation: Exactly 8 g of the dissolved DNA  
solution was added to 8.4 g of CsCl in a plastic universal and vortexed briefly
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to dissolve the CsCl. 0.4 ml of ethidium bromide solution (10 m g/m l) was then 
added to the universal and mixed. The resultant DN A / CsCl/ ethidium  
bromide solution was then divided between two vTi tubes placed in the vTi90
rotor and centrifuged at 70Krpm overnight at 25^C. After separation of the 
DNA on the CsCl gradient the band corresponding to the plasmid DNA was 
removed using a 1 ml syringe and a 19 g needle. The plasmid solution was 
then transferred to a 15 ml tube (Falcon) and the ethidium bromide was 
extracted sequentially with CsCl-saturated isopropanol until the solution was 
completely colourless. The plasmid DNA was then precipitated by the. addition 
of 2 volumes of water and 7 volumes of absolute ethanol and the DNA  
harvested by centrifugation at 4Krpm for 15 min in a JA-20 rotor. After this the 
DNA was washed in 70% ethanol, dried and resuspended in 1 ml TE (10 mM
Tris.Cl pH 8.0,1 mM EDTA, pH 8.0) and stored at -20°C.
2.12 Ligation of plasm id D N A
Ligations were carried out using 50ng of vector and -500ng of insert 
DNA (unless otherwise indicated), which had previously been purified using 
the GeneClean kit (BIO 101). 1 unit of T4 DNA ligase and 1 pi of ligase buffer, 
was added to the DNA for ligation to a total volume of lOpl. For sticky end 
ligations, reactions were incubated at 16®C for 16 hours. Ligation reactions 
were then transformed into competent bacteria as described. A control ligation 
and vector only control for transformation were always included.
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2.13 Preparation of oligonucleotides
These were all made at ICRF Oligonucleotide Service (Clare Hall, UK). 
On receipt, the dried oligonucleotides were precipitated by addition of 20pi of 
3 M Na acetate, ISOpl of distilled H2 0 , 2\û of 1 M MgCl2 and 600^1 of absolute 
ethcinol with incubation on ice for 10 min. The mixture was then centrifuged at 
14Krpm for 10 min in a benchtop centrifuge 5415C (Eppendorf) and the 
precipitate was resuspended in 1ml of sterile water resulting in a final 
concentration of ~40[iM.
2.14 D N A  Sequencing
This was performed on an ABI PRISM 377 DNA sequencer. The 
template sequence to be analysed was first amplified using the ABI Prism Dye 
Terminator Cycle Sequencing Core Kit w ith fluorescent-tagged  
deoxynucleotides which block the progression of the Amplitaq DNA  
polymerase (Perkin- Elmer). Manufacturers instructions were followed. The 
sequence was analysed using Sequence Navigator (ABI Prism) and Sequencher 
(Gene Codes Inc.), software.
2.15 Preparation of w hole cell extracts for W estern blotting
Cells growing in tissue culture were washed once with phosphate 
buffered saline (PBS ), (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HP0 4 -7H2 0 ,
1.4 mM KH2PO4, pH 7.3) and removed from the tissue culture plate using PBS 
with 2.5mM EDTA. Cell number was determined using a haemocytometer and 
approximately 1-5 xlO& ceUs were lysed in 200|il 2X SDS buffer (60mM Tris-
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HCl, pH 6 .8, 1% (w /v) SDS, 5% (v/v) glycerol, 0.001% (w /v) Bromophenol 
Blue and 1% (v /v ) 2-mercaptoethanol). Chromosomal DNA was sheared by 
passing the extract through a 25-G needle 3 times and the sample was boiled 
for 5 minutes before storage at -20°C.
2.16 Protein gel electrophoresis
Single dimensional separation of proteins by polyacrylamide gel 
electrophoresis was always performed under denaturing and reducing 
conditions ie in the presence of SDS and 2-mercaptoethanol, using the 
discontinous buffer system  of Laemmli (Laemmli, 1970). Prior to 
electrophoresis, cell lysates or protein samples were boiled for 3 minutes in 2X 
SDS sample buffer (60mM Tris-HCl, pH 6 .8,1% (w /v) SDS, 5% (v/v) glycerol, 
0.001% (w /v) Bromophenol Blue and 1% (v/v) 2-mercaptoethanol). Gels were 
made up using an acrylamide/bisacrylamide (37.5:1) solution (Boehringer 
Mannheim), in the presence of a catalyst (10% Ammonium persulphate and 
TEMED (N,N,N',N'-tetramethylethylenediamine). The resolving gels were 
prepared in 375mM Tris-HCl, pH 8 .8, 0.1% (w /v) SDS, while the stacking gels 
(6% polyacrylamide) were prepared with a buffer containing 125mM Tris-HCl, 
pH 6 .8, 0.1% (w /v) SDS. The electrophoresis running buffer contained 190mM 
glycine, 25mM Tris and 0.1% (w /v) SDS. For analysis of ATM and BLM, 
samples were resolved by SDS-PAGE on 7.5% gels. Recombinant fragments of
ATM, BLM and p-tubulin were resolved on 13% gels.
Unless otherwise stated all SDS-polyacrylamide gels were prepared on 
the BIORAD miniprotean vertical gel electrophoresis apparatus (Hoefer). A
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large format gel apparatus was used with 7.5% gels when resolution of high 
molecular weight and lower molecular weight proteins was required from the 
same sample.
For detection of unlabelled proteins following electrophoresis, gels were 
stained with 0.1% (w /v) Coomassie Blue in 10% acetic acid and 50% methanol. 
Gels were destained by washing in 10% acetic acid, 10 % methanol. Samples 
were compared against molecular weight standards. Coomassie Blue stained 
gels were then dried onto Whatman 3MM paper using a Hoefer slab gel dryer, 
model SE1160.
For detection of ^^P-labelled proteins after drying as described, gels
were exposed to X-Ray film (Kodak X-OMAT AR) at -70°C in a cassette with 
intensifying screens for autoradiography.
If required, transfer of proteins to Immobilon-P membrane (Millipore) 
for Western blotting was achieved using the semi-dry technique. The 
membrane was pre-wetted in 100% methanol and then placed in the transfer 
buffer containing 10% (v/v) methanol and ImM CAPS (3-[cyclohexylamine]-l- 
propane sulphonic add) in deionised water (Milli-Q). The membrane was then 
laid onto the gel, taking care to exclude any air bubbles and 2 pieces of 3MM 
Whatman blotting paper, pre-soaked in transfer buffer, were placed on both 
sides. This sandwich was then placed into the Semi-Phor transfer tank (Hoefer) 
with the gel side uppermost, before being electrophoresed at 9V for 45 
minutes.
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2.17 Western blotting
This was performed according to the method given in (Ausubel et al.,
1997). Samples were electrophoresed on polyacrylamide gels and semi-dry 
protein transfer was performed as described. The membrane was incubated in 
a blocking solution of PBS containing 5% Marvel dried milk powder (MDMP) 
for 1 hour. The appropriate primary antibody was then added to PBS/0.3% 
(v /v ) Tween-20, 5% MDMP to the appropriate dilution and spotted on the
membrane for incubation for 1 hour at room temperature or overnight at 4 ^0 . 
The membrane was then washed for 10 minutes x3 in PBS/0.3% (v/v) Tween- 
20 and then incubated for 1 hour with the appropriate secondary HRP- 
conjugated antibody. The membrane was then washed for 10 minutes x3 with 
PBS containing 0.3% (v/v) Tween-20. Detection of HRP-labelled conjugates 
was achieved using ECL Western blotting detection reagents (Amersham Life 
Science). The interaction of peroxidase with luminol and an enhancer in the 
supplied developing solutions causes the emission of light which can be 
detected using Kodak Scientific Imaging Film X-OMAT AR (Kodak).
2 1 8  M ammalian cell culture 
Cell lines, culture conditions and m edia
HeLa-S3 cells, (a non A-T cell line), SV40-transformed human cervical 
carcinoma cell line, 2% RPMI medium, 15% FCS.
GM4724 (ATM+/+), human lymphoblastoid cells, 2% RPMI medium, 15% 
FCS.
GM2782a (ATM-/-), human lymphoblastoid cells, 2% RPMI medium, 15% FCS.
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AT5BIVA (ATM -/-), SV40-transformed human AT5BI fibroblasts, alpha 
medium, 20% FCS.
AT2RO (ATM-/-), human fibroblasts, not cultured. Cell lysates were donated 
by Dr M. James.
GM8505 (BLM -/-), human fibroblasts, alpha medium, 20% FCS.
MRC5, a wild type human fibroblast line, alpha medium, 20% FCS.
NCI-H1299 cells (p53 null), a human non-small cell lung carcinoma line, 2% 
RPMI medium, 10% FCS.
Human peripheral blood lymphocytes. 2% RPMI medium, 15% FCS.
(3 mM L-glutamine was added to all media prior to use and cells were cultured
at 37®C in an atmosphere of 5% CO2).
2.19 Preparation of phage D N A
Multiple attempts to isolate the A T M  cDNA by PCR and by 
hybidization from several different human libraries proved unsuccessful and
are not discussed here. A source of the AT7.9 clone in X.CEV-29 was gratefully
received as a gift from Professor Y. Shiloh (Tel Aviv University). Amplification 
of the phage containing the insert was achieved by culture of the phage in host 
LE392 bacteria using a phage plate lysate protocol: A single colony of LE392 
was inoculated into 3 ml of TB medium containing 5g N aC l/L , lOg 
bactotryptone/L, lOmM MgS04 and lOmM maltose and incubated overnight
at 37°C in a shaking incubator. To 0.5ml of the overnight LE392 culture, 2- 
3x10^ c.f.u. of phage were added and incubated at 370C for 15 minutes. 15 ml 
of TOP agarose containing 0.7% agarose in NZY broth (5g NaCl, 2g
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M gS04 H 20, 5g yeast extract, lOg NZ amine (casein hydrolysate)/!), was 
added to the culture, gently mixed and poured onto the top of NZY/agarose
plates and incubated at 39^0 for exactly 8 hours for optimum bacterial 
growth and phage induced bacterial lysis. After this time had elapsed, each 
plate was overlayed with 10ml of phage buffer containing 5.8g NaCl, 2g 
M gS04 H2O, 50ml IM Tris-HCl, pH 7.5, 5ml 2% gelatin/L and 0.5ml of 
chloroform and allowed to elute the phage with gentle shaking overnight at 
room temperature. The following day, the eluate was collected from the plates 
and purification of the phage DNA was achieved using a Lamda DNA  
purification WIZARD kit (Promega) follow ing the manufacturers
instructions.The purified AT7-9 clone insert in the X.CEV-29 DNA was digested
with the restriction enzyme Sail to obtain the AT7-9 insert which was 
originally cloned into the phage Sail site (Fig. 2.1 ).
2.20 F low  cytometry
Cells were harvested and fixed for 30 minutes in ice cold 70% 
ethanol/30% PBS, collected by centrifugation and treated with RNAase A
(100p.g/ml final concentration) and propidium iodide (40|LLg/ml ) in PBS for 30
minutes at 37°C. Cell cycle distribution was then determined using a FACScan 
(Becton-Dickinson) and Lysis II software with the assistance of Dr Chris 
Norbury.
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  Undigested phage DNA
  Phage long armTlS kb)
_  Phage short arm(8.9 kb)
AT7-9 fragment (~6 kb)
Fig. 2.1
Treatment of a preparation of X.CEV-29 DNA with the restriction enzyme Sail 
releases the AI7-9 clone.
2.21 Subcellular fractionation protocol
The protocol followed for analysis of the subcellular localisation of ATM
and BLM proteins was modified from (Watters et al., 1997). 2 x 10^ HeLa cells 
or GM8505 cells were obtained as pellets on dry ice from ICRF Cell Services 
(Clare Hall, UK). These were resuspended in 2ml ice-cold homogenisation 
buffer ( 25 mM HEPES, 0.25 M sucrose, 1 mM EGTA, 5 MM M gS04, 50 mM 
NaF, 1 mM DTT). N.B. All solutions used also contained a cocktail of serine 
and cysteine protease inhibitors (Boehringer Mannheim) together with the 
aspartic protease inhibitor pepstatin. The cell suspension was then 
homogenised for 50 strokes in a type A Bounce Homogeniser, placed in a 15ml 
Falcon tube and centrifuged at 3000 rpm in a Beckman GPR centrifuge for 15 
min to pellet the nuclei.
The supernatant was carefully pipetted off, placed in 11 x 34 
polyaUomer tubes (Beckman) and centrifuged in a TLA-100 rotor at 58,000 rpm 
for 40 min to pellet the microsomal fraction, leaving the cytosolic extract as the 
supernatant. The microsomal pellet was resuspended in lOOpl of 2x protein 
sample buffer. The cytosolic extract was resuspended in an equal volume of 2x 
protein sample buffer.
The nuclear pellet was lysed in 500 i^l of lysis buffer (50 mM Tris-HCl, 
150 mM NaCl, 2 mM EGTA, 2 mM EDTA, 25 mM NaF, 25 mM fi- 
glycerophosphate, 0.1 mM sodium vanadate, 0.2% Triton X-100, 0.3% NP-40 
including protease inhibitors as described). After incubation on ice for 30 min, 
the debris was removed by centrifugation at 16,000 rpm for 15 min in a JA-20
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rotor, yielding the nuclear extract as supernatant. The nuclear extract was 
resuspended in an equal volume of 2x protein sample buffer. All extracts in
sample buffer were then boiled for 3 min, sheared and stored at -ZO^C until 
required. 25fig of protein was loaded per track for analysis by Western blot.
2.22 Protein im m unoprécipitation from nuclear isolates
Nuclear isolates were obtained from batches of 2 x 10  ^HeLa cells 
received from Cell Production Clare Hall, ICRF, using a gentler protocol (KroU 
and Rowe, 1991). The cell pellet from each batch was washed once m ice-cold 
PBS and then resuspended in 3.6 ml of nuclear isolation buffer (30 mM Tris- 
HCl pH 7.5, 1.5 mM MgCl2 , 10 mM KCl, 20% v /v  glycerol together with a
protease inhibitor cocktail and the phosphatase inhibitors, ImM P-
glycerophosphate and 1 mM sodium vanadate. The plasma membrane of the 
cells was lysed by adding 400|il of 10% Triton X-100, briefly vortexing and 
incubating the lysate on ice for 5 min. After centrifuging at 1000 rpm (Beckman 
GPR centrifuge), for 90 s the supernatant was pipetted off and the nuclear 
pellet was resuspended in 3.6 ml of nuclear isolation buffer ( 30 mM Tris-HCl,
1.5 mM MgCl2, 10 mM KCl, 20% v /v  glycerol with protease and phosphatase 
inhibitors and 0.35 M NaCl to elute the nuclear proteins). After a 30 min 
incubation on ice, the eluate was centrifuged at 12,000 rpm (JA-20 rotor), to 
eliminate the debris. The resultant supernatant was then divided for use m 
subsequent immunoprécipitations:
Pre-clearing of nuclear extracts was achieved by incubating the extracts 
with pre-swollen protein A-Sepharose beads (Sigma) on a rocker for 60 min at
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4°C. After this time the beads and non-specifically bound proteins were 
pelleted by centrifuging at 10,000 rpm for 10 seconds (Eppendorf centrifuge 
5415C), and the supernatant (ie the pre-cleared extract), was taken for further 
use.
The pre-cleared extract was added to an equal volum e of 
immunoprécipitation buffer (100 mM Tris-HCl pH 8.0, 500 mM NaCl, 0.75% 
v /v  Triton X-100,10 mM EDTA, 0.02% (w /v) NaNg, and protease inhibitors as 
described. The required immunopredpitating antibody was then added to the 
extracts at the appropriate dilution.
The antibody and extract were incubated at 4°C for 1 hour on a rotating 
wheel prior to addition of 50pl of preswelled protein-A-Sepharose beads. The 
mixture was then incubated for a further 1 hour under the same conditions to 
allow binding of the beads to the antibody with the predpitated protein. After 
this time the beads were pelleted as previously and washed ttiree times with 
immunoprécipitation buffer containing 0.1% SDS, prior to a final wash of 10 
mM Tris-HCl pH 7.5. The beads w ith attached antibody and 
immunoprecipitated protein were then ready for Western analysis or in the 
case of ATM for use in the autophosphorylation, p53 peptide or PHAS-I ATM 
kinase assays. Western analysis simply required boiling of the pelleted beads 
in 30 |il of 2X SDS sample buffer for 5 minutes before loading onto a protein 
gel.
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Chapter 3
Production and Characterisation of Antibodies 
versus ATM and BLM Proteins
3.1 Introduction
Antibodies are potentially very powerful investigative tools which can 
be used for many biological studies including definition of the sub-cellular 
localisation, the cell cycle distribution, the tissue specific or tumour related 
expression and the biochemical actions and interactions of the protein of 
interest. When a novel gene is described therefore, much of the initial effort is 
directed toward raising antibodies against the gene product.
Polyclonal antibodies can in theory be raised against any immunogenic 
protein. At the outset of this thesis, no commercial antibodies against ATM or 
BLM were available and strategies for the expression of full-length epitope 
tagged cDNAs were still being planned. As no source of full length ATM was 
available for use as an immunogen, ATM peptides were designed and 
recombinant partial ATM constructs were expressed with the aim of 
presenting these as immunogens in rabbits for the development of polyclonal 
anti-ATM antisera. Whilst polyclonal antibodies with their range of epitope 
specificities are particularly useful for some purposes eg. immunoprécipitation, 
their source is finite. Development of hybridomas as a source of monoclonal 
antibodies with single epitope specificity is potentially the most useful for 
investigations in the long term as the supply of monoclonals is theoretically 
infinite.
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3.2 Additional materials and methods
3.2.1 Production of anti-ATM antibodies
Several different recombinant ATM fragments were sent for rabbit 
immunisation. These included:
A) 4 biochemically synthesized ATM peptides designed by myself and made 
by the Peptide Synthesis Laboratory, Lincoln's Inn Fields, ICRF. These were 
conjugated to Keyhole Limpet Haemocyanin (Sigma) as a carrier molecule to 
improve the immunological response to the peptide.
B) Two recombinant ATM proteins were generated from plasmids pQE-32 
strains 1 and 2, received as a generous gift from A. Sutcliffe (Birmingham CRC 
unit). These comprised ATM protein sequence from amino acids 288-524 
(strain 1) and from amino acids 992-1144 (strain 2). The proteins expressed 
from both of these strains proved to be considerably insoluble and primarily 
present in the cell pellet. Therefore both proteins had to be sent in the form of 
purified inclusion bodies and they were also sent in the form of an acrylamide 
gel slurry derived from unstained protein gels from which the appropriate 
band was dissected. The production of these is described below:
A) ATM peptide production and KLH conjugation
A variety of ATM peptides were designed and entered into the SHARQ 
database (Alex Whittaker, Lincoln's Inn Fields, ICRF) to identify similarities 
with known proteins. Those without any marked similarities with known 
proteins were then used as potential immunogens for anti-ATM antibody 
production.
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These comprised ATM protein sequence
Peptide 1: VDIMRASQDNPC (amino add  1629-1639) 
Peptide 2: PRFDKENPFEGC (amino add 1778-1789) 
Peptide 3: ERKKEVEKFKRLIRC (amino ad d  22-45) 
Peptide 4: EVESMEDDTNGNLMEVEC (amino add  834-850)
(the carboxyterminal cysteine residues are added for coupling of the peptide 
via sulphydryl groups).
Each peptide was resuspended in distilled water to a concentration of 
Im g/m l. The carrier protein Keyhole Limpet Haemocyanin (Sigma 
Immunochemicals) was dissolved in PBS to a concentration of lOmg/ml and 
the coupling agent MBS (m-maleimidobenzoyl-N-hydroxysuccinimide ester), 
(ICN biomedicals Inc.) was dissolved in dimethylformamide to a final 
concentration of 25mg/ml. lOOpl of this MBS solution was added to 1ml of 
KLH (lOmg/ml), mixed and allowed to incubate at room temperature for 1 
hour. The KLH-MBS was then desalted using the technique of FPLC (fast 
protein liquid chromatography), on a 10ml Sephadex G25 column: Firstly the 
column and the coil were washed with 0.1 M phosphate buffer pH 6.0, then 
1ml of the KLH-MBS solution was injected. The elution of protein was 
determined by A28O and eluted fractions were collected in glass tubes. The 
KLH-MBS caused an initial sharp peak of absorbancy. A second broader peak 
was due to the MBS/dmf which absorbs significantly at ~280nm.
After desalting, 300pl of the peptide of interest (Im g/m l) was added to 
1ml of the KLH-MBS conjugate and incubated at room temperature overnight 
on a rotating wheel. The following day the peptide-KLH conjugate was
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desalted on a 10ml Sephadex G25 column by FPLC as described above. The 
concentration of the peptide conjugate was then estimated using the BCA 
assay (Pierce) against bovine serum albumin standards at A562 nm, according 
to the manufacturer's instructions.
The suggested dose of antigen to be used per injection in the rabbit 
immunisation schedule was 50-1000|Lig. 100 |ig per injection was sent to ICRF 
Biological Resources (Clare Hall), for rabbit immunisation.
B) Overexpression and purification of recombinant fragments of 
ATM protein from E, coli
After failure of expression of ATM fragments cloned into several 
different vectors (pET-14b, Bluescript, pMal, pCR-Script), stab cultures of E. 
coli M15 (Qiagen) containing the pQE-32 vector with a recombinant ATM  
insert were gratefully received from A. Sutcliffe (Birmingham CRC unit). The 
recombinant ATM  fragments were (His)6-tagged and cloned into the BamHl 
site of the vector. Two strains were sent including strain 1: ATM  bp 866-1573 
and strain 2: ATM  bp 2976-3434. These strains have been also been used to 
generate the polyclonal antibodies FP14 and FP-8 respectively (Stankovic et al., 
1998).
Expression of the ATM  fragments was achieved using the following 
method: Each M15 culture was streaked out on agar plates containing 100
jig/Ampidllin and 50 |ig Kanamycin/ml. After overnight incubation at 37°C, a
single colony from each M15 strain was picked, inoculated into 3 ml of LB
25 -
containing 100 pg Ampidllin and 50 |ig Kanamycin/ml and incubated in the
shaking incubator at 37°C overnight.
The next day, 0.5 ml of miniculture was inoculated into 20 ml of 
prewarmed LB/Amp/Kana (100 jig/Am pidllin and 50 \Lg Kanamycin/ml)
and incubated in the shaking incubator at 37°C until the ODeoo reached 0.6 
after which pre-induction samples were taken. 200 |il of culture was pelleted 
by centrifugation and resuspended in 40 pi of 2X protein sample buffer and 
recombinant ATM  fragment expression was induced by addition of 2 mM
isopropyl-P-D-thiogalactopyranoside (IPTG) for 2 hours at 370C. Post­
induction samples were taken after 2 hours and were subjected to SDS-PAGE 
on 13% gels, along with pre-induction samples (25 pi of each sample was used 
with a ratio of post/pre induction culture amounts of 1 /4  to account for 
bacterial growth). The gels were then stained with Coomassie Blue and 
destaining revealed successful induction of both recombinant ATM proteins, 
strain 1 (-30 kDa, expeded size 26 kDa) and strain 2 (21 kDa, expected size 17 
kDa, Fig. 3a). Larger scale inductions were then prepared: For each strain, two 
21 flasks each containing 400 ml of pre-warmed LB/Am p/K ana were
inoculated with 4ml of an overnight miniculture and incubated at 37°C in a 
shaking incubator until the OI^oo reached 0.6. Pre-induction samples were 
then taken as before and ATM fragment expression was then induced by the
addition of IPTG (2 mM) with incubation for a further 2 hours at 37°C. Post­
induction samples were taken at this point (SDS-PAGE was duly performed at 
a later time, as before to check protein induction). The flasks were then placed 
on ice for 10 min prior to transfer of the cultures to eight 50 ml tubes (Falcon)
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21 kDa
Fig. 3a
Induction of a 21 kDa recombinant ATM protein in pQE-32 (strain 
2) whole bacterial lysate. Whole bacterial lysates were made from 
pre and post induction cultures of pQE-32 (strain2) with induction 
conditions of 2 mM IPTG at 37 C for 2hr. 20 pi of each lysate (post 
induction samples were diluted 1:4 to ensure equal protein 
loading) was then subjected to SDS-PAGE and stained with 
Coomassie Blue.
21 kDa
Fig. 3b
The 21 kDa recombinant ATM protein induced in pQE-32 ( strain 
2) is insoluble and predominantly seen in the cell pellet. Whole 
bacterial lysates were made from pre and post induction cultures of 
pQE-32 (strain 2) with induction conditions of 2 mM IPTG at 37 C 
for 2hr. 20 pi of each lysate, the lysate supernatant and cell pellet 
were then subjected to SDS-PAGE and stained with Coomassie 
Blue. (Post induction samples were diluted 1:4 to ensure equal 
protein loading).
and centrifugation at 4.2 krpm (in a Beckman GPR centrifuge) for 5 min at 4°C 
to pellet the cells. The supernatant was then discarded and the equivalent of 
200 ml of culture was resuspended in 4 ml of ice cold binding buffer (5 mM 
imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). The cells were then sonicated 
( Soniprep 150, MSB), to lyse them and shear the DNA, in 30s bursts on ice 
until the viscosity fell. The lysate was then centrifuged in a pre-cooled SW-55ti 
rotor at 39 krpm for 20 min at 4°C.
A His-Bind metal chelation column was then prepared in the cold room 
using 4ml of His-Bind resin (Novagen) which settles to a 2 ml column. The 
column was then washed with 6 ml of sterile distilled water, then 10 ml of 
charge buffer (400 mM NiS04), followed by 6 ml of binding buffer. The 
supernatant from the bacterial extract was then loaded onto the column. After 
this the column was again washed with 25 ml binding buffer followed by 15 ml 
of wash buffer (60 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). The 
expressed His-tagged protein was then eluted with elution buffer (1 mM 
imidazole, 0.5 M NaCl, 20 mM Tris-HCl pH 7.9), and collected in 1 ml 
fractions. Pre and post induction whole lysates and post induction supernatant 
samples were subjected to SDS-PAGE on a 13% gel, alongside each of the 
eluted fractions (50 pi of each fraction was mixed with 50 p,l of 2X protein 
sample buffer and 25 p,l of each sample was run). The gel was then stained 
with Coomassie Blue and destained in 10% methanol, 10% acetic acid, before 
gel drying.
Very little of either protein was found to be present in the supernatant 
and the eluates from the His-Bind columns. Both proteins were found to be 
predominantly insoluble and were largely present in the cell pellet after
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induction (for strain 2 see Fig. 3b). Only small amounts of recombinant protein 
were extractable from the cell pellet using 0.25% Tween 20/ 0.1 mM EGTA 
which can help to extract proteins loosely associated with cell membranes. 
Therefore, further purification of the proteins was achieved by isolating the 
inclusion bodies (insoluble protein aggregates), from post-induction cell pellets
stored at -7CPC: Each pellet was resuspended in 5 ml of freshly made lysis 
buffer ( 25% sucrose, 50 mM Tris-HCl pH 8 ,2  mM EDTA, 2 mM EGTA, 2 mM 
dithiothreitol, 0.5 mM Phenylmethyl-sulphonyl fluoride (PMSF, a serine 
protease inhibitor), and 10 p-g/ml each of L-l-Chloro-3-[4-tosylamido]-7- 
amino-2-heptanone-HCl (TLCK.HCl, a trypsin, serine and cysteine protease
inhibitor) and N-a-p-tosyl-L-arginine methyl ester (TAME.HC1 an inhibitor of
trypsin and other proteases). 5 m g/m l of lysozyme was admixed and the lysate 
was incubated on ice for 15 min after which MgCl2 (to 10 mM) and DNAase I 
(50 ng/m l) were added. Following reincubation on ice for 15 min, the lysate 
was mixed with 2 volumes of inclusion body preparation solution (200 mM 
NaCl, 1% Na deoxycholate, 1.6% NP-40,2 mM EDTA, 20 mM Tris-HCl pH 7.5) 
and centrifuged at 20Krpm in a JA-20 rotor for 20 min. The lysis supernatant 
was then decanted and the pellet was washed three times by resuspension in 
25 ml of 0.5% Triton X-100 with 0.1 mM EDTA prior to recentrifugation at 
20Krpm in a JA-20 rotor for 10 min. The inclusion bodies were resuspended in 
1 ml of PBS. In order to determine whether inclusion bodies containing 
recombinant ATM fragments had been purified from the pellet, 1/50 of the 
final preparation was mixed with 40 |l i 1 of 2X sample buffer, boiled for 5 min 
and 20 p.1 was resolved on a 13% protein gel (Fig. 3c).
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21 kDa
Fig. 3c
The 21 kDa ATM recombinant protein from pQE-32 (strain 2) 
can be partially purified by isolating inclusion bodies from the 
cell pellet. Equivalent amounts (20 pi) of a whole cell lysate 
and an inclusion body preparation from an induced culture of 
pQE-32 (strain 2 ) , (induction conditions of 2 mM IPTG, 37 C for 
2hr) were subjected to SDS-PAGE. Proteins were detected by 
staining the gel with Coomassie Blue.
Ig —
Heavy chain
Bovine serum 
albumin
Fig. 3d
Titration of affinity purified CN-12 antibody against BSA standards. 
(8pl of antibody is equivalent to 2pg of protein). Aliquots of affinity 
purified polyclonal antibody CN-12 in sample buffer were 
subjected to SDS-PAGE alongside bovine serum albumin standards. 
Proteins were detected by staining the gel with Coomassie Blue.
Gel purification of the insoluble proteins was also performed by 
resuspending the induced cell pellet in 2X SDS sample buffer, boiling for 5 min 
and shearing the DNA by forcing the sample through decreasing needle 
gauges using a 1 ml syringe.
For each protein sample a large format 13% polyacrylamide gel was 
prepared with a single large well and two smaller wells at the edge. The large 
wells were loaded with 1 ml of induced pellet lysate for each pQE-32 strain. 
The gel was run at 4W for sufficient time to allow adequate separation of the 
recombinant proteins. After this time a thin horizontal strip of gel was cut 1cm 
above and below the predicted position of the induced protein of interest. This 
gel strip was then sheared by forcing it through needles of decreasing gauges 
using a firmly held 1 ml syringe to produce an acrylamide gel slurry enriched 
for the protein of interest (~lm g protein/ml of slurry). It is possible to use such 
slurries for direct injection of rabbits as the procedure is well tolerated and the 
acrylamide acts as an immunological adjuvant.
3.2.2 Rabbit immunisation
This was performed by Biological Resources at Clare Hall, ICRF using 
their standard rabbit immunisation protocol. The pre-bleeds, test bleeds and 
final bleeds were sent to this laboratory frozen on dry ice.
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3.2.3 BLM antibody production and purification
As a continuation of work performed by Christine Addison in the 
laboratory I was given the anti-BLM rabbit polyclonal antibody IHIC-27 to 
affinity purify. IHIC-27 was raised against an amino-terminal recombinant 
BLM fragment (amino acid residues 300-500) fused to maltose binding protein 
(BLM-MBP).
Due to the lack of purified recombinant BLM, affinity purification of 
IHIC-27 was carried out by affinity chromatography in two steps: firstly 
maltose binding protein specific antibodies from the crude serum IHIC-27 
were removed by adsorption on an affinity column to which MBP was bound. 
Secondly the BLM specific fraction from the eluate of the first column was 
obtained by adsorption onto an affinity column to which the fusion protein 
BLM-MBP was bound.
To prepare the first column, 2mg of MBP was coupled to cyanogen 
bromide-activated sepharose beads 4B (Sigma). (Sepharose is a bead formed 
agarose gel and when activated by CNBr which binds to the hydroxyl groups 
of sepharose, ligands containing primary amino groups react with the cyanate 
ester groups to form isourea linkages to the gel). To form the sepharose gel the 
beads were initially swelled (Ig of freeze dried beads swell to a gel volume of 
-3.5 ml), and washed in 200m l/g of ImM ice cold HCl. (HCL preserves the 
activity of the reactive groups which hydrolyze at high pH). The final aliquot 
of HCL was removed until cracks appeared in the gel. 5mg of MBP was then 
dissolved in 2ml of coupling buffer (NaHCOg 0.1 M, pH 8.3, NaCl 0.5 M ), and
rocked gently with 1 ml of gel overnight at 4°C. After this time the coupled 
slurry was then transferred to the column. The remaining active groups were
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then blocked by amino residues provided by exposing the column to an excess 
of 0.2 M glycine pH 8.0 for 2 hours. Excess adsorbed protein was then washed 
away with 4 rounds of alternate washes with acetate buffer (Na acetate O.IM, 
NaCl 0.5 M) and coupling buffer. The column was then cleared of blocking 
agent by another wash with coupling buffer. The column was then prepared 
for the serum by washing in turn with: 1) 10 ml of 10 mM Tris pH 7.5,2) 10 ml 
of 100 mM glycine pH 2.5, 3) 10 ml of 10 mM Tris pH 8.8, after which the 
column pH was checked and then 4) 10 ml of freshly made triethylamine pH 
11.5, and 5) 10 mM Tris pH 7.5 until the pH reached 7.5. The serum was then 
diluted 1:10 with 10 mM Tris pH 7.5 prior to loading (10 ml of IHIC-27 were 
loaded in 100 ml of the above). The antibody solution was then passed over the 
column three times to ensure binding to the MBP. The final flow through was 
collected as it contained IHIC-27 depleted for MBP specific antibodies and this 
was used to load onto the second column. 2 mg of BLM-MBP fusion protein 
was bound to the second column using the method described above. After the 
second column had been washed as described the flow through from the first 
column was loaded onto the BLM-MBP column and reloaded twice to ensure 
binding of remaining BLM specific antibodies to the fusion protein. The 
column was then washed with 20 ml of 10 mM Tris pH 7.5 followed by 20 ml 
of 500 mM NaCl, 10 mM Tris pH 7.5.
Acid-sensitive anti-BLM antibodies were then eluted with 2.5 ml of 100 
mM glycine pH 2.5. The column eluate was collected in 0.5 ml fractions into 
separate tubes containing 0.5 ml of 1 M Tris pH 8.0 to neutralise the solution. 
The column was then washed in 10 mM Tris pH 8.8 until the pH reached 8.8. 
Base-sensitive antibodies were then eluted using 2.5 ml of freshly prepared
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triethylamine pH 11.5. The column eluate was collected in 0.5 ml fractions into 
separate tubes containing 0.5 ml of 1 M Tris pH 8.0 to neutralise the solution. 
The column was then washed in 10 mM Tris pH 7.5 until the pH was 7.5 and
then the column was stored at 4°C. The amount of protein in the various 
fractions was then checked against the buffers they were collected into by 
measuring the A280-
3.2.4 Testing of polyclonal rabbit sera raised against ATM
The pre-bleed, test bleeds and final bleed of each immunized rabbit 
(Table 3.1), were screened for their ability to detect a -350kDa ATM band by 
Western blotting against a series of positive and negative (ataxia-telangiectasia 
cell line AT2RO) control human cell line lysates .
The crude serum was used as the primary antibody (at a dilution of 
1/500) and the secondary layer was a peroxidase conjugated anti-rabbit 
antibody (Sigma Immunochemicals), also used at a dilution of 1/500. Western 
blotting was performed as described earlier. Although sera from all the rabbits 
CN-3-CN12 were tested, only rabbit CN-12 showed a protein band of of -350 
kDa (the correct size for ATM). Data for the other rabbits are not shown as the 
blots had very high background.
3.2.5 Affinity purification of CN-12 by Western blotting
A large format 13% polyacrylamide gel was prepared with a single large 
well and two smaller wells at the edge. The large well was loaded with 1 ml of 
induced whole cell lysate of bacteria expressing pQE-32 strain 2 (ie the portion
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Antibody Immunogen
CN-3 ATM peptide 1
CN-4 ATM peptide 2
CN-5 ATIvI peptide 3
CN-6 ATN^ I peptide 3
CN-7 ATM peptide 4
CN-8 . ATN^ I peptide 4
CN-9 Inclusion bodies of recombinant ATM 
polypeptide (aa 288-524)
CN-10 Gel slurry containing recombinant 
A l^I polypeptide (aa 288-524)
CN-11 Inclusion bodies of recombinant ATM 
polypeptide (aa 992-1,144)
CN-12 Gel slurry containing recombinant 
ATM polypeptide (aa 992-1,144)
Table 3.1
Description of inunune sera raised against ATM with details of the 
immunogens used.
of the ATM protein to which CN-12 antibody was originally raised). The gel 
was run at 4W for sufficient time to allow adequate separation of the 
recombinant portion of ATM which runs at 21kDa alongside the 21kDa protein 
size marker. After this time a thin horizontal strip of gel w as cut, 1cm above 
and below the 21kDa markers and the recombinant ATM protein was 
transferred from this to Immobilon-P membrane using the semi-dry method as 
described previously.
The membrane was then incubated in blocking buffer (PBS containing 
0.1% Tween and 5% Marvel low fat milk), for 1 hour. The membrane was then 
removed and transferred to a 50 ml Falcon tube to which was added 2 ml of 
blocking solution and 2 ml of crude CN-12 serum. This was then incubated
overnight at 4°C on a rotating wheel. The following day the membrane with 
bound antibody was washed three times in PBS/0.1% Tween for 10 min. The 
membrane was then transferred to a new 50 ml tube (Falcon) and elution of 
bound antibody was achieved by addition of 1 ml 0.1 M glycine.HCl pH 2.5 
and incubation on a rotating wheel for 5 min. The membrane was then 
removed and the remaining eluate was neutralised by the addition of 45|xl of 
3M Tris.HCl pH 8.0.
A 13% acrylamide gel was then run with different amounts of purified 
antibody, alongside a set of BSA standards to determine the amount of 
purified antibody generated (Fig. 3.d).
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3.2.6 Antibodies 
Anti-ATM antibodies:
Affinity purified CN-12: a polyclonal rabbit antibody raised to the amino- 
terminus of ATM (bp 2976-3434, amino acid residues 992- 1,144), used at 
2|j,g/ml unless stated otherwise.
ATM.B: a rabbit polyclonal antibody ( the generous gift of Dr N.Lakin), was 
used at a dilution of 1/1000.
Anti-BLM antibodies:
lHIC-27 rabbit polyclonal antibody used at 1/250 unless otherwise indicated. 
185a mouse monoclonal, neat culture supernatant used.
32e mouse monoclonal, neat culture supernatant used.
Other antibodies used:
Anti- HA tag antibody 12CA5, used at lp,g/ml (Boehringer Maimheim).
Anti His6-tag mouse monoclonal antibody clone 13/45/31-32 (Dr H. Zentgraf, 
DKFZ, Germany) used at a dilution of 1/10.
Monoclonal mouse anti-beta tubulin supplied by Amersham Life Science was 
used at a dilution of 1 /300.
IHIC-7 anti-topoisomerase Ha, rabbit polyclonal used at 1/500 dilution for 
immunohistochernistry.
Secondary layers: Peroxidase conjugated anti-rabbit IgG and peroxidase 
conjugated anti-mouse IgG were supplied by Sigma immunochemicals and 
were diluted by 1/500 in incubation solution prior to use.
All antibodies were preserved in 0.02% Na azide and stored at 4°C.
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3.2.7 Investigation of the expression of ATM protein in the 
National Cancer Institute cell panel
The National Cancer Institute has compiled a panel of 60 tumour cell 
lines spanning a range of human malignancies. A database now exists for these 
cell lines which contains information regarding several different aspects of 
cellular behaviour. Apart from documenting ceU line sensitivity to various 
drugs, information regarding key cellular mediators eg p53, p21 and 
checkpoint function has been collated. It is now possible to obtain these cell 
lines for experimental purposes and compare the results obtained with 
information already present in the NCI database to identify possible 
relationships between the parameters studied. Therefore an investigation of 
ATM expression in these cell lines was conducted.
Equivalent amounts (25 pi) of protein equalized cell lysates from a 27
cell lines in the panel were subjected to SDS-PAGE in duplicate on 7.5 % gels. 
ATM protein was subsequently detected by Western blotting using the affinity 
purified antibody CN-12. A U 20S cell lysate (an osteosarcoma line not 
included in the panel) and later on HCC-2998 lysates were used as positive 
internal standards to allow comparison of ATM protein expression levels 
between different gels. (Representative gels are shown Fig. 3.6-3.10). ATM 
protein levels were then quantitated by band intensity analysis using the 
Bioimage^*  ^Whole Band Analyser System (Millipore) and corrected using the 
internal standards to allow comparison of protein levels across all the samples 
studied. Comparison of the ATM protein levels with: reported p53 mutations 
(assessed by preparing and sequencing the cDNA), p53 protein levels (assessed
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by Western blotting), y  irradiation (6.3 Gy) induced G1 arrest capacity 
(quantitated as the percent of the G1 population that remained in G1 phase 17 
hours after irradiation and incubation with nocodazole) and X-ray induction of 
WAF-1, MDM-2 and gadd45 (measured by RNA isolation and dot blot 
hybridization) for each cell line was performed using the COMPARE 
programme of the NCI Human Tumour Cell Screen Molecular Database 
(http://epnws.l.ncifcrf.gov:2345/dis3d/java/user_compare.html).
3.2.8 Immunohistochemical analysis of ATM and BLM proteins
MRC5 (wild type fibroblasts) (Huschtscha and Holliday, 1983), and 
AT5BIVA (SV40-transformed AT fibroblasts) (Savitsky et al., 1995) cells were 
cultured in the appropriate media on microscope slides with 4 wells (Becton- 
Dickinson). Before the cells reached confluence, the medium was washed off 
and cells were fixed for 5 min in 70% ethanol or oüier fixative (see below). 
(Alternatively, cytospin specimens of these cell lines were used). The slides 
were then microwaved in O.OIM Na citrate buffer pH 6.0 for 5 mins x2 and 
allowed to cool in dH 20 prior to blocking in 10% PCS/PBS for 30 min. After a 
brief wash in PBS the slides were incubated with the relevant primary 
antibody: CN-12 (2pg/ml), anti-BLM monoclonals: 185a or 32e (neat), or IHIC-
7 (anti-Topo Ha 1/500) as a positive control, overnight at 4°C. The following
day they were rinsed three times for 5 min in PBS and the appropriate 
peroxidase conjugated anti-rabbit or anti-mouse secondary layer was applied 
(at a dilution of 1/500) for 1 hour at room temperature. After a final rinse in
PBS, the reaction product was developed using the vector® AEC Substrate Kit
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for Horseradish Peroxidase (Vector) according to the manufacturers 
instructions. A positive reaction is indicated by the development of a red- 
brown reaction product after 30 min (a water based mountant such as Apathy's 
mounting medium was used as the reaction product is soluble in alcohol).
Alternative protocols eg including a protease (0.1% Trypsin) digestion 
step, and pre-treatment with a detergent (0.2% Triton X-100) to reveal nuclear 
epitopes were tried as were alternative fixation methods eg: no fixation, air 
drying, 3.7 % Formalin/PBS, 3% paraformaldehyde/2% sucrose in PBS and 
100% acetone fixation.
IHIC-27 staining of alcohol fixed cytospin specimens was also 
investigated by Helen Turley (ICRF, Department of Cellular Science), in 
dilutions from 1/100 to 1/1500 using the diaminobenzidine reaction method to 
develop the slides which gives a brown reaction product. All slides were 
lightly counterstained with haematoxylin.
3.3 Results
3.3.1 Immune serum from rabbit CN-12 recognises a protein of 
-350 kDa in U 20S cell extracts
When polyclonal antisera from immunized rabbits were tested, only one 
antiserum, that from rabbit CN-12 was found to recognise a band in the 
osteosarcoma cell line, U20S of similar size to ATM (-350 kDa). No distinct 
bands were seen in this region using preimmune serum from this rabbit as a
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negative control (Fig. 3.1). After affinity purification of CN-12 the band 
recognised in U20S and HeLa cells appeared much sharper (Fig. 3.2).
3.3.2 Affinity purified CN-12 antiserum can immunoprecipitate a 
protein of -350 kDa from HeLa cell nuclear extracts
Affinity purified CN-12 immunoprecipitated and recognised a protein of -350 
kDa in HeLa cell nuclear extracts (Fig. 3.3), which was the same size as the 
band recognised a U20S whole cell lysate. Two other fainter bands of -140 and 
160 kDa and -80 kDa were also recognised in the HeLa immunoprecipitates. 
The intense band at -350 kDa was not seen in nuclear extracts 
immunoprecipitated with preimmune serum from CN-12 and no antibody' 
negative controls.
3.3.3 The polyclonal antibodies CN-12 and ATM.B both  
recognise a protein of -350 kDa in HeLa whole cell lysates which 
is not present in an ataxia-telangiectasia cell lysates
Affinity purified CN-12 (raised to ATM amino acid residues 992-1144) and the 
anti-ATM antibody ATM.B, (a gift from Dr N. Lakin, which was raised to ATM 
amino acid residues 1980-2338 (Lakin et al., 1996)), recognised a protein of -350 
kDa protein in HeLa cell lysates but not in the ataxia-telangiectasia fibroblast 
cell line AT2RO lysates (Fig. 3.4). AT2RO cells are homozygous for the 
mutation ATM 5539 del 11 which is predicted to truncate ATM protein at 
codon 1847 (Gilad et al., 1996). If the truncated protein was stable its estimated 
molecular weight would be -211 kDa. ATM.B was raised to a portion of the
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200 kDa
Fig. 3.1
then detected by Western blot analysis using CN-12 or preimmune 
serum (sera were used at a dilution of 1/250).
ATM 
200 kDa
Fig. 3.2
Affinity purified CN-12 recognises a protein of -350 kDa m UZOS 
cells A whole cell lysate was prepared from U20S cells and 25 pi 
of this (equivalent to 125,000 cells), and 15pl of a HeLa cell nuclear 
extract (equivalent to 0.8 million cells), were subjected to 
SDS-PAGE. ATM protein was then detected by Western bio 
analysis using affinity purified CN-12 (2pg/ml).
IP from HeLa nuclear extract
.O' .if
I
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ATM 
200 kDa
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WB; CN-12
Fig. 3.3
Affinity purified CN-12 is able to immunoprecipitate ATM protein from 
a HeLa cell nuclear extract (50 million cells/sample). HeLa cell nuclear 
extracts were immunoprecipitated with or without affinity purified 
CN-12 (2 pg/m l) or preimmune serum and equivalent amounts (23 
million cells per immunoprecipitate) were then subjected to SDS-PAGE. 
25|xl of U20S whole cell extract (equivalent to 125,000 cells) was 
included as a positive control. ATM protein was subsequently detected 
by Western blot analysis using affinity purified CN-12 (2 |ig/m l).
ATM
200 kDa
ATM.B CN-12
Fig. 3.4
Affinity purified CN-12 and ATM.B both recognise a protein of -350 
kDa in HeLa cells but this protein is not present in ataxia telangiectasia 
AT2RO cells. 25 pi (equivalent to 125,000 cells) of HeLa and AT2RO 
whole cell lyéates were subjected to SDS-PAGE. ATM protein was 
detected by Western blot analysis using anti-ATM antibody ATM.B 
1/1000, ( a gift from N. Lakin), and affinity purified CN-12 (2pg/ml).
CN-12
HeLa
ATM
Fig. 3.5
ATM protein is present in HeLa nuclear and microsomal extracts but 
is not identified in HeLa cytosol nor in an AT2RO cell lysate. 
Equivalent amounts (lOOpg protein), of HeLa cell nuclear, cytosolic 
and microsomal extracts, and 25pl (equivalent to 125,000 cells) of an 
AT2RO lysate were subjected to SDS-PAGE. ATM was then detected 
by Western blot analysis using affinity purified CN-12 ( 2 pg/ml).
ATM protein distal to this truncation therefore as expected, ATM.B did not 
identify a protein of this size in AT2RO lysates. The fact that no proteins of 
-211 kDa were seen with CN-12 suggests that the truncated ATM protein in 
AT2RO cells is unstable.
3.3.4 In v estig a tio n  o f the su b ce llu la r  loca lisa tio n  o f  A T M
Affinity purified CN-12 was used to determine the subcellular localisation of 
ATM in HeLa cell nuclear, microsomal and cytosolic extracts by W estern 
blotting. An AT2RO whole cell lysate was used as a negative control. ATM was 
found to be a predom inantly nuclear protein, although small amounts were 
also identified within the microsomal fraction. ATM was not detected in the 
cytosol of HeLa cells nor in the AT2RO whole cell lysate (Fig. 3.5).
3.3.5 A f f in i t y  p u r if ie d  C N -12  can  b e  u se d  to  d e te r m in e  th e  
e x p ress io n  o f  A T M  in  tum ou r ce ll lin es .
Affinity purified CN-12 was used to investigate the expression of ATM in a 
variety of tum our cell lines from the National Cancer Institute Cell Panel (Fig. 
3.6 to Fig. 3.10). U20S cell and later on HCC-2998 lysates were used as positive 
internal controls to allow comparison of different gels. Expression of full length 
ATM was seen in 26 of 27 cell lines from this panel including leukaemia cell 
lines (CCRF-CEM and RPMI-8226), breast cancer cell lines (BT-549, MCF7- 
ADR-RES), ovarian cancer cell lines (OVCAR-3, OVCAR-5, OVCAR-8 and SK- 
OV-3), non-small cell lung cancer lines, (EKVX, HOP-62, NCI-H226, and NCI- 
H322M), colonic cancer cell lines (COLO-25, HCC-2998 and HCT-116), renal
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Western blot of cell line lysates from National Cancer
Institute Cell Panel
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Fig. 3.6
A) Equivalent amounts (50pg) of protein equalised whole cell lysates of U20S, 
A498, ACHN, BT-549, COLO-205, and CCRF-CEM cell lysates were subjected to 
SDS-PAGE. ATM protein was detected by Western blot analysis using affinity 
purified CN-12 antibody (2pg/ml). B) The above lysates were also Western 
blotted with ^-tubulin antibody (1 /300) to monitor protein loading.
Western blot of cell line lysates from National Cancer
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Fig. 3.7
A) Equivalent amounts (50pg) of protein equalised whole cell lysates of 
SNB-19, SK-MEL-28, SK-MEL-5, SK-MEL-2, SK-OV-3, SF539 and HCC-2998 cell 
lysates were subjected to SDS-PAGE. ATM protein was detected by Western blot 
analysis using affinity purified CN-12 antibody (2pg/ml). B) The above lysates 
were also Western blotted with ^-tubulin antibody (1/300) to monitor protein 
loading.
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Fig. 3.8
A) Equivalent amounts (50p.g) of protein equalised whole cell lysates of HOP-62, 
HL-60, HCT-116, HCC-2998, EKVX, and U 20S cell lysates were subjected to 
SDS-PAGE. ATM protein was detected by Western blot analysis using affinity 
purified CN-12 antibody (2|ig/ml). B) The above lysates were also Western blotted 
with p-tubulin antibody (1/300) to monitor protein loading.
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Fig. 3.9
A) Equivalent amounts (SOfig) of protein equalised whole cell lysates of 
OVCAR-5, OVCAR-8, RPMI-8226, RXF-393, 786-0 and HCC-2998 cell lysates 
were subjected to SDS-PAGE. ATM protein was detected by Western blot 
analysis using affinity purified CN-12 antibody (2p.g/ml). B) The above lysates 
were also Western blotted with P-tubulin antibody (1/300) to monitor protein 
loading.
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Fig. 3.10
A) Equivalent amounts (50|ig) of protein equalised whole cell lysates of 
OVCAR-3, NCI-H322M, NCI-H23, MCF-7(ADR-RES), M14 and HCC-2998 cell 
lysates were subjected to SDS-PAGE. ATM protein was detected by Western blot 
analysis using affinity purified CN-12 antibody (2p.g/ml). B) The above lysates 
were also Western blotted with P-tubulin antibody (1/300) to monitor protein 
loading.
tumour cell line (RXF-393, 786-0, ACHN and A498), melanoma lines (M14, SK- 
MEL-2, SK-MEL-28 and SK-MEL-5), brain tumour cell lines (SF-539 and SNB- 
19). ATM was absent from HL-60 (Fig. 3.8), a promyelocytic leukaemia cell 
line, very low in NCI-H23 a non-small cell lung cancer cell line (Fig. 3.10) and 
low in seven other cell lines: HOP-62, HCT-116, HCC-2998, SNB-19, NCI- 
H322M, RXF-393 and 786-0 although equivalent amounts of the cell lysates 
were loaded. In the positive cell lines, several other bands were also seen, most 
notably at -200 kDa, and two further bands between 200 kDa and 97 kDa. In 
the negative cell line no prominent bands of lower molecular weight were seen 
which might have represented truncated m utant ATM protein.
Pearson correlation coefficients for ATM levels versus parameters for these cell 
lines in the NCI database were as follows: p53 mutation: 0.141, p53 protein 
level: 0.2, X-ray induction of WAF-1: 0.219, X-ray induction of MDM-2: 0.072,
X-ray induction of gadd45: 0.002, G1 arrest post 6.3 Gy of y radiation: -.041 ie
no significant correlations with any of the parameters chosen was identified. 
(+1 would represent a perfect positive correlation and -1 a perfect negative 
correlation).
3.3.6 Polyclonal an tib o d y  IHIC-27 id en tifies  BLM pro te in
Western blot analysis of pure recombinant BLM protein, and MRC5 (wild type) 
and GM8505 (a Bloom's cell line) whole cell lysates was performed using the 
affinity purified polyclonal antibody IHIC-27. IHIC-27 recognised full-length 
recombinant BLM and a protein of the same molecular weight (-180 kDa) in 
MRC5 cells. This protein was not present in the Bloom's cell line GM8505. 
Three other prominent protein bands of approximate molecular weights of 110
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and 90 kDa and 69 kDa and a weaker band of 160 kDa are detected in both 
MRC5 and GM8505 using this antibody (Fig. 3.11). The BLM m utation in 
GM8505 is not published but is reported to be a missense mutation which, if 
stable, would result in a protein of -80 kDa. However expression is unlikely as 
only small am ounts of the mRNA are detected due to mRNA instability 
(personal communication, Nathan Ellis).
3.3.7 A ff in ity  p u r if ie d  IH IC-27 id e n tif ie s  BLM p ro te in  in  a 
varie ty  of cell lines
Western blot analysis of pure recombinant BLM protein and whole cell lysates 
from MRC5 and U20S (wild type cell lines), GM8505 and GM2932 (Bloom's 
cell lines) was performed using the affinity purified polyclonal antibody IHIC- 
27. IHIC-27 recognised full-length recombinant BLM (-180 kDa) and a protein 
of the same molecular weight in U20S and MRC5 cells Fig. 3.12). This protein 
was not present in the Bloom's cell line GM8505 but a weak band was 
identified at this molecular weight in GM2932 cells. Numerous other proteins 
were also recognised by IHIC-27 in wild type and Bloom's cells including 
bands already identified at -110 kDa and 90 and 69 kDa, which differed in 
intensity from one cell line to another.
3.3.8 BLM is a nuclear p ro te in
Affinity purified IHIC-27 was used to investigate the subcellular localisation of 
BLM in HeLa cell nuclear, microsomal and cytosolic extracts by W estern 
blotting (Fig. 3.13). A Bloom's whole cell lysate (GM8505) was used as a
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Fig. 3.11
BLM is absent in Bloom's cells but present in MRC5 cells. Protein extracts from: 
1) 0.5pg of purified full length recombinant BLM , and 30 pi (equivalent to 
150,000 cells) of 2) and 3) MRC5 cells (BLM +/+) (3 was an older lysate), and 
4) and 5) GM8505 cell lysates (BLM-/-) were subjected to SDS-PAGE. BLM 
protein was detected by Western blot analysis using affinity purified IHIC-27.
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Fig. 3.12
Affinity purified IHIC-27 recognises multiple proteins in wild type and 
Bloom's cells. 25 pi (equivalent to 125,000 cells) of the wild type cell 1 
ines U20S and MRC5, the Bloom's cell lines GM2932 and GM8505, and 
0.15pg of pure recombinant BLM protein were subjected to SDS-PAGE 
a 7.5% gel. Western analysis was then performed and BLMon
protein was identified using affinity purified IHIC-27.
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Fig. 3.13
BLM is a nuclear protein. A whole cell extract was prepared from GM8505 
cells (BLM -/-) and nuclear, cytosolic and microsomal extracts were 
prepared from confluent HeLa cells (BLM +/+). Equivalent amounts (25 
pg) of these protein extracts and 0.2pg of purified recombinant BLM 
(positive control), were subjected to SDS-PAGE. BLM was detected by 
Western blot analysis using affinity purified IHIC-27.
negative control. BLM was found to be a nuclear protein and no band 
corresponding to full-length BLM was identified in HeLa cytosolic or 
microsomal fractions or in the Bloom's cell line GM8505 whole cell lysate, 
although bands were seen above and below 180 kDa. The nuclear, cytosolic 
and m icrosom al fractions tested were representative of these cellular 
compartm ents as evidenced by their relative expression of ATM which was 
investigated concurrently (Fig. 3.5).
3.3.9 M o n o c lo n a l an tib o d y  185a recogn ises re c o m b in a n t BLM 
p ro te in
Samples of BLM-MBP fusion protein, yeast lysates expressing recombinant 
BLM (both uninduced and induced) and purified recom binant BLM were 
subjected to SDS-PAGE. ( The yeast lysates described and the purified 
recombinant BLM protein were provided by J. Karow). Western blot analysis 
was then performed using the monoclonal antibody 185a raised against BLM- 
MBP (Fig. 3.14a). 185a recognised both the fusion protein against which it was 
raised, recombinant BLM expressed by induced yeast cultures and purified 
recombinant BLM. However, as expected, no BLM protein was detected in the 
uninduced yeast cultures. When HeLa cell nuclear extracts were prepared 
(w ith or w ithout subsequent im m unoprécipitation w ith  IHIC-27) and 
separated by SDS-PAGE along with an induced yeast culture lysate expressing 
BLM, the monoclonal antibody 185a only recognised the recombinant yeast 
BLM and BLM in the im m unoprecipitated nuclear extracts (Fig. 3.14b).
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Fig. 3.14a
Monoclonal antibody 185a recognises the portion of BLM against 
which it was raised (amino acid residues 300 - 500) and full length BLM. 
20 |ig of 1) a partial length BLM-MBP fusion protein, equivalent 
amounts (7.5 |il ) of crude lysate from 2) uninduced yeast and 3) 
induced yeast expressing 0.15 |ig of full length recombinant BLM and 0.5 
|ig  of 4) purified full length recombinant BLM were subjected to 
SDS-PAGE. BLM was then detected by Western blot analysis using 
monoclonal antibody 185a.
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Fig. 3.14b
Monoclonal antibody 185a recognises BLM in HeLa cell nuclear 
extracts only after immunoprécipitation with the anti-BLM poly clonal 
antibody IHIC-27. A HeLa cell nuclear extract equivalent to -30 million 
cells, 15 pi (equivalent to 14 million cells) of 2 HeLa cell nuclear extracts 
immunoprecipitated with IHIC-27 and 0.15pg of recombinant BLM 
expressed in yeast were subjected to SDS-PAGE on a 7.5% gel. BLM 
protein was detected by Western analysis using monoclonal antibody 
185a.
3.3.10 BLM p ro te in  is u n stab le
Purified BLM (with a His-tag at the carboxy-teminus) was subjected to 
Western analysis and blotted with either the anti-BLM monoclonal antibody 
185a (raised to the amino-terminus of BLM) or an anti-His tag antibody (Fig. 
3.15a). Both antibodies identified full-length BLM at 180 kDa but an additional 
protein of molecular weight -75-90 kDa was identified using the anti-Fïis 
antibody. This extra lower molecular weight protein, presum ably carboxy- 
terminal BLM, was not recognised by 185a. Interestingly no protein of -90-105 
kDa, corresponding to the amino-terminal portion of BLM was identified by 
185a either. This may be due to further proteolytic processing of the amino- 
terminus. As shown previously, additional lower molecular weight proteins 
have been identified by IHIC-27 in Western blots of cell lysates, some of which 
appear more intense the longer the lysate is kept (Fig. 3.11). In addition, when 
recombinant BLM from induced yeast lysates and MRC5 cell lysates were 
separated by SDS-PAGE, BLM protein was detected by Western analysis using 
either the anti-BLM monoclonal antibody 185a or the anti-His tag antibody. 
Full length BLM protein was identified in all lysates bu t a second smaller 
protein >97 kDa was also identified in the yeast lysate expressing BLM. Both of 
these proteins were also seen much more faintly in the MRC5 lysates, however 
the smaller protein was not identified using the anti-His tag antibody (Fig. 
3.15b).
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Fig. 3.15 a
BLM protein is susceptible to breakdown. 0.5 pg of purified 
His-tagged recombinant BLM was subjected to SDS-PAGE. BLM was 
detected using either a monoclonal antibody 185a directed against the 
amino-terminus or with an anti His-tag antibody directed against the 
carboxy-terminus.
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Fig. 3.15 b
BLM is susceptible to breakdown. (25 pi ) of an MRC5 cell lysate (equivalent 
to 125,000 cells) and 0.15pg of recombinant BLM from a yeast lysate were 
subjected to SDS-PAGE on a 7.5% gel. BLM protein was detected by Western 
analysis using the polyclonal antibody IHIC-27 directed against the amino 
terminus of BLM or an anti-His tag antibody directed against the carboxy 
terminus of BLM.
3.3.11 M o n o c lo n a l a n tib o d y  32e re co g n ise s  w ild  ty p e  a n d  
recom binan t BLM p ro te in
Nuclear isolates prepared from HeLa cells and im m unoprecipitated with 
affinity purified IHIC-27 were subjected to SDS-PAGE together w ith an 
induced lysate from yeast expressing BLM as a positive control. W estern 
analysis using the monoclonal anti-BLM antibody 32e to detect BLM was then 
perform ed (Fig. 3.16). 32e recognised a band of 180 kDa in the HeLa cell 
nuclear isolate im m unoprecipitated with IHIC-27 and in induced yeast 
cu ltures expressing BLM. No BLM was detected by 32e w hen the 
immunoprecipitating antibody IHIC-27 was omitted.
3.3.12 Im m u n o s ta in in g  of cells w ith  an ti-A T M  a n d  anti-B L M  
an tib o d ies
As described above imm unostaining for ATM and BLM was attem pted in a 
variety of different ways with the same result. Representative examples of the 
immunostaining for both are included here (Fig. 3.17 to Fig. 3.19).
Although immunostaining for Topoisomerase Ila  (the positive control) using
the polyclonal rabbit antibody IHIC-7 was successful, (a red-brown reaction 
product stained the metaphase chromosomes of both AT5BIVA (Fig. 3.17A) 
and MRC5 fibroblasts (Fig. 3.17B)), im m unostaining of form alin fixed 
AT5BIVA (Fig. 3.17C) and MRC5 cells (Fig.3.17D) using CN-12 (2 pg/m l) was 
negative.
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Fig. 3.16
Monoclonal antibody 32e recognises BLM protein in HeLa cell 
immunoprecipitates. Nuclear isolates were prepared from HeLa cells 
and immunoprecipitated with affinity purified antibody IHIC-27. 20pl 
of the immunoprecipitated proteins (equivalent to 18 million cells) 
and 0.15pg of full length recombinant BLM protein (from a yeast 
lysate) were then subjected to SDS-PAGE. BLM protein was detected 
by Western blot analysis using anti- BLM monoclonal antibodies 185a 
and 32e.
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Fig. 3.17
The anti-ATM polyclonal antibody CN-12 is not useful for detection of ATM by 
immunohistochemistry: AT5BIVA (ataxia telangiectasia fibroblasts) and MRC5 (wild type 
fibroblasts) were analysed by immunohistochemistry for the presence of Topoisomerase II 
a  using IHIC-7 (A and B respectively) and ATM protein using CN-12 (2jig/ml), (C and D 
respectively), after fixation in formalin/PBS. In this experiment the vector AEG substrate kit 
was used and the formation of a red-brown reaction product indicates a positive result.
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The polyclonal anti-BLM antibody IHIC-27 is not useful for immunohistochemistry: 
GM8505 (a Bloom's cell line), (A and C) and MRC5 cells (B and D) were analysed by 
immunohistochemistry using the polyclonal antibody IHIC-27 at 1/100 (A and B) 
and 1 / 200 (C and D) for the presence of BLM protein. The DAB reaction was used 
for development and the formation of a brown reaction product indicates a 
positive result.
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Fig. 3.19
The monoclonal anti-BLM antibodies 185a and 32e are not useful for the detection 
of BLM by immunohistochemistry: GM8505 (Bloom's cells), (A, C and E) and 
MRC5 cells (B, D and F) were analysed by immunohistochemistry using the mouse 
monoclonal antibodies 185a (C and D) and 32e (E and F) for the presence of BLM 
protein. In A) GM8505 and B) MRC5 cells, the primary antibody was omitted. The 
vector AFC substrate kit was used and the formation of a red-brown reaction 
product indicates a positive reaction.
When immunostaining for BLM was attempted using alcohol fixed cytospin 
specimens of GM8505 cells and MRC5 cells using the polyclonal rabbit 
antibody IHIC-27 at dilutions of 1/100 and 1/200 a pale brown reaction 
product was seen in the cytoplasm of both cell types at all dilutions (Fig. 3.18). 
No specific nuclear staining of any type was identified. A negative control 
om itting the prim ary antibody was negative; a positive control showed
Topoisomerase I la  staining of lymphocytes in lymph node sections (not
shown).
Cytospin specimens of GM8505 cells and MRC5 cells were also used for 
immunostaining with the monoclonal anti-BLM antibodies 185a and 32e (Fig. 
3.19). Weak reddish-brown staining of the cytoplasm was seen in GM8505 with 
both monoclonals 185a and 32e (Fig. 3.19 C and E) and this cytoplasmic 
staining was noted to be slightly stronger in MRC5 cells (Fig. 3.19 D and F). 
(This additional cytoplasmic staining is not due to detection of full length BLM 
protein as this is not cytoplasmic in location Fig. 3.13) . No specific nuclear 
staining of any type was identified. Primary antibody was omitted as negative 
control and revealed pale pink cytoplasmic staining in both GM8505 and 
MRC5 cells (Fig. 3.19 A and B).
3.4 D is c u s s io n
The polyclonal antibody CN-12 recognises a -350 kDa protein which is 
not present in ataxia telangiectasia cell lines and which is the same size as a
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protein detected by the polyclonal antibody ATM.B despite the fact that the 
regions of ATM these antibodies were raised against are dissimilar and do not 
overlap. It was therefore concluded that the 350 kDa protein recognised by 
CN-12 was ATM. The identity of the other weaker bands seen in cell line 
immunoprecipitates and whole cell lysates (including the NCI panel), remains 
speculative. They may represent as yet unidentified cross-reacting proteins 
which show sequence similarities to the region of ATM against which CN-12 
was raised (although CN-12 recognises the amino-terminus of ATM which 
does not show any similarity with any other known proteins at present). It is 
possible that some of the additional bands may represent ATM breakdow n 
products retaining the region to which CN-12 is directed. Whilst a range of 
transcript sizes from 2-12 kb has been observed in several different tissues 
(Savitsky et al., 1995), no alternative splicing has been identified in the coding 
region of A T M  (Savitsky et al., 1997), implying that these are not splice variants 
of ATM protein.
Most A T M  m utations are null (Gilad et al., 1996) and as m entioned, 
protein instability may explain why no truncated ATM protein is detected in 
AT2RO cell lysates which could potentially express a protein of 211 kDa. This 
has been documented for many other truncation m utants of ATM previously 
(Brown et al., 1997), (Stankovic et al., 1998) and is therefore not an unexpected 
finding.
The subcellular localisation of ATM was described in 1996 (Lakin et al.,
1996). The finding that it is a predominantly nuclear protein is in keeping with 
its putative role as a sensor of DNA damage and in the transduction of DNA 
damage response pathw ays, including DNA repair. Immunohistochem ical
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studies have since shown colocalisation of ATM with replication protein A 
(RPA), at the synapsing areas on homologous chromosomes in meiosis and a 
role in recombination has been suggested (Hawley and Friend, 1996), (Keegan 
et a l, 1996), (Plug et al., 1997). The discovery of ATM in as yet indeterminate 
microsomal structures raises the possibility of a role for ATM in cytoplasmic 
signalling (Lavin and Shiloh, 1996), as seen for some of its homologues eg 
phosphatidyl inositol 3-kinase or the yeast Vps proteins which are also 
mem brane associated. It is possible that derangem ent of cytoplasmic ATM- 
related effects may account for some aspects of the pleiotropic nature of the 
disorder.
CN-12 is a relatively good antibody for Western blotting and detected 
apparently full-length ATM protein in 26/27 of the cell lines in the NCI 
tum our cell line panel examined, although the levels were rather variable. The 
underlying molecular defects in the range of tumour cell lines tested are likely 
to differ from one cell line to another and variability in the levels of ATM 
protein detected may reflect differences in regulation or degradation of the 
protein in the context of these tumour cell lines (whereas in normal cells ATM
does not show upregulation after y or UV irradiation (Lakin et al., 1996),
(Brown et al., 1997)). It is possible that Western blotting may underestimate the 
true  num ber of  A T M  m utations in these tum our cell lines as missense 
mutations, extreme carboxy-terminal truncations and small in frame deletions 
not associated with protein instability may be overlooked as they may not alter 
the apparent size of the protein. AT M  heterozygotes may also be missed for 
similar reasons, although it is possible that tum our lines showing reduced 
levels of ATM may be A-T heterozygotes with one allele coding for an unstable
118
truncated protein or one or both alleles featuring m utations generating 
potential splice sites or missense mutations, where a small proportion of the 
full length protein may be expressed.
The complete lack of ATM expression seen in the prom yelocytic 
leukaemia cell line HL-60 is of interest because of the association of AT M  
m utations and T-cell leukaemias (as described in Chapter 1). Clustering of 
A T M  missense m utations (rather than the more common null m utations) 
particularly in the kinase domain of A T M  has been shown in the tum our DNA 
from patients with sporadic T-prolymphocytic leukaemia (Vorechovsky et al.,
1997), which is similar to the leukaemia seen in A-T patients. Missense 
mutations can give rise to mutated full length A T M  protein so it is doubtful 
that such a m utation is present in HL-60. The lack of expression of ATM in 
HL60 probably results from truncation mutations leading to unstable protein. 
A case of acute myeloid leukaemia has been documented in A-T previously in 
association with ATM protein expression from 2125dell26nt which deletes 42 
amino acids from the full length ATM protein. The m utation on the second 
allele in this case was unknown (Stankovic et al., 1998). The marked reduction 
in ATM levels in the non-small cell lung cancer cell line NCI-H23 and the less 
marked reduction in HOP-62 and NCI-H322M is surprising, as lung cancer is 
not noted to be one of the more common tumours in patients with AT or their 
relatives (Swift et al., 1987), (Morrell et al., 1986). The reduction of ATM levels 
observed in the colonic carcinoma cell lines HCT-116 and HCC-2998 and the 
renal carcinoma cell lines RXF-393 and 786-0 is not reflected in a particular 
predisposition to these tumours in AT, although the brain tum our cell line 
SNB-19 showed reduced levels of ATM and brain tum ours are recognised in
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the spectrum of non-lymphoreticular tumours seen in A-T (Morrell et ah, 1986). 
It is possible that ATM is reduced in these lines due to protein regulatory 
changes or due to secondary m utations in one or both A T M  alleles. The 
significance of reduced levels of ATM is difficult to ascertain because it is not 
clear w hat absolute level of functional ATM is required under norm al 
circumstances for appropriate regulation of the cell processes it influences. In 
this respect a functional assay of the protein or gene sequencing w ould be 
more useful. ATM protein levels of from 1-100% of norm al have been 
documented in AT variants with a milder AT phenotype (Gilad et al., 1998), 
(Stankovic et al., 1998). Milder variant A-T phenotypes are associated with 
m utations generating functional splice sites from cryptic splice sites (aberrant 
splicing signals can then create m utant products but may also alternatively 
allow production of small amounts of wild type protein (McConville et al., 
1996)) or with missense mutations which allow expression and some residual 
degree of ATM function. The missense mutation 7271T->G results in the amino 
acid substitution V2424G and is associated with full length stable m utated 
ATM protein. This m utation confers a milder A-T phenotype, especially in 
homozygote rather than compound heterozygote A-T individuals, suggesting 
it has some residual wild type activity (although it is associated w ith an 
increased risk of breast cancer (Stankovic et al., 1998)). Therefore protein 
function cannot necessarily be inferred from protein levels unless no protein at 
all is detected. This may explain why no significant correlation of ATM levels 
w ith downstream effectors (p21 induction, p53 levels and G1 arrest capacity
after 6.3 Gy of y irradiation) was found in the NCI Database correlation screen.
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In addition other defects in the cell lines tested may intefere w ith normal 
cellular transduction pathways thus obscuring expected associations.
The polyclonal antibody IHIC-27 recognises a protein of molecular 
weight -180 kDa in cells which are wild type for BLM (HeLa, U20S and MRC5 
cells), however no band is seen in the Bloom's fibroblastic cell line GM8505. 
IHIC-27 also recognises purified recombinant BLM with a molecular weight of 
-180 kD, although the predicted molecular weight for the BLM gene product is 
-156 kDa. On this basis, the protein identified by IHIC-27 is believed to be 
BLM. A weak band corresponding to a protein of the same size as BLM was 
identified by IHIC-27 in GM2392 cell lysates (Bloom's cells). This may 
represent m utated but near full-length BLM or alternatively, this may be a 
revertant clone of GM2392 although no details of the recent phenotype of this 
cell line were available. Further characterisation of the mutation in this cell line 
and an examination of the phenotype is required before any other conclusions 
can be drawn.
Cellular fractionation of HeLa cells and Western blotting with IHIC-27 
was used to demonstrate that BLM is a nuclear protein. This is consistent with 
its proposed role as a 3'-5' DNA helicase (Karow et al., 1997). Unfortunately 
this antibody was of limited use despite affinity purification because of the 
recognition of multiple other bands both in wild type and Bloom's cells (Fig. 
3.12). The additional bands may represent proteins cross reacting with BLM or 
maltose binding protein, as even the affinity purified IHIC-27 was known to 
contain MBP-specific antibodies (data not shown). Alternatively explanations 
include splice variants or breakdown products of BLM. The fragility of BLM, 
possibly due to a protease sensitive site, was suggested by the identification of
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smaller sized products, derived from His-tagged recombinant BLM, by the 
His-tag antibody (Fig. 3.15a) and native BLM by IHIC-27 (Fig. 3.15b). These 
products were of different sizes -85-90 kDa (carboxy-terminus) and -110 kDa 
(am ino-term inus) respectively which may represent two fragm ents from 
breakdow n of BLM-180 kDa at a single site (whether these products are 
functional is not known ). The reason for failure of 185a to identify the smaller 
breakdown product (Fig. 3.15a) in comparison with IHIC-27 (Fig. 3.15b) may 
relate to alteration of the epitope recognised by monospecific 185a in the 
processed fragment. Newly prepared recombinant BLM does not show the 
smaller product of BLM which may explain why it is not detected by the anti-
His-tag antibody (Fig. 3.15b). Storage of the protein in 25% glycerol at -70°C 
was found to improve BLM stability (J. Karow, personal communication). The 
180 kDa BLM band was difficult to distinguish from these additional bands 
and therefore monoclonal antibodies were developed against the BLM-MBP 
fusion protein (Helen Turley, ICRF) in the hope of improving the specificity.
Several monoclonal antibodies were tested of which monoclonal 185a 
recognised purified recombinant BLM, recombinant BLM expressed in yeast 
with a molecular weight of -180 kD and the BLM-MBP fusion protein (62 kDa). 
Unfortunately this did not recognise BLM protein in whole cell lysates of wild 
type cell lines (data not shown). This may be due to low abundance of the 
protein or low affinity of the antibody as BLM was recognised in HeLa cells 
immunoprecipitated with IHIC-27 and Western blotted with 185a (Fig. 3.14b). 
The same was true for monoclonal 32e (Fig. 3.16), which again limits the 
usefulness of these antibodies. CN-12, IHIC-27 and 185a and 32e were not 
useful for immunohistochemistry with the protocols attempted. No differences
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in staining could be seen in wild type cells compared to m utant cells. This 
prevented studies of the precise localisation of the gene products in normal 
tissues and studies of their expression in tumours. Other groups have had 
similar problems and have developed epitope tagged ATM and BLM (P. 
North, personal communication), to study the localisation of the recombinant 
proteins within cells. The lack of cellular staining seen when CN-12 was used 
in immunohistochemical studies may be due in part to the absence of post- 
translational modification of the immunogenic polypeptide due to induction in 
a bacterial expression system. It is possible that induction of the protein in a 
eukaryotic expression system, (eg a yeast or baculovirus system), might have 
provided an immunogen closer in this respect to the native ATM protein and 
improved the immunohistochemical performance of the antibody. Refinement 
of the im m unostaining detection method and further studies of the ATM 
negative cell line HL60 will be conducted as detailed in Future Directions.
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Chapter 4
Investigation of the Putative Protein Kinase
Activity of ATM
4.1 Introduction
At the outset of this thesis, although the phenotype of cells lacking ATM 
had been characterised, the precise biochemical function of ATM itself 
remained a unclear. In die hope of elucidating a putative enzymatic role for 
ATM, a considerable amount of interest was focused on the carboxy-terminus 
of the protein because it contained a conserved DXXXXN and DLG protein 
kinase motif (Taylor et al., 1992) and it featured significant homology with the 
catalytic subunit of phosphatidyl inositol 3-kinase (Savitsky et al., 1995), 
(Zakian, 1995), (Jackson, 1996) (Fig. 1.1), an enzyme known to function as a 
lipid kinase which is important in the generation of phosphatidyl inositol 
derived second messengers (Kappeller and Kantley, 1994). Other ATM 
homologues including Vps34 were also established as PI 3-kinases (Keith and 
Schreiber, 1998). In addition to these lipid kinases, DNA-PK, an enzyme of 
similar size to ATM, also featuring the PI3-kinase domain described above 
does not appear to function as a lipid kinase but is known to be a 
Serine/Threonine protein kinase dependent on DNA ends for its activation 
(Jackson, 1996), (Hartley et al., 1995). Some homologues are able to 
phosphorylate both proteins and lipids eg Vps34 (Stack and Emr, 1994) and the 
pllO catalytic subunit of mammalian PI 3-K which phosphorylates its own p85 
regulatory subunit (Carpenter et al., 1993).
However, at the time these studies were undertaken, there was no 
incontrovertible evidence that ATM possessed either protein or lipid kinase 
activity. The possibility that ATM is able to autophosphorylate and thereby 
perhaps modulate its own function has been suggested because activated 
DNA-PK shows autophosphorylation. This causes dissociation of the catalytic
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from the Ku regulatory subunit and a reduction in DNA-PK activity (Chan and 
Lees-Miller, 1996). FRAP, another mammalian ATM homologue is also capable 
of autophosphorylation (Keith and Schreiber, 1998). Indeed, phosphorylation 
of a protein the same size as ATM (-350 kD), has been documented in vitro in 
cell lysates of the human lung fibroblast cell line MRC5 immunoprecipitated 
with the anti-ATM antibody 6076 (Keegan et al., 1996). Mouse ATM was
shown to be phosphorylated using metabolic ^^P labelling followed by 
immunoprécipitation (Chen and Lee, 1996). In the light of this suggestive 
evidence therefore, an attempt to demonstrate ATM autophosphorylation in 
HeLa cells was made.
In addition two other ATM kinase assays were designed. In order to 
choose a substrate for each of these assays, parallels with DNA-PK, RAD-3 and 
the TOR family were drawn. A variety of candidate substrates have been 
suggested as targets for phosphorylation by ATM, partly because they are 
known to be substrates of DNA-PK. These include p53, c-Abl, SP-1, cjun, cFos, 
cMyc and Ku (Jeggo, 1997). As described in Chapter 1, ATM acts upstream of 
p53 and since DNA-PK is an ATM homologue, synthetic p53 peptides were 
designed to include DNA-PK phosphorylation sites, p53 serine 15 and p53 
threonine 18 and used as potential ATM substrates in the ATM/p53 peptide 
kinase assay, (Table 4.1) (Shieh et al., 1997), (S. Jackson personal 
communication).
The translation initiation factor elF4E binding protein, PHAS-I 
(Lawrence and Abraham, 1997), (which has properties of heat and acid 
stability) was also chosen as anotiKer potential ATM substrate for use in the 
ATM/PHAS-I kinase assay for several reasons. PHAS-I has been reported to be
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p53 Peptide Sequence
wild type = 
p53iû-i9 BIO-N-eahx-VEPPLSQETF
p53 Ser 15 BIO-N-eahx-PPLSQEAFSDLW
p53Thrl8 B IO -N-eahx-PPLAQEIFSDLW
p53 Ala/Ala BIO-N-eahx-PPLAQEAFSDLW
Table 4.1
p53 peptides used in the ATM/p53 kinase assay.
(BIO-N-eahx indicates the N-terminal biotinylation with an eahx 
spacer linking this to the p53 peptide used). '
phosphorylated by ATM homologues including m lOR (Brunn et al., 1997) 
and Rad3 (Tamar Enoch personal com m unication), (Fig. 4.1). 
Hypophosphorylated PHAS-I is a repressor of translation inititiatiôn as it 
blocks the binding of elF4E (which is the protein responsible for recognition of 
the mRNA cap) to elF4G. PHAS-I and elF4G compete for the same binding 
site on elF4E. This interaction prevents the formation of a complex containing 
elF4E and elF4G which is necessary for efficient binding and proper 
positioning of the 40S ribosomal subunit on the mRNA. Phosphorylation of 
PHAS-I, which occurs after transduction of signals from insulin or growth 
factors binding at the cell surface, allows elF4E release, complex formation and 
initiation of translation. The phosphorylation of PHAS-I can be inhibited by 
factors affecting ATM homologues (eg rapamycin which also inhibits the TOR 
protein family) and by inhibitors of PI3-kinase (eg wortmannin and LY294002). 
This suggests that a PI3-kinase or PI3-kinase homologues, possibly including 
ATM, contribute to regulation of PHAS-I.
4.2 Additional materials and methods
4.2.1 ATM autophosphorylation assay
Pelleted protein-A-Sepharose beads bound to CN-12 w ith  
immunoprecipitated ATM were washed in kinase buffer (25 mM HEPES pH  
7.5, 75 mM KCl, 10 mM MgClz, 0.2 mM EGTA, 0.1 mM EDTA, freshly added 1 
mM dithiothreitol and unlabelled ATP to a final concentration of 10 |iM).
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PHAS-I have the (S/T)-P motif, they are likely to be prolme d ir e ^ .  Mitogen 
can also be inhibited by rapamyan.
Following repelleting of the beads, kinase buffer containing [t^^pjaTP 
sufficient to provide each sample with 2.5 jiCi of [y^^PjATP in a volume of 15 
\xl was prepared and carefully mixed into each pellet. Each kinase sample was 
allowed to incubate at 37^C for 15 min. After this time the reaction was 
stopped by the addition of an equal volume of 2X SDS sample buffer. The 
samples were then boiled for 5 min and separated by SDS-PAGE on a 7.5% gel. 
When optimal separation of the protein markers was achieved the gel was 
fixed in a mixture of 50% methanol and 10% acetic acid for 30 min prior to gel 
drying. The dried gel was then exposed to X-OMAT AR X-ray film (Kodak) to 
reveal the position of p^P]-labelled proteins.
4.2.2 ATM kinase assay using p53 peptides as substrates
ATM was immunoprecipitated from 50x10^ HeLa cells per sample,
lymphoblastoid cell line GM4724 (5x10  ^cells/ sample) or A-T lymphoblastoid
cell line GM2782a (5x10^ cells/ sample) and the pelleted beads were 
resuspended in kinase buffer with unlabelled ATP and repelleted as described
previously. At this stage 15 i^l of kinase buffer containing [t^ p^ja tP to provide 
2.5 p.Ci per sample, the required p53 peptide (p53io-i9, p53 serine 15, p53 
threonine 18 or the p53 alaninel5/alaninel8 which were synthesized in the 
Peptide Synthesis Laboratory, ICRF, Lincoln's Inn Fields, Table 4.1) to a final 
concentration of 0.2 mM and lOOng of restriction enzyme treated pCR-Script 
(Stratagene) to provide a potentially activating source of DNA with double 
strand breaks were added to each sample including the negative control 
immunoprecipitated with preimmune serum from rabbit CN-12 and the
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positive control containing 10 units of DNA-dependent protein kinase 
(Promega). The DNA-PK sample was prepared last as DNA-PK is known to 
autophosphorylate and deactivate itself. (The DNA double strand break source 
and the DNA-PK positive control were not used in initial experiments with
p53io-i9). The samples were then incubated at 37°C for 15 min and after this 
the reactions were stopped by addition of 500^1 per sample of 5 mM EDTA in 
PBS which chelates the Mg^+ required for kinase action.
As the p53 peptides were biotin labelled they were collected on 200 pi 
of streptavidin coated para-magnetic beads (Sigma), by mixing the streptavidin
coated beads and the sample at 4°C for 15 min. The beads were then collected 
on a magnetic stand (Dynal). After the first collection, the beads were washed 
in PBS and recollected three times in PBS. After the final wash the beads were 
resuspended in 50pl of PBS and each sample was transferred to small squares 
of Whatman 3MM paper on parafihn. These were allowed to dry in the fume 
hood and once they were dry they were transferred to 5 ml of scintillation fluid 
in scintillation vials and counted (Beckman LS 5000CE ).
4.2.3 Production of recombinant PHAS-I protein
A recombinant His-tagged PHAS-I cDNA in the expression vector pET- 
14b (Novagen), was provided as a generous gift by Professor John Lawrence. 
The plasmid was transformed into chemically competent BL21 (deS) pLysS E. 
coli (Novagen), using the heat shock method: 0.15 pg of the above plasmid was 
added to 100 pi of the bacteria and mixed gently. The mixture was left on ice
for 15 min and was then subjected to a heat shock at 42°C for 90 s before being
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replaced on ice to cool. After this the bacteria were plated out on selective 
LB/AMP plates to select for transformants (a no DNA control was also
included). The plates were incubated at 37°C overnight and the following 
morning 3 ml minicultures in LB/AMP were made from colonies picked from 
the pET-14b transformed plate (No colonies were seen on the negative control 
plate, -300 were seen on the test plate). The minicultures were incubated in the
shaking incubator at 37^C overnight and the following day, bacterial 
minipreps were made from the minicultures as previously described. 3pl of 
each miniprep was then digested simultaneously with the restriction enzymes 
Xbal and EcoRV. Aliquots of the digests were then subjected to 0.7% agarose 
gel electrophoresis to check that the bacteria were carrying the plasmid and 
that the plasmid and the insert sizes were correct. When this was verified, test 
inductions of the colonies with the correct sized insert were prepared (colonies 
A-B): Fresh minicultures were made by adding 10 pi of the old miniculture 
from the chosen colonies to 3 ml of LB/AMP and incubated in the shaking
incubator at 37°C overnight. The next day, 0.5 ml of miniculture was 
inoculated into 20 ml of prewarmed LB/AMP and incubated in the shaking
incubator at 37°C until the ODgoo reached 0.6 after which pre-induction 
samples were taken ( 200 pi of culture was pelleted by centrifugation and 
resuspended in 40 pi of 2X protein sample buffer) and PHAS-I expression was
induced by addition of either 0.4 mM or 2 mM isopropyl-P-D-
thiogalactopyranoside (IPTG) for 2 hours at 370C. Post-induction samples were 
taken after 2 hours and were subjected to SDS-PAGE on a 13% gel, along with 
pre-induction samples (25 pi of each sample was used with a ratio of post/pre
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induction culture amounts of 1 /4  to account for bacterial growth). One such 
gel was then stained with Coomassie Blue and destained in 10% methanol, 10% 
acetic acid, before gel drying (Fig. 4.2). Another was transferred using the 
semi-dry technique and subjected to Western analysis; anti-His tag antibodies 
were used to identify His-tagged PHAS-I protein (Fig. 4.3).
4.2.4 Purification of PHAS-I protein
Two 21 flasks each containing 400 ml of pre-warmed LB/AMP were 
inoculated with 4ml of an overnight miniculture of colony B and incubated at
37°C in a shaking incubator until the ODeoo reached 0.6. Pre-induction samples 
were then taken as before and PHAS-I expression was then induced by the
addition of IPTG (0.4 mM) with incubation for a further 2 hours at 3^C . Post­
induction samples were taken at this point (SDS-PAGE was duly performed at 
a later time, as before to check protein induction). The flasks were then placed 
on ice for 10 min prior to transfer of the cultures to eight 50 ml tubes (Falcon)
and centrifugation at 4.2 Krpm (in a Beckman GPR centrifuge) for 5 min at 4°C  
to pellet the cells. The supernatant was then discarded and the equivalent of 
200 ml of culture was resuspended in 4 ml of ice cold binding buffer ( 5 mM 
imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH 7.9). The cells were then sonicated 
(Soniprep 150, MSE), to shear the DNA in 30s bursts on ice until the viscosity 
fell. The lysate was then centrifuged in a pre-cooled SW-55ti rotor at 39Krpm 
for 20 min at 4^0.
The His-Bind metal chelation column was then prepared in the cold 
room using 4ml of His-Bind resin (Novagen) which settles to a 2 ml column.
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Fig. 4.2
Lack of visible recombinant PHAS-I expression in BL21 DE3 pLys S 
strain on a Coomassie Blue stained gel (induction conditions 
0.4/2mM IPTC, 2 hours at 37 C). 20 pi of bacterial lysate was loaded 
per lane and subjected to SDS-PACE on a 13% acrylamide gel . 
Proteins were detected by staining with Coomassie Blue.
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Fig. 4.3
Recombinant His-tagged PHAS-I protein is expressed by BL21 DE3 
pLys S strain (induction conditions : 2 hour incubation, 0.4 mM 
IPTG at 37 C). 20 pi of bacterial lysate was loaded per lane and 
run on a 13% acrylamide gel. The PHAS-I protein was detected by 
Western blot analysis using anti-His-tag antibodies. A bacterial 
lysate expressing His-tagged HAP-1 protein was used as a positive 
control.
The column was then washed with 6 ml of sterile distilled water, then 10 ml 
of charge buffer (400 mM NiS04), followed by 6 ml of binding buffer. The 
supernatant from the bacterial extract was then loaded onto the column. After 
this the column was again washed with 25 ml binding buffer followed by 15 ml 
of wash buffer (60 mM imidazole, 0.5 M NaCl, 20 mM Tris-HCl, pH  7.9). The 
expressed His-tagged protein was then eluted with elution buffer (1 mM 
imidazole, 0.5 M NaCl, 20 mM Tris-HCl pH 7.9), and collected in 1 ml 
fractions. Pre and post induction whole lysates and post induction supernatant 
samples were subjected to SDS-PAGE on a 13% gel, alongside each of the 
eluted fractions (50 pi of each fraction was mixed with 50 pi of 2X protein 
sample buffer and 25 pi of each sample was run). The gel was then stained 
with Coomassie Blue and destained in 10% methanol, 10% acetic acid, before 
gel drying (Fig. 4.4). PHAS-I fractions 2-5 were then pooled and aliquoted for
storage at -70°C prior to use, (25 pi of stored eluate was roughly equivalent to 
5 pg of PHAS-I protein).
4.2.5 A T M  k in a se  assay  u s in g  PH A S-I as a su bstrate
Im m unoprecipitates were prepared for W estern analysis and for the 
kinase assay, using affinity purified CN-12 (anti-ATM) and pre-immune serum 
from rabbit CN-12 as previously described but using the following cell lines: 20
X 10^ cells GM4724 hum an lymphoblastoid cell (ATM + /+), 28 x 10^ cells
GM2782a hum an lymphoblastoid cells (ATM -/-) and 2 x 10^ HeLa S3 cells. 
(For Western blotting this resulted in the immunoprecipitate in the 30pl loaded
per track being derived from 5, 7 and 50 x 10^ cells respectively. A HeLa
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Fig. 4.4
His-tagged recombinant PHAS-I protein can be purified over a His Bind 
column. Recombinant PHAS-I expression was induced in BL21 DE3 
pLys S strain after 2 hours incubation at 37 C with 0.4 mM IPTG . 25|il of 
bacterial lysate was loaded in lanes 1) preinduction: whole cell lysate , 2) 
2 hour post induction: whole cell lysate, and 3) 2 hour post induction 
bacterial supernatant. PHAS-1 protein was purified by passing the 
supernatant over a His-Bind column. 12.5 fil of eluted PHAS-1 protein 
(resuspended in an equal volume of 2X protein sample buffer) from the 
first five collected fractions was loaded in lanes 4-8 respectively. The 
samples were subjected to SDS-PAGE on a 13% acrylamide gel and 
proteins were detected after staining with Coomassie Blue.
sample containing 10 x 10^ cells was also included to determine if cell num ber 
was limiting in terms of ATM immunoprecipitated.
The sam ples for the ATM/PHAS-I kinase assay were treated  as 
described above for the autophosphorylation assay but with addition of lOpl of 
purified PHAS-I (~ lpg of PHAS-I protein) and lOOng of restriction enzyme 
treated pCR-Script per sample, as a source of DNA with dsbs, to the [t32p ]a t P
containing kinase buffer. DNA-PK was used as a positive control (as described 
in the p53 peptide assay). The samples were incubated and processed as before 
prior to PHAS-I (-21 kDa) separation by SDS-PAGE on a 13% gel. The gel was 
fixed, stained in Coomassie Blue for 10 min then destained for 30 min to check 
PHAS-I localisation prior to gel drying. The blot was then w rapped in Saran 
wrap and exposed to X-OMAT AR film (Kodak) to determine the am ount of 
PHAS-I phosphorylation in each sample including the DNA-PK positive 
control.
4.3  R e s u lt s
4.3.1 Im m u n o p re c ip ita ted  ATM  from  H eLa cell n u c lea r extracts 
p h o sp h o ry la te s  associa ted  p ro te in s of M W  -  350 kD a an d  ~ 200- 
97 kD a
The ability of ATM to phosphorylate co-immunoprecipitated proteins in HeLa 
nuclear extracts was investigated. Proteins were isolated using the affinity 
purified anti-ATM antibody CN-12 and analysed using the ATM kinase assay 
followed by W estern blot analysis and autoradiography (Fig. 4.5A and B).
138
IP antibody: »c/ ” x,\T- / ’°
200 kDa.
97 kDa
/ ""S.
w
r/
%
IP antibody:
200 kDa
97 kDa
1 2
B
Fig. 4.5
Protein species phosphorylated by immunoprecipitated ATM in 
HeLa cells. ATM from HeLa cell nuclear extracts was 
immunoprecipitated with affinity purified antibody CN-12 (samples 1 
and 3). CN-12 was omitted in samples serving as negative controls 
(samples 2 and 4). A kinase assay was then performed as previously 
described. Subsequently, 30pl of phosphorylated HeLa cell nuclear 
extract (equivalent to 20 million cells per sample) was loaded in each 
lane of a 7.5% acrylamide gel and subjected to SDS-PACE. Subsequent 
auto-radiographic exposure of the fixed and dried gel of three days 
(4.5A) or one week (4.5B), revealed three phosphorylated protein 
species of the following molecular weights: a) 350 kDa, b) and c) 
between 200-97 kDa.
After a three day exposure, phosphorylation of two protein species of 
molecular weights -  160 kDa and 140 kDa was detected (Fig. 4.5A). Longer 
exposures, identified two other phosphorylated protein species of molecular 
w eight -200 and 350 kDa, (Fig. 4.5B) in the CN-12 im m unoprecipitated 
samples although the background was increased. A discrete -  140 kDa band 
and faint indistinct bands at -200 kDa and -  350 kDa were also seen in the 'no 
antibody' negative control.
4.3.2 Im m u n o p rec ip ita ted  ATM  from  H eLa cell n u c lea r extracts 
does n o t p h o sp h o ry la te  the  p53 p ep tid e  10-19
The ability of immunoprecipitated ATM from HeLa nuclear extracts to directly 
phosphorylate the p53 peptide p53io-i9 was investigated using the affinity 
purified antibody CN-12 to immunoprecipitate ATM followed by analysis with 
the ATM/p53 kinase assay and measurement of p53io-i9 [y incorporation 
in a scintillation counter. The experiment was perform ed on two separate 
occasions with [y ATP of a different activity date, hence the results are 
presented separately (Fig. 4.6 and Fig. 4.7). In the first experiment, the highest 
m ean p53io-i9  [y ^^P] incorporation  was greatest for the sam ple 
immunoprecipitated with affinity purified CN-12 immune serum (Fig. 4.6) and 
in the second experiment, the highest mean p53io-l9 [y^^P] incorporation was 
greatest for the preim mune serum negative control (Fig. 4.7). However, there 
was an overlap in the range of the p53io-i9 [y^^P] incorporation for the 
samples immunoprecipitated with CN-12 and the preimmune serum negative
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Fig. 4.6
Immunoprecipitated ATM does not phosphorylate the p53 peptide p53l0-19. 
HeLa cell nuclear extracts (50 million cells/sample) were immunoprecipitated 
with preimmune serum (black bar, n=2), or affinity purified CN-12 (red bar 
n=2). The ATM/p53 peptide kinase assay was then performed using [ y32]-ATP. 
Biotinylated p53 was then collected on streptavidin beads and associated [ Y32P] 
activity was measured in a scintillation counter. (The height of each bar 
represents the mean and the vertical error bars the range of the two readings).
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Immunoprecipitated ATM does not phosphorylate the p53 peptide p53l0-19. 
HeLa cell nuclear extracts (50 million cells/sample) were immunoprecipitated 
with preimmune serum (black bar, n=2), or affinity purified CN-12 (red bar 
n=2). The ATM/p53 peptide kinase assay was then performed using [ Y32]-ATP. 
Biotinylated p53 was then collected on streptavidin beads and associated [Y32P] 
activity was measured in a scintillation counter. (The height of each bar 
represents the mean and the vertical error bars the range of the two readings).
control on both occasions indicating lack of significant phosphorylation above 
background by immunoprecipitated ATM.
4.3.3 Im m u n o p rec ip ita ted  A TM  from  HeLa cell n u c lea r extracts 
does no t p h o sp h o ry la te  the  p53 p ep tid es p53 Ser 15 or p53 T h r 18
The ability of imm unoprecipitated ATM to directly phosphorylate the p53 
peptides p53 Ser 15 and p53 Thr 18 was investigated in two separate 
experiments, using the affinity purified antibody CN-12 to immunoprecipitate 
ATM from HeLa cell nuclear extracts. The ATM/p53 kinase assay was then 
performed with a source of potentially activating DNA double strand breaks
(DNA dsbs) followed by measurement of p53 peptide [y^^P] incorporation in a
scintillation counter. Negative controls included immunoprécipitations with
preim mune serum and assessment of [y^2p] incorporation in the p53 peptide
A lal5 /A lal8  which cannot be phosphorylated on these residues (Table 4.2, Fig. 
4.8). Phosphorylation of the p53 peptides by an external source of DNA-PK
was used as a positive experimental control. The level of [y incorporation
for each sample was displayed as a percentage of that observed for the p53 Ser
peptide by DNA-PK. This corrected for the difference in the [y ^ ^P]ATP activity
dates between the experiments and allowed the results to be combined (Table 
4.2, Fig. 4.8): DNA-PK phosphorylates the p53 Serl5 peptide to the greatest 
extent followed by the p53 Thrl8 peptide. No phosphorylation of the negative 
control p53 A la l5 / Alal8 peptide could occur due to replacement of the serine 
and threonine with non-phosphorylatable alanine. Levels of phosphorylation 
of this peptide therefore represent non-specific background effects. Although
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Sample ['/32p]
Incorporation 
Expt 1/Expt2
% of
DNA-PK /p53 Ser 
Incorporation 
Exptl/Expt2
Mean % [y^^P] 
Incorporation
DNA-PK/p53 Ser 63,798/250.709 100/100 100
DNA-PK /p53 Thr 30,936/- 48.5/- 48.5
DNA-PK /p53 Ala 4,308/- 6.75/- 6.75
Hela/p53 Ser 643/807 1.007/0.322 0.665
Preimmune
H ela/p53 Ser 1,884/1,101 2.953/0.439 1.696
CN-12
H ela/p53 Thr 453/1080 0.710/0.431 0.571
Preimmune
H ela/p53 Thr 769/1136 1.205/0.453 0.829
CN-12
Hela/p53 Ala 844/1,108 1.323/0.442 0.883
Preimmune
Hela/p53 Ala 598/1,689 0.937/0.674 0.806
CN-12
Table 4.2
p53 peptide incorporation in the ATM/p53 peptide kinase assay using
preimmune serum or CN-12 immunoprecipitates from 50x10^ HeLa cells per 
sample.
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Fig 4.8
Immunoprecipitated ATM protein does not phosphorylate the p53 peptide 
substrates; p53 Ser 15 or p53 Thr 18. HeLa cell nuclear extracts ( 50 
million cells / sample ) were immunoprecipitated with preimmune serum 
or affinity purified CN-12. The ATM/ p53 peptide kinase assay was then 
performed . Biotinylated p53 from each sample was subsequently 
collected on streptavidin beads and the associated [y 32P] activity was 
measured in a scintillation counter. The experiment was performed twice. 
Results are presented as a percentage of the DNA-PK p53 Ser 15 peptide 
positive control. ( The bar height is the mean of the two readings taken 
in Table 4.2 ).
there w as som e varia tion  in the p53 pep tides tested, all show ed 
phosphorylation levels of less than 2% of the positive DNA-PK p53 peptide 
Serl5 (ie less than that seen for the negative control (DNA-PK A lal5/18) 
described above), indicating lack of specific phosphorylation of these p53 
peptides by ATM immunoprecipitated from HeLa cells.
4.3.4 Im m u n o p r e c ip ita te d  A T M  from  H eL a an d  G M 4724  c e ll  
n u clear  extracts d o e s  n o t p h osp h ory la te  the p53 p e p t id e s  p53 Ser  
15 or p53 Thr 18
The ability of im m unoprecipitated ATM to directly phosphorylate the p53 
peptides p53 Serl5 and p53 Thrl8 was investigated in two separate 
experiments, using the affinity purified antibody CN-12 to immunoprecipitate 
ATM from HeLa, GM4724 (wt) and GM2782a (ataxia telangiectasia) cell 
nuclear extracts. The ATM/p53 kinase assay was then performed as described
above (Fig. 4.9). Negative controls included assessment in each cell line of [y
32p] incorporation in the p53 peptide Alal5/18. Phosphorylation of the p53 
peptides by an external source of DNA-PK was again used as a positive 
experimental control. (The peptide p53 Thr 18 was not tested in the second 
experiment). The level of [y ^2p] incorporation for each sample was again 
displayed as a percentage of that observed for the p53 Ser peptide by DNA-PK. 
This corrected for the difference in the [y ^2p]ATP activity dates between the 
experiments and allowed the results to be combined (Table 4.3, Fig. 4.9). 
Although there was some variation in the mean % [y 32p] incorporation for 
each p53 peptide in each cell line the highest level of incorporation was still
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Fig. 4.9
Immunoprecipitated ATM protein does not phosphorylate the p53 peptide 
substrates: p53 Ser 15 or p53 Thr 18. Nuclear extracts from HeLa cells ( 50 
million cells sample ), GM 2782a and GM 4724 cells ( 5 million cells /  sample), 
were immunoprecipitated with affinity purified CN-12.The ATM /  p53 peptide 
kinase assay was then performed using for each of the p53 peptides shown. 
Biotinylated p53 from each sample was collected on streptavidin beads 
and the associated [y32P] activity was measured in a scintillation counter. 
Excluding the p53 Thr 18 peptide, the experiment was performed twice. Results are 
presented as a percentage of the DNA-PK p53 Serl5 peptide positive control. ( The 
bar height represents the mean of the two readings taken, as shown in Table 4.3 ).
Sample [y32p] 
Incorporation 
Expt 3/Expt 4
%of
DNA-PK /  p53 Ser 
Incorporation 
Expt 3/Expt 4
Mean % [y^^P] 
Incorporation
DNA-PK/p53 Ser 190,393/224,464 100/100 100
DNA-PK /p53 Thr 16,119/- 8.466/- 8.466
DNA-PK /p53 Ala 3,266/- 1.715/- 1.715
2782a/ p53 Ser 
IP:CN-12
2,396/7,241 1.258/3.226 2.242
2782a/p53 Thr 
IP:CN-12
1,355/- 0.712/- 0.712
2782a/p53 Ala 
IP:CN-12
1,874/1,468 0.984/0.654 0.819
4724/p53 Ser 
IP:CN-12
2,070/2,430 1.087/1.083 1.085
4724/p53 Thr 
IP:CN-12
3,253/- 1.709/- 1.709
4724/p53 Ala 
IP:CN-12
2,507/1,680 1.317/0.748 1.033
H ela/p53 Ser* 
IP:CN-12
11,175/1,547 5.869/0.689 3.279
Hela/p53 Thr* 
IP:CN-12
7,634/- 4.010/- 4.010
Hela/p53 Ala* 
IP:CN-12
10,312/822 5.416/0.366 2.891
Table 4.3
p53 peptide [y^^P] incorporation in the ATM/p53 peptide kinase assay using 
CN-12 immunoprecipitates from -5x10^ ataxia telangiectasia lymphoblastoid 
cells (GM2782a), -5x10^ GM4724 (wt) lymphoblastoid cells and * 50x10^ HeLa 
cells per sample.
only 4.01% (HeLa p53 Thrl8), that of the positive control*. The greatest
m easurem ent in GM2782a and GM4724 combined was for p53 Serl5 [y32p]
incorporation in GM2782a of 2.242%, indicating background or non-ATM
related [y32p] incorporation levels. Levels of [y^2p] incorporation in all
peptides with HeLa precipitated ATM were greater than that seen for both p53
Serl5 [y32p] incorporation in GM2782a and the DNA-PK p53A lal5 /A lal8
negative control. This observation was abolished on correcting for the effect of 
cell num ber (*the HeLa immunoprecipitates were made from ten times as 
many cells) and after considering the mean for DNA-PK negative control in
experiments 1 and 3 (4.233%). In addition values of [y^2p] incorporation in
HeLa cells show  small inter-experim ental variations: If the % [y ^^P ] 
incorporation in the p53 Serl5 peptide is averaged across experiments 1-4 (ie 
mean = 2.315%) it can be seen that this value is very close to the internal AT 
cell line (2782a) p53 Serl5 peptide negative control from experiments 3 and 4 
(mean = 2.242%) even without correcting for the increased cell number used in
the HeLa cell immunoprecipitates. This is evidence that [y 32p] incorporation
levels for all peptides in the cell lines examined can be accounted for by non­
specific background rather than ATM-related effects.
4.3.5 Im m u n o p r e c ip ita te d  A T M  from  H eL a an d  G M 4724  c e ll
n u clear  extracts d o es n ot p h osp h ory la te  PH A S-I
The affinity purified antibody CN-12 immunoprecipitates ATM from HeLa 
cells (Fig. 4.10, lanes 2 and 4), and GM4724 lymphoblastoid cells (Fig. 4.11, lane
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IP antibody; ^
WB:CN-12
ATM
Fig. 4.10
ATM protein can be immunoprecipitated from HeLa cells. 
Immunoprécipitation of ATM from HeLa cell nuclear extracts 
containing 2) 25 million cells per sample and 4) 5 million cells per 
sam ple, was performed using affinity purified CN-12. 
Immunoprécipitation using pre-immune serum from rabbit CN-12 
was also performed in samples 1) and 3) respectively as negative 
controls. The total immunoprecipitated nuclear extract (30 pi ), for 
each sample was loaded on a 7.5% acrylamide gel and subjected to 
SDS-PAGE. Subsequent Western blotting was performed with 
CN-12 antibody (1 pg/m l). These samples were prepared in 
parallel with the paired kinase samples (Fig. 4.12).
IP antibody:
WB:CN-12
I I ATM
Fig. 4.11
ATM protein can be immunoprecipitated from lymphoblastoid cell 
line GM4724 (ATM +/+) but not from the A-T lymphoblastoid cell 
line GM2782a (ATM-/-). Attempted immunoprécipitation of ATM 
from 2) GM4724 and 4) GM2782a cell nuclear extracts was 
performed using affinity purified CN-12. Immunoprécipitation 
using pre-immune serum was also performed in 1) GM4724 and 3) 
GM2782a cell lines for negative controls. 30 pi of extract (equivalent 
to 5 million cells per sample) was loaded in each lane of a 7.5% 
acrylamide gel and subjected to SDS-PAGE. Subsequent Western 
blotting was performed with CN-12 antibody (1 pg/m l). These 
samples were prepared at the same time as the paired kinase 
samples (Fig. 4.13).
2) but not from the A-T lymphoblastoid cell line GM2782a (Fig. 4.11, lane 4). 
Preimmune serum  immunoprecipitates an indistinct band from HeLa cells, 
GM4724 and GM2782a cells which is of a slightly lower molecular weight than 
ATM (Fig. 4.10 and 4.11). (NB less ATM is immunoprecipitated from 25 million 
FleLa cells in comparison with 5 million HeLa cells Fig. 4.10 lane 2 versus lane 
4. This may be due to inefficient cell lysis when 5 fold more cells are used). 
Paired samples for each of the above immunoprecipitates were subjected to the 
ATM/PHAS-I kinase assay, to investigate if immunoprecipitated ATM is a 
protein kinase capable of phosphorylating PHAS-I. Immunoprecipitates from 
the A-T cell line and immunoprecipitates using preimmune serum served as 
negative controls. Phosphorylation of PHAS-I by an external source of DNA-
PK served as a positive control. PHAS-I [y ^^P] incorporation for each sample
was determined by Western analysis and autoradiography of the transferred 
proteins (Figs. 4.12 and 4.13). A three day exposure was used to detect PHAS-I 
phosphorylation potentially caused by ATM and a 30 min exposure was used 
to detect PHAS-I phosphorylation  caused by added DNA-PK. W eak 
phosphorylation of a band equivalent to the lower band of purified PHAS-I 
(Fig. 4.4), was seen with HeLa cell, GM4724 and GM2782a immunoprecipitates 
(Fig.4.12 and 4.13). As GM2782a is an AT cell line, any phosphorylation of 
PHAS-I detected with GM2782a immunoprecipitates cannot be due to ATM. 
The likelihood of such phosphorylation being due to non-specific effects is 
increased by the fact that the PHAS-I phosphorylation seen was greater in 
GM4724 and HeLa (25 million cell derived sample) with non-affinity purified 
preimmune serum (Fig. 4.13, lane 4 and Fig. 4.12 lane 5). Non-affinity purified 
preimmune serum was known to contain more non-specific antibodies (data
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IP antibody: ^ o
I _ Phosphorylated 'PHAS-I
Fig. 4.12
Phosphorylation of PHAS-I in immunoprecipitates from HeLa 
cell nuclear extracts. ATM was immunoprecipitated from 2) a HeLa 
cell nuclear extract (equivalent to 5 million cells ) and 4) a HeLa 
cell nuclear extract (equivalent to 25 million cells) using the affinity 
purified antibody CN-12. Pre-immune serum was used as the 
immunoprecipitating antibody as a negative control for 2) and 4) in 
3) and 5) respectively. The ATM/PHAS-I kinase assay was then 
performed on the extracts as described previously. The total nuclear 
extract of 30 pi from each kinase reaction was then loaded onto a 
13% acrylamide gel. 1) Phosphorylation of purified PHAS-I protein 
by DNA-PK was used as a positive control. Subsequent radiographic 
exposure of the gel for 3 days revealed the phosphorylated protein 
bands in each extract. The DNA-PK/PHAS-I positive control band 
was excised from the dried gel and exposed for 30 minutes only.
IP antibody:
C
a-
e,
Phosphorylated
PHAS-I21 kDa
4
Fig. 4.13
Phosphorylation of PHAS-I in ATM immunoprecipitates from a 
lymphoblastoid cell line GM4724 (ATM +/+) and an A-T 
lym phoblastoid cell line GM2782a (ATM -/-). ATM was 
immunoprecipitated from 1) GM2782a and 3) GM4724 nuclear 
extracts using affinity purified antibody CN-12. Pre-immune serum 
from rabbit CN-12 was used as the immunoprecipitating antibody as 
a negative control in 2) GM2782a , and 4) GM4724 respectively. The 
ATM/PHAS-I kinase assay was then performed on the extracts as 
described previously. 30 pi of nuclear extract (equivalent to 5 million 
cells) from each kinase reaction was then loaded onto a 13% 
acrylamide gel. 5) Phosphorylation of purified PHAS-I protein by 
DNA-dependent protein kinase was used as a positive control. 
Subsequent radiographic exposure of the gel for three days revealed 
the phosphorylated protein bands in each extract. The 
DNA-PK/PHAS-I positive control band was excised from the dried 
gel and exposed for 30 minutes only.
not shown) perhaps capable of immunoprecipitating proteins which might 
phosphorylate  PHAS-I. In addition although more ATM protein  was 
im m unoprecipitated from 5 million than from 25 million HeLa cells, no 
corresponding difference in the level of PHAS-I phosphorylation was seen 
betw een these two samples (Fig. 4.12 lane 2 versus lane 4) which also 
suggested that the weak phosphorylation of PHAS-I seen was ATM- 
independent.
4.4 D iscussion
Several assays using different substrates and a variety of modifications 
have been em ployed to investigate w hether ATM has a protein kinase 
function . P relim inary  'au tophospho ry la tion  assay ' resu lts  show ed 
phosphorylation of a protein of similar size to ATM, together with proteins of 
160 and 140 kDa. It was tem pting to speculate that the observed 350 kDa 
phosphoprotein represented autophosphorylated ATM and the 160 and 140 
kDa proteins were co-immunoprecipitated, phosphorylated substrates of ATM. 
However, this could not be stated with certainty for two reasons. Firstly a 
further study of the phosphoproteins was not possible because additional 
attem pts at the assay proved unsuccessful. Secondly, the possibility of non- 
specifically co-purifying proteins in the immunoprecipitates was raised by the 
presence of much weaker bands of similar size (-350, 160, 140 kDa) with the 
negative (no immunoprecipitating antibody) control, potentially due to non­
specific protein carry over on the protein-A-Sepharose beads. Pure, active 
ATM obtained by biochemical fractionation is extremely difficult to prepare 
and even with this source of ATM, the possibility of co-purifying proteins
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perhaps including kinases has to be considered (S. Jackson, personal 
com m unication). Related problem s may also apply  to the use of 
immunoprécipitation to provide an ATM source as anti-ATM antibodies may 
also precipitate other known or unknown homologous proteins.
The lack of demonstrable ATM -dependent phosphorylation of p53 
peptides and PHAS-I seen in the other assays may be explained in several 
ways: It is possible that ATM does not function as a protein kinase, at least 
under the conditions used, the substrates or the portion of the substrate chosen 
may have been inappropriate or perhaps unknown co-factors are required for 
ATM kinase function which were not included in these experiments. In the 
later assays, a source of restriction enzyme treated plasmid DNA was chosen 
to mimic radiation induced DNA damage instead of using cell irradiation to 
activate ATM, however this modification of the assay still did not result in 
detectable specific kinase activity.
The extent to which the observed levels of phosphorylation achieved 
were truly non-specific and not related to ATM function was investigated by 
including ataxia-telangiectasia cell immunoprecipitates as a negative control in 
the later experiments. These showed phosphorylation levels of a similar order 
to the non-AT cell lines tested which provided further evidence that the 
phosphorylation observed in the samples was not ATM-dependent.
The attempts to demonstrate an ATM protein kinase function described 
above were either negative or inconclusive. However, there has been 
considerable interest in this area recently and other groups investigating the 
putative protein kinase function of ATM have published positive results. His 
tagged full-length A T M  cDNA has been cloned into a baculovirus vector and
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the recombinant protein expressed (Scott et aL, 1998). Despite a very low yield 
(nanogram quantities) of recombinant ATM, autophosphorylation activity was 
observed in baculovirus infected Sf9 insect cell lysates imm unoprecipitated 
with an anti-His tag antibody. Interestingly more than one phosphorylated 
band was seen (as for the autophosphorylation assay described previously). 
This observation m ight indicate ATM -dependent phosphorylation of co- 
im m unoprecipitated proteins or breakdown products of ATM itself. The 
smaller phosphorylated proteins are unlikely to be due to internal splice 
variants of ATM protein because although alternative splicing of upstream  
and downstream regions of ATM  mRNA occurs, splicing affecting the coding 
region has not been described (Savitsky et al., 1997). Amongst other potential 
ATM targets which have been investigated, evidence for c-Abl as an ATM 
substrate has also been provided: a c-Abl interaction domain has recently been 
characterised between amino acids 1366-1466 of ATM using a yeast 2 hybrid 
system  (Shafman et ah, 1997). This may be functionally im portan t as 
stimulation of the c-Abl tyrosine kinase activity has been found to occur after 
ionising radiation in ATM wild type cells but does not occur in cells from AT 
patients nor in cells from ATM knockout mice. Ectopic co-expression of a 
functional ATM kinase domain and c-Abl in abl null 3T3 cells activates the 
tyrosine kinase activity of c-Abl to a similar maginitude to that stimulated by 
ionising irradiation. This c-Abl activation did not occur with expression of a 
m utated ATM kinase domain nor if the co-expressed c-Abl was m utated 
(S465A). Therefore, ATM appears to phosphorylate c-Abl on Ser 465 in vitro 
and activate its tyrosine kinase activity (Baskaran et al., 1997).
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ATM has also been reported to phosphorylate IkB-œ (Jung et aL, 1997), 
an inhibitor of the nuclear factor NF-kB transcritional activator. It is possible 
that aberrant regulation of IkB-œ and NF-kB contribute to the A-T cellular
phenotype because a cDNA encoding a truncated form of IkB-œ has been
shown to correct the radiosensitivity and radioresistant DNA synthesis defect 
post irradiation in SV40 immortalised ataxia telangiectasia fibroblasts (Jung et 
al., 1995).
Interest has always focused on p53 as a possible direct downstream  
target of ATM, hence the attempted development of ATM/p53 peptide kinase 
assays, but recent investigations have suggested that the ATM-p53 interaction 
may be more indirect. These studies have shown that ionising radiation causes 
dephosphorylation of p53 on Ser 376 which allows binding of 14-3-3 proteins 
to p53 to enhance its sequence-specific DNA binding. Interestingly, Ser 376 
dephosphorylation and 14-3-3 binding of p53 do not occur in A-T cells which 
exhibit delayed and reduced p53 responses (Waterman et al., 1998). It was 
therefore proposed that ATM might be responsible for the activation of a 
phosphatase to dephosphorylate p53 on residue Ser 376 to transduce the 
radiation response, although the target phosphatase is not known. If this 
hypothesis is true it w ould provide an explanation for the lack of 
phosphorylation seen in the p53 peptide assays described above and direct 
attention towards other regions of p53 and the development of ATM kinase 
assays incorporating preparations of ATM with additional enzymes or co­
factors.
158
The use of p53 peptides in these experiments, rather than full length 
recombinant or immunoprecipitated p53 may also have created problems if 
carboxyterm inal regions of p53 are im portant in p53 / ATM interactions 
required for ATM kinase activity. Therefore in theory, these assays could be 
improved upon by the use of a full length substrate. Since the submission of 
this thesis however there have been two reports of DNA damage dependent 
phosphorylation of short p53 peptides on p53 SerlS (p53 residues 1-47, and p53 
residues 1-24) and PHAS-I by ATM (Banin et al., 1998), (Canman et al., 1998). 
ATM activation in these studies was due to DNA dam age caused by 
neocarzinostatin  or 5 Gy of ionising irradiation. It is of considerable 
importance that in contrast to DNA-PK, the protein kinase activity of ATM 
was dependent on the presence of 4-lOmM of Mn^+ ions and it was also noted 
that an external source of DNA double strand breaks was ineffective in the 
activation of ATM (Canman et al., 1998). The lack of Mn^+ ions and the use of 
restriction enzyme cut plasmid to provide an activating source of DNA dsbs in 
the current study provide sub-optimal conditions for ATM activation and may 
largely explain the negative results obtained.
My original intentions were to develop and use an ATM kinase assay 
for estimation of the functional integrity of ATM in women with breast cancer. 
Due to problems with the development of such an assay I decided to perform a 
study of the DNA repair capacity in the peripheral blood lymphocytes I had 
collected from these patients. This study is described in Chapter 6 .
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Chapter 5
Construction of a Potentially Dominant Negative 
Mutant of the ATM Kinase Domain
5.1 Introduction
The S. cerevisiae VPS34 (vacuolar protein sorting) gene is related by 
sequence to the hum an ATM gene and has PI 3-kinase activity (Stack et al., 
1995) (Fig. 5.1). When active, the serine/threonine protein kinase Vpsl5 
recruits Vps34 to the membranes of yeast golgi apparatus and stimulates 
Vps34 PI 3-kinase activity. This then activates the sorting of proteins eg. 
carboxypeptidase Y, to the yeast vacuole. M utant vps34 alleles which differ 
from the wild type sequence in certain critical regions of the conserved kinase 
motif, if over-expressed in a wild type strain display a dom inant negative 
phenotype with a reduction in PI 3-kinase activity and missorting of soluble 
vacuolar proteins. This effect appears to be due to the m utant Vps34 titrating 
active Vpsl5 away from wild type Vps34 protein as over-expression of the 
wild type VPS34 allele suppresses the dominant negative phenotype. One such 
vps34 m utant allele creates the protein coding change D749E in the kinase 
motif (Schu et al., 1993). Therefore it was reasoned that by creating an identical 
m utation in the conserved kinase motif of hum an A TM  (D2889E) and 
overexpressing this in a hum an cell line it might be possible to abolish any 
kinase activity of wild type ATM protein in a dominant negative fashion. The 
role of ATM kinase activity might then be elucidated by studying aspects of 
the resulting cellular phenotype. Of particular interest was the putative role of
ATM kinase activity in the response to DNA damage and cell survival post y 
irradiation.
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PI-3K like 
domain
ATM
2650 3056
C^T/CTA/GC^ Wild Type Sequence
SVATSSIVGYILGLGDRHVQN V H ID LG V A
2855
ATP- binding and phosphotransferase 
activity
2893
PGR mutagenesis
GAG/CTA/GGT 
\  /  
VHIELGVA
Mutated Sequence
D R H L D N L  ...............DFG wild type Vps34
■ protein catalytic motif
D R H L D N L   EFG. Mutated Vps34
Fig. 5.1
Schematic diagram showing the construction of the ATM kinase domain T8667G 
mutation by PGR mutagenesis. The wild type and mutated Vps34 catalytic 
motif is shown below for comparison.
5.2 A dditional materials and methods
5.2.1 C lo n in g  o f a p u ta tiv e  A TM  d o m in a n t n e g a tiv e  k in a s e  
dom ain  b y  PCR-site d irected  m utagenesis
The purified AT7-9 fragment released from the phage DNA by Sail 
digestion (Chapter 2, Fig. 2.1), was amplified and mutated using a modified 
polymerase chain reaction that relies on a first round PGR amplification of two 
fragments, one 5' and one 3' which overlap in the region where the m utation is 
to be generated. (The internal primers of these reactions were designed to 
include the required mutation).
The two fragments from the first round were then used as the template 
for the second round PGR which is a simple amplification reaction using the 
external primers. 8081s was designed to include a Sail site (GTGGAÇ) and a 
Haemagglutinin (HA) tag sequence (YPYDVPDYA). (Homology with the ATM 
sequence begins at the 9171r includes the ATM stop codon (TGA) ie 5'TGA 
and a N otl site (GGGGGGGO. Base changes creating the mutation at bp 8667 
are denoted in bold.
5' ->3' Primer 8081s (external):
G /A G A /GTG/GAG/AGG/ATG/TAG/GGG/TAG/GAG/GTG/GGG/GAG/
TAG/GGAVGGA/GGT/GTA/AAT/TTA/GG
5'->3' Primer 8651s (internal):
GA A/GTT/GTA/GAT/ATA/GAG /G TA/GG T/GTT/G GT
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3'->5' Primer 8679r (internal);
A G C/A A C/A CC/TA G /CTC/TA T/A TG /TA C/A A G /TTC 
3'->5' Primer 9171r (external):
A G A/GG C /G G C /C G C Z-^ TCA/C A C /C C A /A G C /T T T /C C A /T rr/T G n  
First Round PGR
For each reaction, l)ig of the purified AT7-9 Sail fragment was used as a 
template, 2.5 pi of each 40 pM primer (For reaction 1 primers 8081s and 8679r 
were used and for reaction 2, primers 8651s and 9170r were used), 0.5 pi of 
Pwo DNA polymerase (Boehringer Mannheim), 10 pi of lOX Pwo buffer with
Mg2+ and 10 pi of 2.5 mM dNTPs were used with dH 20  to a final volume of 
100 pi. A drop of mineral oil was then placed on top of the mixture to prevent 
evaporation. PGR was performed in an Omnigene PGR machine (Flybaid), for
15 cycles of the following: Dénaturation at 95°G for 30s, Annealing at 55°G for 
45s and extension at 72^C  for Imin. The entire reaction m ixture was then 
extracted with an equal volume of phenol isoamylalcohol/ GGI4 (24:1:24). The 
aqueous phase was taken off and precipitated with a O.IX volume of 3 M Na 
acetate pH  5.2 and 2.2X volume of 100% ethanol. The mixture was vortexed 
and incubated on ice for 10 min centrifuged (14,000 rpm, 10 min), followed by 
a wash in 70% ethanol. The pellet was then resuspended in 10 pi of dH 20 . The 
DNA from  each reaction was then subjected to 0.7% agarose gel 
electrophoresis and bands of the appropriate size were visualised under a low 
intensity UV light and excised. Both gel slices were then allowed to freeze on a 
glass plate over dry ice before being placed in a single spin column (made from 
a 1ml blue pipette tip with the upper end cut off, placed in a 1.5 ml tube) and
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being spun in a microcentrifuge (Eppendorf) at 6000rpm for 45 s. Prolonged 
spinning should be avoided as the agarose can inhibit subsequent reactions. ~ 
15 pi of combined DNA from PCRs 1 and 2 was obtained off the column. This 
was used as the template for the second round PCR.
Second Round PCR
The entire combined DNA from reactions 1 and 2 was used as the 
template for this reaction together with 0.5 pi of Pwo DNA polymerase, 2.5 pi
of the 40 pM external primers 8081s and 9170r, Pwo buffer with Mg^+ and 10 
pi of 2.5 mM dNTPs were used with dH 20 to a final volume of 100 pi. After 
covering the reaction mixture with a drop of oil, the PCR was performed for 15 
cycles of the following: Dénaturation at 95°C for 30s, Annealing at 37^C for 45s
and extension at 72^C  for Im in. 5 pi of the reaction product was then 
subjected to 0.7% agarose gel electrophoresis to check that a band of the 
appropriate size was produced. 15 pg of the m utated fragm ent was then 
digested with the restriction enymes Sail and N otl and the digest was then 
extracted with an equal volume of phenol isoamylalcohol/CCl4 . The aqueous 
phase was taken off and precipitated with a O.IX volume of 3 M Na acetate pH 
5.2 and 2.2X volume of 100% ethanol. The mixture was vortexed and incubated 
on ice for 10 min followed by a wash in 70% ethanol. The pellet was then 
resuspended in 10 pi of dH 20  to concentrate it. Meanwhile the expression 
vector pCD2-CMV (O'Connell et al., 1994), was also digested with Sail and 
N otl and 1 pg of the cut vector and 2 pg of the AT8081-9170 fragment were
ligated at 16 overnight using 0.5 pi T4 DNA ligase and 0.5 pi ligase buffer in 
a final reaction volume of 4 pi. Vector only and alternative insert controls were
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also included as well as a control with neither vector nor insert. 0.7  pi of each
reaction product was then used to transform E.coli DH10(3 by electroporation
as decribed previously. Transformed bacteria were then plated on LB/AM P
plates and incubated overnight at 37°C. No colonies were seen on the negative 
control plate, 1 was seen on the vector only control plate and 400 colonies were 
seen on both insert plates. Colonies were picked from the AT8081-9170 insert 
plate from which bacterial minicultures and then plasm id m inipreps were 
m ade. Restriction digests w ith Sail and N o tl and 0.7% agarose gel 
electrophoresis confirmed the presence of the vector with the 1.1 kb insert in 
the 10 minicultures tested. Large scale preparation of plasmid DNA was then 
performed and the resultant plasmid DNA was sequenced using the external 
primers 8081s, 9170r and several other primers including:
8804r(5019r):
CCTGAGAGTTTCTCATCACTTCC
8286s(4501s):
GCGAAGTGGTGTTCTTGAATGGT
CMV T7 lead in primer: AATACGACTCACTATAG
Sequencing was performed and analysed as described previously.
The wild type AT7-9  clone DNA from the phage had been previously 
sequenced by myself during earlier cloning attempts and deviated from the 
published sequence (Savitsky et al., 1995), by two base changes: G9093A which 
was a silent change (Glut->Glut), and G9007A which resulted in Asp>Asn. 
Professor Yosef Shiloh agreed that the changes were present in the clone he
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sent me but wondered if they were specific to that clone or if they were rare 
polym orphism s. Both of these sequence anomalies have, how ever been 
iden tified  subsequen tly  in norm al and A-T ind iv idua ls  (personal 
communication from Dr Louise Izatt) and they may represent the true wild 
type sequence in this region.
5.2.2 T ran sien t tran sfec tio n  and  clonogenic assay  of H1299 cells 
expressing  a m u tan t ATM  k inase  dom ain
Transient transfection of human non-small cell lung carcinoma NCI- 
H1299 cells w ith a mammalian expression vector pCD2-CMV containing a 
m utated ATM kinase domain ( pCD2-CMV-ATELG) or the empty vector pCD2- 
CMV), was achieved using the calcium phosphate method (Graham and Eb, 
1973): The H1299 cells were cultured until they were in the log phase of growth
and then seeded at 0.5-1 x 10^ cell/9cm Falcon tissue culture plate (Becton 
Dickinson) 24 hours before transfection. They were then refed with medium 2 
hours before adding the precipitate. The following solutions were then made
up: 2X Hepes buffered saline (Hepes lOg/1, NaCl 16g/l pH  to 7.10 ± 0.05 with 
NaOH and filter sterilised), IOOXPO4 (35 mM Na2HP04^ 35 mM NaH2P04^) 
and 2M CaCl2 , filter sterilised. To make a precipitate of 1.1 m l/9  cm dish, 550 
|il of 2XHBS was added to l lp l  of IOOXPO4 in a falcon tube, while 20 pg of 
DNA (pCD2-CMV-ATELG, or pCD2-CMV) was diluted in dH 20 with 125 mM 
CaCl2 to a total volume of 539 pi in a separate tube. The DN A/CaCl2 was then 
mixed in drop wise to the HBS/PO4 , while air was bubbled through the latter 
using a pipettor and a pasteur pipette. The precipitate was then allowed to
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stand for 30 min at room temperature and finally mixed with a vortex before 1 
ml of the precipitate was added dropwise over the surface of each 9cm dish. 
The cells were returned to the incubator for 16 hours after which they were 
washed once with PBS, 2.5 mM EDTA to chelate excess calcium and refed with 
medium. (Transient expression of the mutated kinase domain should peak 48 
hours later). Anti-CD2 bearing magnetic beads (Dynal M.450) were then used 
to harvest transfected cells which were then transferred to separate 15 cm 
Falcon tissue culture plate (Becton Dickinson) and were re-fed before being
incubated at 37°C for 48 hours prior to harvesting in PBSA/2 mM EDTA and 
resuspending cells from each 10 cm plate in lOOpl of 2X SDS protein sample 
buffer. 40pl of each H I299 transfectant lysate was then subjected to SDS-PAGE 
on a 12% gel. After protein transfer as described previously, haemagglutinin- 
epitope bearing proteins were detected by Western blot analysis using anti-HA 
tag antibody. The expected size of the HA-tagged m utated ATM kinase 
domain was -40 kD.
For clonogenic study H1299 cells transiently transfected w ith empty 
vector or pCD2-CMV-ATELG were harvested as described above, resuspended 
in culture m edium  in 15 ml tubes (Falcon) and irradiated at a rate of 0.3 
G y/m in  to a total of 0.5 Gy, 1 Gy, 2 Gy, 3 Gy, 4 Gy and 6 Gy. Cells from each 
timepoint were subsequently plated in triplicate on 9 cm tissue culture plates 
in DMEM medium with 10% FCS and left undisturbed for 10 days prior to 
fixation in 2:1 methanol : acetic acid and cell staining for 30 min w ith Crystal 
Violet (1 m g /m l in H 2 O) followed by colony counting (n.b a colony was 
defined as a group of 50 or more cells). Numbers of colonies were adjusted
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according to the plating ratio of unirradiated empty vector: pCD2-CMV-ATELG 
transfectants.
5.3 Results
5.3.1 C reation  of the  T8667G m uta tion  in  the ATM  k in ase  dom ain
Automated sequencing of both the wild type AT7-9 clone and the A T M  kinase 
domain (after PCR site directed mutagenesis), was performed (Fig. 5.2). This 
confirmed the presence of the desired mutation (T8667G) in the m utant ATM  
fragm ent and showed an intact lead-in sequence from the CMV promoter. 
Comparison of both of the above with the published sequence also revealed 
the presence of the two other base changes G9007A and G9093A which 
probably represent the true wild type sequence as previously described. No 
other mutations were detected.
5.3.2 E xp ressio n  of th e  m u ta n t ATM  k in a se  d o m a in  in  H1299 
pCD2-CM V-ELG transfectan ts
W estern b lo tting  of H1299 cell pCD2-CMV-ATELG transfectants and 
subsequent detection using an anti-HA tag antibody confirmed the presence of 
an HA-tagged protein of -40 kDa (the expected size of the m utant kinase 
domain). This protein was not detected in H1299 cell lysates transfected with 
the empty pCD2-CMV vector alone (Fig. 5.3). Multiple other heavier proteins 
were detected in both samples and probably represent anti-CD2 antibody 
chains non-specifically detected by the secondary antibody layer. HA-tagged
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Fig. 5.2
C h r o m a t o g r a m s  to d e m o n s t r a t e  the w i ld  type  s e q u e n c e  o f  the  A TM  
g e n e  ( u p p e r  p a n e l )  a n d  the  T 86 6 7 G  m u t a t i o n  g e n e r a t e d  by PCR  
m u t a g e n e s i s  ( l o w e r  p a n e l ) .  T h e  l ac k  o f  a l i g n m e n t  o f  th e  
c h r o m a t o g r a m s  is d u e  to base  s p a c i n g  d i f f er enc es  as the se  s a m p l e s  
w er e  s e q u e n c e d  on  d i f ferent  gels .
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Fig. 5.3
HI299 cells transfected with pCD2-CMV-ATELG 
express the mutant ATM kinase domain. 40 pi 
(equivalent to 120,000 cells) of H I299 cells 
transfected with the empty vector pCD2-CMV 
(CD2), or vector with the mutant ATM kinase 
domain (CD2-ELG), were subjected to 
SDS-PAGE. The HA-tagged mutant ATM kinase 
domain was detected by Western blot analysis 
using anti-HA antibody. HA-tagged POH was 
used as a positive control.
POH protein was provided as a positive control for the anti HA-tag antibody 
and the proteins of larger molecular weight described above w ere not 
identified in this sample.
5.3.3 E ffect o f  th e  m u tan t A T M  k in a se  d o m a in  on  H 1299 p C D 2 -  
CM V-ELG  c lo n o g en ic  su rv iva l
An assay of clonogenic cell survival was performed in triplicate on H1299 cells 
transfected w ith pCD2-CMV-ATELG or the em pty vector for a range of 
different doses of y radiation (0 , 0.5, 1, 2 , 3, 4 and 6 Gy). There w as no
difference between these two cell populations except at the 4 Gy dose point 
w here the m utant ATM kinase dom ain transfectants show ed a reduced 
clonogenic cell survival (26.18% vs 46.11% for the empty vector transfectants). 
This difference was not maintained at the 6 Gy dose point (Fig. 5.4).
5.4 D iscussion
The m utant ATM kinase domain which was apparently expressed in 
H1299 transfectants did not cause an A-T cell phenotype in terms of cellular 
radiosensitivity (measured here by clonogenic survival after IR) which would 
have been expected if the m utant domain impeded the activity of the wild type 
protein in a dom inant negative manner. Several explanations may account for 
the observations made. Firstly, there is the unlikely possibility that the 40 kDa 
protein identified in the pCD2-CMV-ATELG transfectants by Western blotting 
may have represented a protein other than the recombinant ATM kinase 
domain. As no anti-ATM kinase domain antibodies were available for use at
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Dose of gamma radiation (Gy)
Graph to illustrate the relative clonogenic survival of HI299 cells transfected 
with the empty vector pCD2-CMV (CD2) and vector containing the 
mutated ATM kinase domain pCD2-CMV-ATVlELG (ELG), with increasing 
dose of Y radiation. (The experiment was performed in triplicate and the 
sample means are presented).
the time of this study, the identity of the presumed recombinant protein could 
not be verified. This was of importance because -15 bp at the extreme 3' end of 
the m utant construct was not sequenced and the presence of the native stop 
codon was not confirmed. Secondly, the small m utant kinase dom ain 
expressed may have lacked the relevant protein-protein interaction sites 
required to inhibit the wild type protein in a dominant negative fashion. This 
possibility was entertained prior to conduction of this work but attem pts at 
cloning larger fragments of the AT7-9 clone 5' to the m utant kinase domain 
were unsuccessful due to difficulties with the secondary stage PCR reactions 
(data not included).
The importance of upstream  regions in ATM function is suggested by 
the fact that expression of ATM fragments containing the ATM leucine zipper 
motif enhanced the radiosensitivity and chromosomal breakage and abrogated
the S-phase checkpoint after y radiation in a hum an RKO colorectal carcinoma
cell line (Morgan et al., 1997). Moreover, in 1996 a "kinase-dead" m utant of 
Rad3 (Rad3 D2249E) resulted in a phenotype with increased radiosensitivity 
(Bentley et al., 1996). Even more recently, a kinase inactivated m utant of the
ATR  (ataxia telangiectasia and rad3+ related) gene has been described in 
which the equivalent conserved residue in the DFG motif in the kinase domain 
was altered by site directed mutagenesis such that the conserved D (aspartic 
acid) at residue number 2494 was substituted by an E (glutamic acid), as for the 
ATM kinase dom ain described in the current study and the Rad3 m utant 
described above. The expression of constructs containing this substituted ATR 
kinase domain in an SV40-transformed hum an fibroblast cell line resulted in
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increased radiosensitivity and reduced colony forming ability consistent with a 
dominant negative effect of the kinase-inactive form. In support of this 
hypothesis, expressed mutant kinase domain constructs were found to form 
part of a larger protein complex when analysed by gel filtration, consistent 
with their presumed ability to titrate other important proteins from active ATR 
kinase species (Wright et al., 1998).
The H1299 cell transfectants in the current study were p53 null and to 
investigate whether this explained their lack of increased radiosensitivity after 
IR, Dr Weg Ongkeko, a PhD student in the laboratory performed some 
additional work using the mutated ATM kinase domain. Dr Ongkeko stably 
transformed the plasmid pCD2-CMV-ATELG, into H1299 cells bearing a 
temperature sensitive p53 allele. Two resulting clones AT6 and A T ll and two
empty vector pCD2-CMV controls were treated with 0, 1, 2, 4, or 7 Gy of y
irradiation and each treatment group was replated in triplicate and incubated
at 32°C (p53 active) or 37°C (p53 inactive) for 48 hours. The plates were then
allowed to incubate at 37^C for 10 days prior to colony staining and counting. 
No differences in clonogenic survival were observed between any of the cell 
lines tested (data not shown), although all the clones were CD2 positive by 
flow cytometry.
As discussed, the small size and lack of extensive upstream regions of 
the protein kinase domain used for these studies may have prevented 
interactions necessary for the dominant negative effect however the technique 
could also have been improved upon by performing assays of expression of 
the recombinant kinase domain over the timecourse of the experiment. Short
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term assays eg the comet assay could also have been used to estimate the 
amount of DNA damage due to apoptosis and inadequate DNA repair at 
different timepoints in the experiment rather than just using the final 
clonogenic survival post irradiation, which is remote from the transient 
expression period, as an index of ATM function.
For these reasons and because increased radiosensitivity which is a 
hallmark of absent ATM kinase activity was not observed in the transfectants 
investigated in the current study, this project was not developed any further.
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Chapter 6
Investigation of the Constitutional DNA Repair 
Capacity of Patients with Breast Cancer using the
Alkaline Comet Assay
6.1 Introduction
The following investigation into the constitutional DNA repair capacity of 
lymphocytes from women with breast cancer using the comet assay was 
embarked upon because of an interest in genome instability in the aetiology of 
the disease. This was stimulated by reports of the association of A T M  
heterozygosity and breast cancer (Swift et al., 1976), (Swift et al., 1987), 
(Pippard et al., 1988), (Borresen et al., 1990), (Swift et al., 1991), as discussed in 
Chapter 1 and secondly by the finding of elevated chromosomal 
radiosensitivity in lymphocytes from breast cancer patients compared with 
normals (Scott et al., 1994). An introduction to the comet assay together with 
the reasons for its suitability for this study is given below. A detailed review of 
breast cancer, genome instability and DNA repair is provided in Chapter 1.
6.1.1 The comet assay
The single cell gel electrophoresis SCGE assay otherwise known as the 
comet assay was developed in 1986 (Singh and Stephens, 1986), (Singh et al., 
1988), based on an assay to detect DNA damage which had been designed 
previously (Ostling and Johanson, 1984), (Rydberg and Johanson, 1978). It has 
been of considerable value in investigating cellular responses to DNA damage, 
in animal and in vitro studies of genotoxicity and more recently in human 
toxicity biomonitoring (Collins et al., 1997). Many variations of the comet assay 
now exist and have recently been reviewed (Fairbum et al., 1995). When 
performed under alkaline conditions, the assay is an extremely sensitive 
indicator of DNA damage due to single strand breaks (a major component of
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DNA damage due to y rays), and alkali-labile sites. About 50 single-strand 
breaks per cell (equivalent to 0.05 Gy), can be resolved using the method 
described below. DNA double strand breaks can also be also detected under 
these conditions (Collins et al., 1997).
The technique relies on a suspension of single cells (with damaged or 
undamaged DNA), being embedded in agarose and then lysed under alkaline 
conditions using high salt to extract the proteins. Cell lysis with detergent 
causes the nucleus of the cell to be converted into a non-membrane bound, 
nucleoid' (comet head), containing non-nudeosomal supercoiled DNA. Under 
alkaline conditions, which assist the detection of DNA single strand breaks, the 
supercoiled DNA within the nucleoid is relaxed and denatured into negatively 
charged broken single strands which then migrate toward the anode during 
electrophoresis to form the comet tail. The alkali also converts alkali-labile 
sites, such as apurinic/  apyrimidinic (AP) sites created when bases are lost, 
into DNA breaks (weakly alkaline conditions are less able to do this than is 
strong alkali). The high salt enhances the rate of strand separation which 
allows extended comet tails to form. To estimate the number of DNA double 
strand breaks formed post DNA damage, the electrophoresis can be performed 
under neutral conditions. Under these conditions DNA loops are formed and 
exten d  out from the nu cleo id  to create more solid, elongated comets 
(McKelvey-Martin et al., 1993). Both the neutral and alkaline comet assays 
detect DNA single strand breaks (Ostling and Johanson, 1984), (Singh et al., 
1988), although this is often overlooked in the literature as described by 
(McKelvey-Martin et a]., 1993). After the electrophoresis stage of the assay, a
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fluorescent dye such as propidium iodide which binds to DNA is used to 
reveal the comets when viewed with a flourescence microscope.
The relative intensity of fluorescence in the comet tail is dependent on 
the frequency of DNA breaks. This can be measured using a variety of comet 
parameters eg comet tail length, % comet tail DNA, and the tail moment. The 
tail moment is most often quoted and is the product of the amount of DNA in 
the tail and the mean distance of DNA migration in the tail. Because the comets 
from a population of single cells can be observed, this method is able to detect 
whether all cells within a population are able to tolerate or process DNA  
damage equally or whether particularly sensitive sub-populations exist.
Apart from genotoxicity testing, the assay can also be used to measure 
DNA repair. In this case the cells are allowed varying amounts of time to 
recover from DNA damage prior to performing the comet assay. The kinetics 
with which cells perform DNA repair can then be measured (Singh, 1996), 
(Collins et al., 1997). This is a major advance because until the advent of the 
comet assay no tests were suitable or sensitive enough to monitor DNA repair 
differences between individuals. Now the constitutional (although perhaps 
lymphocyte specific), ability to repair various lesions (eg single or double 
strand breaks) can be determined by performing the comet assay on peripheral 
blood lymphocytes from the individual in question. Differences in human 
DNA repair processes have been implicated as a predisposing factor in the 
development of malignancy and several papers examining DNA repair and the 
occurrence of particular human cancers including lung cancer (Wei and Spitz, 
1997), and breast cancer (Jaloszynski et al., 1997), have recently been published.
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Despite the popularity and obvious applications of the comet assay, few 
studies have concentrated on the reliability and validity of results obtained. 
Those studies which have been performed (Collins et al., 1997), (Visvardis et 
al., 1997), suggest that whilst there is considerable inter-individual variability 
in DNA damage responses, samples taken from the same individual prepared 
on different slides or at different times after cryopreservation do not differ 
statistically in the assay results. However initial DNA damage can vary on an 
intra-individual basis and this can be seen when the same individuals donate 
cells on two different occasions for testing (Collins et al., 1997). This may 
represent real physiological variations with time related for example to 
changes in the amount of oxidative stress, genotoxic burden or dietary 
antioxidant profiles. Environmental genotoxins (eg tobacco smoke) may 
produce DNA damage, probably due to the effect of tar derivatives and such 
factors should be considered in study design (Piperakis et al., 1998), (Collins et 
al., 1997). Allowing for such caveats, the comet assay now offers a valuable 
opportunity to investigate the phenomenon of genome instability caused by 
faulty DNA repair processes.
Genomic instability in peripheral blood lymphocytes of women with 
breast cancer has been investigated previously (Scott et al., 1994), (Parshad et 
al., 1996) and was described in Chapter 1. In these studies chromatid breaks 
were used as a measurement of genomic instability as unrepaired DNA strand 
breaks are processed to chromatid breaks which can be detected at the 
susequent metaphase (Natarajan et al., 1980). Other end-points such as 
aberrations in metaphase chromosomes and micronucleus formation have also 
been used as indicators of genome instability. Apart from the fact that the
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analysis of such endpoints required skilled observers and was extremely time- 
consuming, the endpoints themselves are indirect and somewhat removed 
from the damaging and reparative processes. The comet assay is relatively easy 
to perform and analyse and the endpoint reflects the level of DNA damage 
itself which is more closely related to causative factors. It can also be modified 
to investigate particular types of DNA lesions (Collins et al., 1997).
Investigation of the DNA repair capacity of peripheral blood  
lymphocytes from breast cancer patients and healthy controls may help to 
further elucidate the role which DNA repair defects play in predisposition to 
the disease. If a clear association with defective repair is found, the comet assay 
might provide a means of selecting women for more intensive breast cancer 
screening.
6.2 Additional materials and methods
6.2.1 C o llec tion  of b lood  sam ples
10ml blood samples were collected in EDTA tubes by Margaret Dean, 
phlebotomist for the local breast surgery unit, from patients with breast cancer 
who had given prior informed and signed consent after discussion with the 
Breast Care Sisters, Sarah Babb and Andrea Gamble. Treatment response data, 
family histories and information on smoking were collected from the clinical 
notes and the Breast Cancer Database at the Churchill and John Radcliffe 
Hospitals, Oxford. Control samples of 10ml of blood were collected from
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women volunteers working in the Institute of Molecular Medicine, who had 
no history of breast cancer in first degree relatives and who were non-smokers.
6.2.2 S epara tion  of m ononuclear cells from  b lo o d
Samples of peripheral lymphocytes were prepared within 4 hours of 
phlebotomy by first diluting the blood 1 /3  with 2% RPMI medium prior to 
gently laying this over lOmls of Lymphoprep (Nycomed). Studies of the effects 
of storage conditions on human blood suggest that samples are suitable for use
in the comet assay for up to four days after collection when stored at 4°C or at 
room temperature (Anderson et al., 1997). Samples were then centrifuged at 
2000 rpm for 20 minutes (Beckman GPR centrifuge) to achieve density gradient 
separation of lymphocytes from the plasma and the erythrocytes. The 
leukocyte layer was then gently pipetted off and washed once by placing into 
10 mis of 2% RPMI and recentrifuging at lOOOrpm for 10 minutes. The 
supernatant was then discarded and the cell pellet was resuspended in 1ml of 
10% DMSO in 2% RPMI in a cryotube. The samples were then taken to a
temperature of -70°C at a rate of 1°C/m inute and transferred to a liquid 
nitrogen storage facility as soon as possible. When required, cells were thawed
quickly in a 37°C water bath and resuspended slowly in lOmls of 2% RPMI. 
Samples were then centrifuged at 1000 rpm for 10 minutes and the ceU pellet 
was resuspended in lOmls of 2% RPMI supplemented with 3mM glutamine
and 20% FCS. The cells were cultured overnight at 37°C in a humidified 
atmosphere of 5% CO2 to allow recovery from freeze-thaw and to allow cell 
disaggregation. A cell count was performed on each sample at this stage and
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lymphocyte number was found to range from 0 .2- lx l 06 with a viability, 
assessed by trypan blue exclusion, of >95%. Cells from each sample were then 
subjected to 4Gy of ionising radiation on ice or at room temperature (or mock 
irradiation) before harvesting at timepoints of 0, 30, and 120 minutes post 
treatment, by centrifugation at 1000 rpm for 10 minutes. (The samples 
irradiated at room temperature were immediately placed on ice for 10 min 
prior to the t=0 timepoint to allow time for samples to be transferred from the 
radiation source back to the laboratory for harvesting. The remaining samples
were then allowed to incubate at 37°C in a waterbath prior to harvesting at the 
30 and 120 min timepoints). After this cell pellets were resuspended in 1 ml of
ice cold 10% DMSO in PBS and stored at -70^C prior to alkaline single cell gel 
electrophoresis (comet assay).
6.2.3 C om et assay
Lymphocyte samples from each subject and time point were analysed in 
batches including 1-2 controls and 4-5 patient samples (controls and patient 
samples had previously been coded so as to be indistinguishable during the 
assay and subsequent analysis). After rapid thawing, the 1ml stored samples 
were added to 1ml of PBS and then this mixture was added to 2ml of molten 
2% low melting point agarose. The resulting cell suspension was then quickly 
layered onto a poly-L-lysine slide (BDH) which had been previously coated 
with 0.3% agarose (the agarose coated slides were edged w ith an 
immunohistochemistry pen (Dako), to help prevent the gels slipping off during 
the assay). This was performed in duplicate for every timepoint analysed.
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Samples were allowed to dry briefly and for subsequent stages slides were 
kept under foil to exclude DNA damage induced by UV light. The slides were 
then transferred into freshly prepared cell lysis buffer containing IM NaCl, 
30mM NaOH, and 0.1% N-lauroyl sarcosine for 1 hour at room temperature. 
Slides were then washed twice for 30 minutes each in buffer containing 30mM 
NaOH and 2mM EDTA prior to electrophoresis. Electrophoresis was 
performed in buffer containing 30mM NaOH and 2mM EDTA at 40mA for 25 
minutes in a horizontal tank (Pharmacia). After this, slides were transferred 
into a solution of 2pg/m l propidium iodide for 30 minutes to stain the DNA.
Slides were stored under foil at 4°C prior to image analysis of 60 cells per 
timepoint (ie 30 cells/slide in duplicate), which was performed with a 
fluorescence microscope (Zeiss Axioskop), using Komet 3.1 software (Kinetic 
Imaging, UK).
6.2.4 Io n is in g  rad ia tio n
Cells were irradiated in suspension in 15 ml centrifuge tubes (Falcon) 
using a Gammacell 1000 y-irradiator (Atomic Energy Corporation,
Canada) at a dose rate of 3 Gy/minute.
6.3 Results
6.3.1 P a tien t an d  contro l p o p u la tio n s
Clinical information on the patients and controls entered into this study is 
given in Tables 6.1 and 6.2. All patients and controls studied were female. The
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Category Patients (n=33) Controls (n=25)
Sex Female Female
Age range 37-83 years -22-55
Median age 55 years -28
History of 11/30, None
Smoking:
Current 8/30, None
smokers: tN R
Family History 5/30 None
of breast cancer 3NR
Tumour type IDC (Gl) 10* 
(G2) 7 
(G3) 16 
Colloid Ca 1 
ILC 1(a) 
Tubulo-lobular 1(b)
Tumour size: Range 0.8-5cm, -
Range and Median size 1.8cm
M edian size
(cm)
Nodal 12/29 cases -
involvement 4N R
Table 6.1
Summary of the clinical information on patients and controls entered into 
the comet assay study.
* One was a Colloid carcinoma
(a) Patient 10 had two primary tumours,
(b) Patient 19 had two primary tumours, see Table 6.2 
NR: not recorded in the clinical notes.
Table 6.2
Clinical information on the breast cancer patients in the current study
(AR) Adverse reaction, N (none), Y (yes), G (tumour grade), DOS (ductal carcinoma 
in situ), ADH (atypical ductal hyperplasia), CMF (Cyclophosphamide, 
methotrexate, 5-fluorouracil), CAP ( Cyclophosphamide, doxorubicin, 5- 
fluorouracil), ATAC trial (Tamoxifen or Arimidex (Anastrazole) alone), MEGACE 
Megesterol acetate, Ov Ca (ovarian carcinoma).
(a) Local oedema.
(b) The patient's mother also had a history of ovarian carcinoma.
(c) Reddening of the skin.
(d) Soreness of the nipple.
(e) Reddening of the skin.
(f) Soreness of the nipple
(g) Mother and father both had gastric cancer.
(h) Peeling of the axillary skin.
(i) Mother had breast cancer. Father died of gastric cancer.
(j) Reddening of the skin.
(k) Soreness of the skin with ulceration.
(l)’Skm reaction’.
No. Age Pathology Family
History
Smoker Therapy (AR)
1 58 2cm, G2 Ductal, 
OCXS, 1 /8  
nodes +ve
Mother 
(age 70) 
and 2 
aunts
N Radiotherapy
Tamoxifen
N
2 67 1.8cm, G2 
Ductal,
DCIS, 0 /7  
nodes, vascular 
invasion seen
N 20 yr 
ago
Radiotherapy
ATAC
N
3 45 1.1cm, GI 
Ductal, 
0 /6  nodes
N 1/day Radiotherapy
Tamoxifen
N
4 41 1.6cm, G3 
Ductal, 
DCIS, 0/12  
nodes
N 15/day Radiotherapy N
5 69 5cm, G3 Ductal, 
DCIS, 13/13 
nodes +ve
Sister 
(age 50)
1 year 
ago
Radiotherapy
Tamoxifen
CMF
N
6 47 2.5cm, G3 
Ductal, 
0 /8  nodes
N N Radiotherapy Y (a)
7 50 4.2cm, G2 
Ductal + 
lobular, 2/15  
nodes +ve
Mother 
(age 77) 
(b)
Aunt 
(age 80)
N Radiotherapy
Tamoxifen
CMF
N
8 52 3.4cm, G3 
Ductal,
DCIS, 0 /1  
nodes, vascular 
invasion seen
N N Radiotherapy
Tamoxifen
CAF
N
Table 6.2
Continued overleaf.
No. Age Pathology. Family
History
Smoker Therapy (AR)
9 55 1.2cm, G2 
Ductal, DCIS, 
0 /9  nodes
N ' N Radiotherapy
ATAC
N
10 62 1)1.7cm, Gl 
Ductal, DCIS
2) 1.3cm, 
Lobular Ca, 
LCIS,0/14 
nodes
N N Radiotherapy
Tamoxifen
N
11 35 3.6cm, G3 
Ductal, 
DCIS, 5/16  
nodes +ve
N 8/day Radiotherapy
Chemo­
therapy
N
12 75 4.4cm, G3 
Ductal, 0 /7  
nodes
Breast Ca 1978 
other side
N N 1978 Surgery+
Radiotherapy
1998
Radiotherapy
ATAC
Y(c)
13 49 1.2cm, G3 
Ductal, 0/14  
nodes
N 8/day Radiotherapy Y(d)
14 73 1cm, Gl Ductal, 
DCIS, 0/14  
nodes
Aunt 
(age 80)
N Radiotherapy Y(e)
15 39 1.5cm, G3 
Ductal 1998,
2 /2  nodes +ve. 
Previous 
lobular Ca, 1989
N 20/day 1989: Radio­
therapy + 
CMF 
1998:
Tamoxifen
N
Table 6.2
....Continued overleaf.
No. Age Pathology Family
History
Smoker Therapy (AR)
16 58 2.1cm, G3 
Ductal, DCIS, 
0 /6  nodes
N
OvCa
1985
N Radiotherapy
Tamoxifen
N
17 70 1.5cm, G2 
Ductal, 0 /6  
nodes
N 20
years
ago
Radiotherapy
MEGACE
Y(f)
18 59 2cm, G3 Ductal, 
DCIS, 0/12  
nodes
N (g) N Radiotherapy
ATAC
N
19 43. 1996: 2.6cm, G2 
Ductal, DCIS, 
1 /7  nodes +ve, 
0.7cm tubulo- 
lobular Ca, 
1997: 4.5cm G2 
Ductal + 
lymphatic inv.
N 10
years 
ago. 
Now 1 
/month
Radiotherapy
Tamoxifen
CMF
Y(h)
20 51 1.1cm, Gl 
Ductal, DCIS, 
2 /8  nodes +ve
No No Radiotherapy
CMF
Tamoxifen
N
21 61 0.8cm, Gl 
Ductal, 
DCIS, 0 /1  
nodes
N N ATAC N
22* 60 1.5cm, G3 
Ductal, 4 /5  
nodes +ve, 
previous Ca
N N Radiotherapy
Tamoxifen
CAF
N
23 67 0.8cm, Colloid 
Ca,
DCIS, ADH
N 15/day Radiotherapy
Tamoxifen
N
24 83 1.2cm, Gl 
Ductal, 3/21  
nodes +ve
N N Arimidex N
Table 6.2
....Continued, (* excluded from statistical analysis as t=0 damage at 0 Gy > 4 Gy).
No. Age Pathology Family
History
Smoker Therapy (AR)
25 57 2.2cm, G3 
Ductal, DCIS, 
0 /7  nodes
N N Tamoxifen N
26 47 1.8cm, G3 
Ductal, DCIS, + 
Previous 
tumour
Mother
(i)
Y Radiotherapy
Tamoxifen
Y(j)
27 48 1cm, Gl Ductal, 
DCIS
N N Radiotherapy
Tamoxifen
N
28 47 2.1cm, Gl 
Ductal, DCIS, 
0 /8  nodes
N N Radiotherapy
Tamoxifen
Y(k)
29 70 2.8cm, G3 
Ductal, DCIS, 
2 /9  nodes +ve
N ? Radiotherapy
ATAC
Y(l)
30 49 1992: Previous 
tumour. 1998: 
2.4cm, G3 
Ductal, DCIS, 
lymphatic 
invasion.
N N 1992:
Radiotherapy
1998:
Recurrence:
CMF
N
31* 50 1.9cm, G3 
Ductal, DCIS, 
0 /7  nodes
N ? Radiotherapy
Tamoxifen
N
32 48 4cm, G2 Ductal, 
DCIS, 2 /4  . 
nodes +ve
N N Radiotherapy
Tamoxifen
CMF
N
33 82 Gl Mucinous 
Carcinoma, 
Vascular 
invasion
N N Tamoxifen N
Table 6.2
(* excluded from statistical analysis as t=0 damage at 0 Gy > 4 Gy).
median age of the patients was noted to be older than the controls (55 versus 
28 years). Although occupational information is not provided the patients 
came from a variety of backgrounds whereas all the controls studied worked at 
the Institute of Molecular Medicine, Oxford and twenty of these worked in a 
laboratory environment. None of the controls had a personal history of 
smoking nor of breast cancer in a first degree relative as they were selected as 
controls on this basis. Eleven of the thirty one patients in which the 
information was recorded had a history of smoking and eight of these 
continued to smoke. Four gave a history of breast cancer in a first degree 
relative (mother or sister). In addition the mother of patient 7 also had a history 
of ovarian carcinoma and patient 14 had an aunt with breast cancer. Other 
tumours mentioned in the clinical notes in first degree relatives include fatal 
gastric cancer in the father of patient 26 (whose mother had breast cancer) and 
a history of gastric carcinoma in both parents of patient 18. Four patients had 
previous history of breast cancer or recurrent tumour and two patients had 
two separate tumours diagnosed at the time of presentation. The median age 
for primary presentation was 55 years with a range of 35-83 years and the 
median tumour size was 1.8cm. Most patients had Grade 3 invasive ductal 
carcinoma (IDC) of the breast, followed in frequency by Grade 1 and Grade 2 
tumours. One had a variant of IDC (Colloid carcinoma). One patient had 
invasive lobular carcinoma of the breast (ILC) and another has a variant of this 
tumour called Tubulo-lobular carcinoma (Millis et al., 1994). Of the patients 
who underwent axillary nodal dissection (29/33) by the time of completion of 
this study, twelve were found to have positive lymph nodes.
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6.3.2 4 G y of io n is in g  irrad ia tio n  dam ages lym phocy te D N A  and  
le a d s  to  co m e t fo rm a tio n  a f te r  a lk a l in e  s in g le  ce ll g e l 
e lectrophoresis.
DNA from unirradiated, undamaged single cells which were subjected to the 
comet assay and stained with propidium  iodide formed bright, round 
'nucleoids' with a symmetrical narrow halo lacking a tail (Fig. 6.1).
In contrast some cells irradiated with 4 Gy ionising radiation (IR) sustained 
considerable levels of DNA damage and were termed highly damaged comets 
(HDCs). The nucleoid of such comets was small and faint and appeared 
detached from the tail of the comet which was broad, long and very faintly 
staining (Fig. 6.2). Cells with intermediate levels of damage were seen most 
often after 4 Gy IR. The comet nucleoids were bright but smaller than those of 
undam aged cells and the presence of a broad moderately bright tail gave each 
comet a 'fried egg' shape (Fig. 6.3 and 6.4). In some individuals HDCs and 
more moderately damaged comets were observed after 4 Gy of IR, resulting in 
a dual population with respect to the amount of damage detected (Fig. 6.5).
6.3.3 In d iv id u a l control and  p a tien t com et assay resu lts
The results of the comet assay are displayed for each control and patient, in the 
form of 1): simple line graphs of tail moment versus time for irradiated and 
unirradiated samples and 2): a tail DNA frequency histogram for the different 
timepoints of irradiated and unirradiated samples. The tail DNA is presented 
in 'bins' of <0%, 1-10%, 11-20%, 21-30%, 31-40%, 41-50% and >50% to show the
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Fig. 6.1
An undamaged comet from patient 25. In this case 99% of the DNA 
is present in the large round comet head, (t= 0 min, 0 Gy).
Fig. 6.2
A  h ig h ly  d a m a g e d  c o m e t is sh o w n  w ith  tail D N A  75%. T he m ajority  
o f the D N A  is p resen t in  the broad  tail w h ich  is s l ig h tly  d e ta c h e d  from  
the u n d a m a g e d  D N A  in the h ea d  w h ic h  is rep resen ted  b y  the sm a ll  
n u c leo id .
Fig. 6.3
Com et with 14 % tail D N A  from patient 25, (t=0 min, 4 Gy).
Fig. 6.4
C om et with 20 % tail D N A  from patient 25, (t=0 min, 4 Gy).
Fig. 6.5
Two populations of comets from patient 26, which vary in the amount of tail DNA, (t=0 min, 4 Gy)
profile of DNA damage in the lymphocyte population at each timepoint, ( see 
Appendix 1, presented at the end of Chapter 6).
6.3.4 A ssessm en t of the  nu m b ers of m odera te  to h ig h ly  dam aged  
com ets
Some of the samples tested showed initial diminution of DNA damage, at t=30 
min post IR followed by a marked increase in DNA damage at the later t=120 
min timepoint (See Appendix 1 controls 8,11, and 16 and patients 3 ,4 ,6 ,11 , 24, 
30 and 33). Fragmented DNA in apoptotic cells can be detected in the comet 
assay and contributes to the apparent DNA damage. Therefore in order to 
discover if cell death was a potential cause of the increase in DNA damage, the 
number of comets with tail DNA over 40% were also counted for each sample, 
treatm ent and tim epoint as an indication of the num ber of apoptotic cells 
present (Table 6.3). Samples in which >10% of the cells (ie >6 comets) showed 
DNA damage over 40% included two of the controls (controls 7 and 8) and 
nine of the patients (patients 3, 4, 6,16, 21, 23, 30, 31 and 32). Some comets with 
tail DNA exceeding 40% were seen in other patients eg patient 26, alongside 
the more usual DNA damage levels seen after 4 Gy of IR (Fig. 6.5).
6.3.5 E xam ination  of levels of in itia l D N A  dam age su sta in ed
Some of the cases tested in the comet assay showed very low initial damage 
levels at 4 Gy compared with the 0 Gy level (eg control 5 and patient 22, see 
Appendix 1). Because the samples were treated (IR or mock IR) at room 
tem perature, DNA repair enzymes would have been functional and some
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No. Controls (0 Gy), Controls (4 Gy), Patients (0 Gy), Patients (4 Gy),
t=0 30 120 t=0 30 120 t=0 30 120 t=0 30 120
1 0 0 0 2 2 0 2 1 1 1 1 -
2 3 1 0 3 4 3 3 1 0 3 4 3
3 0 0 1 2 0 0 0 1 1 5 6 13
4 0 0 2 1 1 3 1 8 9 6 4 22
5 1 0 0 0 2 3 0 0 5 0 3 -
6 0 0 1 1 1 1 6 2 14 17 9 23
7 7 4 3 6 7 8 0 2 0 1 0 0
8 6 6 4 2 1 10 2 3 3 2 3 2
9 4 1 1 3 2 3 2 2 0 1 2 1
10 2 3 1 2 1 1 5 1 2 2 0 4
11 1 4 3 3 1 2 2 3 1 4 2 6
12 3 0 1 1 3 1 0 2 0 1 0 1
13 0 0 2 1 0 0 0 1 0 0 1 1
14 0 2 0 1 1 0 3 0 1 3 1 0
15 0 0 0 1 0 1 0 0 0 0 0 1
16 0 0 0 0 0 1 1 5 3 13 14 9
17 1 0 0 1 0 0 3 2 0 1 1 0
18 2 3 4 4 5 3 3 3 2 2 3 3
19 1 0 1 1 0 0 2 1 4 1 1 2
20 1 4 4 1 0 3 1 2 4 2 2 2
21 0 0 0 0 2 0 3 7 3 6 3 5
22 0 0 0 0 0 0 2 1 1 0 0 0
23 0 0 0 0 0 0 3 0 0 7 0 0
24 0 0 0 0 0 0 0 0 0 0 0 1
25 0 0 0 0 0 0 1 0 1 1 0 0
26 3 1 4 1 5 6
27 2 0 2 3 2 3
28 2 2 0 3 0 0
29 2 0 4 2 2 2
30 15 9 8 11 7 11
31 11 5 3 2 4 9
32 3 0 9 2 0 0
33 0 0 0 1 0 0
Table 6.3
Number of comets with tail DNA > 40% in control and patient samples at timepoints 
t=0, 30 and 120 min after 0 or 4 Gy IR.
DNA damage could be repaired by the cells during the 1.3 min it took to 
deliver the full 4 Gy dose. Therefore a possible explanation for this 
phenomenon was that very fast DNA repair occured in these samples in the 1.3 
minutes prior to the t=0 timepoint. To investigate this possibility, a study of the
remaining cases was conducted with an additional sample kept at 4^0  (to 
inhibit DNA repair enzymes), just prior to and during  irradiation. An
unirradiated control at 40C was also included. Results for control and patient 
cases with these additional samples are presented in Table 6.4. As expected in a 
proportion of cases of both the controls and the patients the initial damage was
increased at 40C (after both IR and mock IR), at t=0. However, the unexpected 
finding was that in some the initial damage was less than the level measured at
t=0 for the equivalent samples treated at room tem perature (2 5 ^ 0  eg control 
14 and patient 9.
6.3.6 C om parison  of con tro l an d  p a tien t D N A  re p a ir  capac ity  at 
30 an d  120 m in  p o st 4 G y of ion is ing  rad ia tion
The combined results for controls and patients are presented in Table 6.5 and 
graphically as a scatter plot of % DNA repair for each irradiated group studied 
(ie controls and patients after exposure to 4 Gy of IR at 30 and 120 min at room 
temperature; Fig. 6.6). The corrected DNA damage at each timepoint was taken 
as the damage at 4 Gy minus the damage at 0 Gy. Values for repair at t=30 min 
and t=120 min, were calculated as the percentage diminution of DNA damage 
from 100% at t=0. Patients 22 and 31 were excluded from the analysis because 
the damage at t=0 was greater in the mock irradiated than in the irradiated
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No. I % DNA Repair 
Control (t=30)
87.3
115.3 
90.6 
72.1 
- 10.6
7
77.7
-94
19.5
% DNA Repair 1 % DNA Repair % DNA Repair
Control (t=120) Patient (t=3Q) ^atient (t=120)
99 -1635 gels slipped off
65.1 78 79.5
93.1 20.8 -21.6
88.3 124.3 25.5
-33.6 44.5 gels slipped off
103.3 59.4 76.5
-124.3 82.5 107.4
-53.7 91 108.9
28.9 98.8 72.1
90.9 51.2 -47.4
85.7 49.3 24.4
78.9 138.4 70.2
116.1 65.7 75.5
98.5 66.9 98.4
79.6 35.9 58.3
31.1 60.6 70
69.4 98.6 69
125 74.9 76.2
114 49.7 129.1
95.9 66.8 835
113.3 104.7 79.8
117.8 *
*
94.02 96.5 104.8
82.9 91.9 33
96.8 76.9 106.6
-58.1 64.1
68.3 66.8
81.9 101.1
55.5 94.8
22.4 -64.1
*
109.3 114.1
110___________ 89.3___________
9 25.8
10 112.5
11 103
12 49.1
13 98.6
14 113.4
15 54.6
16 99.4
17 72
18 46.4
19 97.9
20 129.3
21 63.7
22 93.2
23 105.9
24 81.4
25 I 79.3
26
27
28
29
30
31
32
i l
Table 6.5
Percentage repair of DNA m penpheral blood lymphocytes of controls and breast 
cancer patients after 4 Gy of IR, (* excluded from statistical analysis as damage at t=0
OGy > 4 Gy).
n=31n=25150 n=29
cc
100 81.4 90.9
76.268.3oCu
nsQ.
<zÛ -50
- 1 0 0 -
- 1 5 0 -
-200
C30 P30 C120 PI 20
Fig. 6.6
Percentage DNA repair in peripheral blood lymphocytes of a group of controls 
(C30 and C120) and breast cancer patients (P30 and P120) at 30 and 120 min after 
4 Gy of ionising radiation. (Numbers in bold indicate median % values for repair).
sample. In patient 22 this was not due to increased num bers of highly 
damaged cells (Table 6.3) but the possibility of fast repair was not excluded as 
the cause. In patient 31, there was a predominance of highly damaged comets 
in the mock irradiated sample at t=0 for unknown reasons and the results
obtained at 4^0 suggest that this patient was performing very fast repair. As 
can be seen there was considerable inter-individual variability in the amount of 
DNA repair within each group tested (ie DNA repair at: 30 min in controls, 120 
min in controls, 30 min in patients and 120 min in patients). Within each group 
examples of very high repair and very low repair could be found at both 
timepoints. Overall however, the median values for repair were higher at both 
timepoints in the control compared with the patient samples (81.4% versus 
68.3% at t=30 min) and (90.9 versus 76.2% at t=120 min) respectively however, 
this observed difference was not statistically significant using the Mann- 
Whitney U-test (with the assistance of Mike Bradburn, ICRF, Medical Statistics 
Group, Oxford). The results of this are presented in Table 6.6.
6.3.7 D N A  rep air  cap acity  an d  r a d io se n s it iv ity  in  b reast cancer  
p a tien ts  treated  w ith  radiotherapy.
Nine of nineteen patients who were treated with radiotherapy for breast cancer 
suffered an adverse reaction sufficient to be recorded in their clinical notes. 
These were patients 6,12,13,14,17,19, 26, 28 and 29 (see Table 6.2 for details). 
These reactions ranged in severity from sore or reddened skin, through to skin 
ulceration. Six of the nine had % DNA repair values at 30 min which were 
below the m edians for both the control and the patient groups. At 120 min.
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only three had % DNA repair values which were below the medians for both 
the control and the patient groups. Of the nine, only one (patient 6), showed 
>10% of the damaged cells with DNA damage >40% (possibly representing 
apoptotic cells).
6.4  D is c u s s io n
In studies of potential risk factors for common malignancies including 
breast cancer, the choice of controls is hampered by the fact that despite using 
individuals without a personal or family history of the tum our it is impossible 
to avoid the potential presence in the control population of individuals who 
will subsequently develop the disease. In a control population of 25 women (as 
used in this study), it is estimated that two to three will become breast cancer 
patients at some stage in their lives. This inevitably reduces the differences 
measured between these two groups from the levels which might have been 
observed if the comparison group behaved as true controls and all remained 
disease free.
In setting the criteria for 'normal' controls for this study other factors 
w hich m ight adversely affect the comet assay itself (eg the sm oking of 
cigarettes (Piperakis et al., 1998)), also had to be considered and excluded, 
especially as this is a minor risk factor for the development of breast cancer 
(Goss and Sierra, 1998). A review of the literature reveals a variety of 
additional conditions and environmental agents which affect levels of DNA 
damage and which can be detected in the comet assay. These include older age 
(Piperakis et al., 1998), diet (including foods rich in genotoxins or antioxidants
eg P-carotene (Collins et al., 1997), (Collins et al., 1997), (Sheng et al., 1998),
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ascorbic acid and vitam in E (Taj and Nagarajan, 1994) ), drugs (including 
Tamoxifen used to treat oestrogen-receptor positive breast cancer (Taj and 
Nagarajan, 1994)) and occupational exposure to genotoxins (Collins et al., 
1997), which would be very difficult to control for. In criticism of the study 
design, the volunteer controls were younger than the patient group studied, no 
effort was made in this study to control for diet and drug exposure and the 
nature of the laboratory work environment might have subjected most of the 
controls to a risk of genotoxin exposure above that for the general population.
Thirty three breast cancer patients and 25 female controls were entered 
into the study. This num ber is slightly larger than that seen in the previous 
investigation of breast cancer and DNA repair using the comet assay 
(Jaloszynski et al., 1997). The latter study included volunteer healthy female 
controls and 26 wom en w ith breast cancer (the control group was younger 
than the patient group in this study also). The breast tum our type and grade 
were not docum ented in Jaloszynski's study and so cannot be commented 
upon  bu t the group of patients in the current study are not perfectly 
representative of breast cancer patients in general, in that although the 
commonest tum our is invasive ductal carcinoma as expected, grade three 
tum ours rather than grade 2 tumours predominate. This may be the result of 
chance due to the relatively small number of patients studied.
D uring the current study, several observations were m ade which 
required explanation and therefore further investigation. Firstly, in some cases 
after initial damage and repair, evidence of increased DNA damage was seen 
at the 120 min timepoint. There are a number of possible explanations of this 
phenomenon. The num ber of apoptotic cells might be increasing and making
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the DNA repair appear to decrease. Alternatively, excision repair pathw ays 
might be creating single strand breaks which were then slowly or inadequately 
processed and revealed in the assay (Collins et al., 1997). It is already 
established that apoptotic cells which digest their DNA into small fragments 
(-180 bp), can be detected and quantified in the comet assay (Olive et al., 1993) 
and appear as highly damaged comets (HDCs), (Singh, 1996). In necrotic cells, 
the cell membrane integrity is lost before degradation of the DNA occurs and 
therefore no increase in tail moment (and by implication tail DNA) is seen with 
this m ode of death (Olive et al., 1993). For this reason cells which have 
undergone necrotic death prior to conduction of the assay are not detected. 
Because the comet assay is such a sensitive indicator of DNA fragmentation, 
cells in the first stages of apoptosis were detectable earlier by the comet assay 
than by flow cytometry and were visualised using the former method between 
two and twenty four hours after irradiation of peripheral blood lymphocytes. 
Analysis of lymphocytes from a small number of subjects by FACS prior to the 
current study only revealed a sub-Gl population (representing apoptotic cells) 
six hours after 4 Gy of IR (data not shown). The later stages of apoptosis, when 
the DNA is highly fragmented, are much more difficult to detect because of the 
extreme faintness of the comets (Olive et al., 1993) (Fig. 6.2). The effect of 
apoptosis on the comet assay may be problematic in genotoxicity testing, as 
dead or dying cells may give false positive responses due to cytotoxicity 
(H enderson et al., 1998). To determ ine the extent to which excessively 
dam aged apoptotic cells w ere contributing to the increase in DNA 
dam age/reduction  in DNA repair seen, comets with tail DNA >40% were 
counted for each timepoint. The choice of the 40% tail DNA cut off value was
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based on the observation that in the cases analysed the % tail DNA seen after 4 
Gy IR at time=0 was usually less than 20%. In addition, although HDCs with 
tail DNA of -90% or tail moments of -30 are said to be apoptotic (Olive et al., 
1993), non-apoptotic cells had tail moments of <2 or <20% (Schwartz et al., 
1995). Given that early apoptotic cells may be detected, and the fact that it was 
important not to underestimate the number of apoptotic cells, the value of 40% 
tail DNA appeared reasonable to use for this purpose and these cells were 
described as moderate to highly damaged comets (M/HDCs). Whilst nine of 
thirty three of patients showed a timepoint where >10% of their tail DNAs 
were >40%, only two of the twenty five controls did, suggesting that the 
patients were more susceptible to this sort of DNA damage. It is interesting to 
note that in a few of the cases (control 11, patient 6 and patient 33), the 
increasing damage at the later timepoints is seen for both the irradiated and 
unirradiated samples. This may indicate a greater degree of susceptibility to 
apoptosis possibly caused by other experimental conditions superimposed on 
the radiation damage.
In five cases ( control 8 and patients 3, 4, 6 and 30) the increasing DNA 
dam age after initial repair was associated w ith increased num bers of 
M /HD Cs. In the five other cases showing increasing damage (control 11 and 
16 and patients 11, 24, and 33), M /HDCs were not seen in large numbers. This 
m ight be due to the fact that the increasing damage in these cases is 
contributed to by greater numbers of comets in bins corresponding to lower 
levels of damage than those assessed here. W hether or not such cases are 
distinguished due to cells that are in extremely early apoptosis is impossible to 
say as additional morphological criteria for, and other assays of, apoptosis
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were not perform ed on these samples. In patients 16, 21, 23, 31 and 32, 
M /H D C s of >10% total cell num ber at a particular timepoint were observed 
but this was not associated with rising DNA damage levels overall. In these 
cases it is possible that the extreme damage in some cells was masked by the 
levels of repair found in these samples (Table 6.5). In control 7 good repair 
cannot account for this phenomenon but at every timepoint in this individual 
(IR or mock IR), comets with >50% tail DNA damage are found (also see the 
tail DNA frequency histogram  relating to this case in Appendix 1). It is 
possible that a discrete population of very highly dam aged comets might 
explain these results.
It is also important to mention that DNA strand migration can occur not 
only due to DNA damaging agents and apoptosis as invoked above but also as 
a consequence of DNA strand breakage during the excision repair processes 
themselves. The incision step of base and nucleotide excision repair has been
found to be very fast and is even active at 40C (Klaude et al., 1996). If repair is 
slow or stops at this point these strand breaks can be detected in the comet 
assay (Collins et al., 1997). Further processing can generate large stretches of 
single stranded DNA around the original lesion and the dam age m ay be 
greater if these processes are inadequate or faulty than if they were absent 
altogether. Thus the interpretation of comet assay results may not be entirely 
straightforw ard, as repair processes themselves generate transient DNA 
damage that, if incompletely processed due to interruption or aberration, can 
be detected in the assay. Whether apoptosis or a faulty type of repair is the true 
explanation of the rising DNA damage seen in the cases mentioned is not clear
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because individual pathw ays of DNA strand break repair and alternative 
assays of apoptosis were not included in this investigation.
The second cause for concern during the early phases of this study was 
the finding of cases in which the initial level (ie at t=0) of DNA dam age 
sustained after 4 Gy of irradiation appeared rather low (eg control 5 and 
patient 23), in comparison to the others studied. The absolute amount of direct 
DNA damage sustained due to the ionising radiation should be equivalent in 
all the cases, however the possibility was entertained that in these cases the 
low initial damage m ight be accounted for by more rapid repair occurring 
during the timeframe of irradiation such that the remaining damage at t=0 was 
lower than expected. To investigate this possibility additional samples (IR and 
mock IR) were treated on ice to reduce the activity of the repair enzymes. As 
described in the results higher values of initial damage were then attributed to 
some of these samples, in keeping with the hypothesis outlined above (Table 
6.4). However a similar num ber showed exactly the opposite effect w ith a 
reduction in the initial damage recorded. This effect was not expected but it 
may be explained by the relative levels of direct and indirect damage to DNA 
that occurs due to ionising irradiation. Ionising radiation (frequency >10^^ Hz) 
including diagnostic and therapeutic X-rays contains sufficient energy to break 
chemical bonds directly creating single and double strand DNA breaks and 
base damage. Deposition of energy from the radiation also results in the
formation of reactive oxygen species (ROS) eg the superoxide anion (O2"), and 
hydrogen peroxide (H2O2 ), from water in the cell. The hydroxyl radical (OH-) 
is formed from H 2 O 2 and  O2" via the Haber-Weiss reaction. This reaction is
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slow and in biological systems it is usually catalysed by transition metal ions, a
process called the Fenton reaction. Ferrous iron (Fe^+) appears to be the major 
intracellular mediator of the Fenton reaction, although the precise source and 
form of the iron is unknown. The ROS cause oxidative damage to the cellular 
m acrom olecules including lipid peroxidation, the oxidation of cysteine 
residues and amino groups in proteins and strand breaks and oxidation of 
guanosine residues in DNA. The amount of indirect oxidative damage caused 
by IR is dependent on the activity of the enzymes catalysing the above reaction 
and the cellular antioxidant reserves eg glutathione. These may vary on an 
individual to individual basis dependent on genetic and environmental factors 
including the level of antioxidants found in the diet. Therefore the levels of 
initial DNA damage may reflect the sum effect of all of the above. At room 
tem perature, a high level of initial DNA damage may be due to poor 
antioxidant status, more active oxidative systems, or slower repair processes, 
whereas low levels of initial damage may reflect high antioxidant levels, less 
active oxidative systems and faster repair processes.
If both the irradiated and the mock irradiated samples are kept on ice 
just prior to and during treatment, the level of activity of the enzymes of both 
repair and oxidative metabolism will be reduced and in theory, the initial 
damage should approximate to the level of direct DNA damage sustained. This 
maybe greater than or less than the value obtained for initial damage at room
temperature. However, subsequent incubation at 37^Q to allow the removal of 
DNA damage restores the activity of the repair enzymes and the enzymes 
generating and dealing with the reactive oxygen intermediates, complicating 
the picture once again.
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In the analysis of the levels of DNA repair the measurements obtained 
after treatm ent of the samples at room temperature, rather than those on ice 
were used (Table 6.5 , Table 6.6 and Fig. 6.6) but where available the results of 
the latter were provided graphically (Appendix 1). This decision was made on 
the basis that in vivo, the impact of direct and indirect DNA dam age is 
im portant and will influence inter-individual differences in DNA damage. 
Clearly this modification of the comet assay as a DNA repair assay cannot be 
simply interpreted, but in this study it was considered im portant to identify 
individuals in whom DNA damage was persistent after the original insult.
The overall results of the study show that in most individuals the 
greatest reduction in DNA damage post irradiation is seen in the first 30 
minutes. This compares well with the kinetics of repair documented in other 
studies (Olive et al., 1990). There was marked inter-individual variability in the 
DNA repair recorded in both the control and the patient group. This is a 
phenomenon which has been previously documented in studies of lymphocyte 
DNA damage or repair using the comet assay (Collins et al., 1997), (Jaloszynski 
et al., 1997). This fact alone would preclude the use of the assay as an indicator 
of potential breast cancer risk in individual patients. Median % values for DNA 
repair were found to be higher for the controls at both the 30 min and the 120 
min timepoints however the statistical analysis described generated p values of 
0.36 and 0.26, suggesting that the observed differences between the controls 
and the patients in repair at both timepoints was no greater than that expected 
by chance alone (Table 6.6). This is in contrast to the findings of the previous 
study into DNA repair and breast cancer which showed that breast cancer 
subjects appeared to be significantly more sensitive to exposure to the
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radiomimetic drug bleomycin those of healthy control subjects. Breast cancer 
patient lymphocytes were shown to have higher levels of DNA damage and a 
weaker DNA repair capacity which was statistically significant by the Mann- 
Whitney îi-test (Jaloszynski et al., 1997). The latter study differs in a number of 
ways from the current study in that the DNA damaging agent was Bleomycin 
rather than IR, the study was smaller, the cells were treated on ice prior to 
incubation and a visual scoring method was used to assign the comets to 5 
categories of damage rather than an image analysis package as used in the 
current study. Com puterised image analysis gives a precise result for each 
comet detected and the mean comet tail moment and other parameters can be 
statistically calculated for each sample and timepoint tested. Visual scoring 
methods have been shown to correlate well with image analysis packages in 
the past (Collins et al., 1997), but this may not be the case when low levels of 
damage are generated and slightly different populations of comets are present 
in the same sample. In some respects however, the findings of these studies are 
somewhat similar especially in the inter-individual variability and the fact that 
in m any cases, the calculated repair exceeded 100% im plying that once 
stim ulated by bleomycin or IR, the cells were capable of reparing other 
procedure related and spontaneous DNA lesions. It is possible that the 
difference in the overall results reflects the marked inter-individual variability 
in the results of the assay and that with such variation much larger patient and 
control groups may be required to satisfactorily test the hypothesis.
Additional information on the relationship between radiosensitivity 
reactions in breast cancer patients and the capacity for DNA repair was also 
provided by the current study. About 5% of patients undergoing therapeutic
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cancer radiotherapy sustain severe normal tissue dam age after standard 
radiotherapy regimens (Norman et a l, 1988), (Ribeiro et al., 1993). A test to 
identify such susceptible patients prior to treatment would be very welcome 
both to avoid the morbidity associated with adverse reactions and to produce 
dosage schedules for non-sensitive patients which can be increased to 
maximize their efficacy. Interest in the possible causes of radiosensitivity 
reactions was stimulated by the finding that A-T sufferers receiving the usual 
radiotherapy doses for cancer therapy have demonstrated severe normal tissue 
necrosis with life threatening consequences (Gotoff et al., 1967), (Cunliffe et al., 
1975), (Abadir and Hakami, 1983) and cells from both A-T homozygotes and 
A-T heterozygotes show in vitro radiosensitivity, the latter being intermediate 
in degree between normals and homozygotes (Paterson et al., 1979), (Arlett 
and Priestley, 1985). As A-T heterozygotes may have an increased cancer 
susceptibility com pared w ith normal controls, it has been suggested that 
subjects w ho have cancer and who display m arked sensitivity  post­
radiotherapy might be A-T heterozygotes (Dahlberg and Little, 1995), (Jones et 
al., 1995). If this is the case then screening for the A TM  gene could be used to 
identify highly radiosensitive patients prior to radiotherapy. To date only a 
few studies have addressed the question of the role of A T M  heterozygosity in 
adverse radiotherapy reactions in vivo. One study did not detect any mutations 
in the A T M  gene in 16 breast cancer patients and 7 patients with other cancer 
types all of whom had severe radiotherapy reactions (Appleby et al., 1997). The 
restriction endonuclease fingerprinting assay which only identifies about 70% 
of the m utations was used in this study but provided that the assum ed 
proportion of cancer patients who were A-T carriers (4%) and the likelihood
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that A T M  mutations will lead to radiation reactions after radiotherapy (100%), 
were correct, some m utations would have been expected. A part from the 
controversy regarding cancer risk in A-T heterozygotes discussed in Chapter 1, 
the issue of whether A-T carrier status leads to radiosensitivity in vivo has not 
yet been clarified. Anecdotally at least, A-T heterozygosity does not seem to be 
associated with radiosensitivity, (Swift, 1994). No large studies focussing on 
this subject are available but incidental information has come to light from 
investigations of A T M  and breast cancer. Out of 3 ATM  mutation carriers with 
breast cancer identified in two separate studies only one showed a mild skin 
reaction w ith minimal late effects following radiotherapy while the other 2 
showed no reaction (Ramsay et al., 1996), (Fitzgerald et al., 1997). It is possible 
that the wild type allele is able to obviate the radiation sensitivity or perhaps 
the specific genetic or epigenetic background found in different patients makes 
a difference. Indeed, other factors m ust be relevant in adverse radiation 
responses because the 2 patients in the latter study who did have an adverse 
reaction to radiotherapy sufficient to interrupt treatment did not have A T M  
mutations. Clearly this subject has profound clinical implications and merits 
further investigation. Although outcome of radiotherapy was not consistently 
comm ented upon in the clinical notes and the num bers of patients w ith 
unacceptable adverse reactions were low, one patient in this study was said to 
have sustained ulcerated skin due to radiotherapy (patient 28). This patient 
gave no family history of breast cancer and had DNA repair values above that 
seen for the m edian % DNA repair value for the control group at both 
tim epoints (81.9% at t=30 and 101.1% at t=120 respectively) and very few 
M /HD Cs. Eight others, two of whom had a positive family history of breast
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cancer (patients 14 and 26), suffered minimal clinically irrelevant radiotherapy 
reactions which might not always be commented upon. All showed at least one 
timepoint of repair which was below the median % repair of both the controls 
and the patients. Only one (patient 6), showed high levels of M /HDCs. ATM  
sequence and ATM protein expression was not investigated in these patients 
and therefore their A T M  status cannot be commented upon. The considerable 
inter-individual variability in patients and controls suggests that levels of 
persistent DNA damage post IR are unlikely to be useful in the prediction of 
adverse responses to radiotherapy.
Four patients (patients 1,5, 7 and 26), gave a history of breast cancer in a 
first degree relative (mother or sister). Three of these showed % median repair 
values which were below those observed for the controls at both timepoints 
but patient seven showed no obvious repair defect. A larger study of such 
cases w ould be required to determine if defective DNA repair is associated 
with a close family history of breast cancer.
To sum m arize, no significant association was found betw een DNA 
repair capacity and breast cancer in this study. Closer analysis suggests that 
the differences in DNA damage revealed by the comet assay cannot be 
accounted for solely by inter-individual differences in DNA repair. Other 
contributory factors including apoptosis may have to be taken into account.
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FUTURE D IRECTIO N S
Several lines of future work arise from the studies described. Firstly 
given the experience of others it w ould seem possible to refine the 
im m unostaining protocols employed for ATM eg by using fluorescently 
labelled secondary antibodies and visualisation with confocal microscopy to 
im prove subtle antigen detection. In addition, now that m any non­
commercial ATM antibodies are available, some of these may be used in the 
future to investigate ATM localisation in a range of normal and tum our 
tissues including breast cancers. The antibody CN-12 will be used to complete 
the study of ATM in the cell lines of the NCI panel for which there are 
currently no results.
The complete absence of ATM protein in the hum an promyelocytic 
leukaem ia cell line HL60 is of considerable interest and m erits further 
investigation. In particular sequencing of the ATM gene in this cell line will 
be undertaken to determine if it is m utated and the protein destabilised as 
predicted. Following on from this, a study of ATM expression in a variety of 
sporadic hum an lym phom as and leukaem ias including prom yelocytic 
leukaemia should now be conducted.
Given the recent success of (Canman et al., 1998) and (Banin et al., 
1998) in demonstrating the protein kinase activity of ATM against p53 Ser 15 
and PHAS-I, using Mn^+ containing buffers and effective methods of ATM 
activation it is now theoretically possible to assess the integrity of signalling 
via ATM in hum an peripheral blood lym phocytes. Considering the 
interindividual variability usually seen in this type of study, large numbers of 
individuals should be entered to obtain meaningful results. It would also be 
worthwhile investigating ATM function in markedly radiosensitive patients 
to elucidate the relationship of this phenotype with a compromised ATM 
pathway rather than ATM protein defects per se.
Appendix 1
Appendix 1
DNA damage profiles (Tail moment versus time) and comet tail DNA frequency histograms 
are presented for all individuals studied (controls and patients).
DNA damage profiles:
The black line represents the mock irradiated sample and the red line represents the samples 
treated with 4 Gy IR at room temperature. The green point and the blue points represent 
samples mock irradiated or treated with 4 Gy IR at 4°G respectively.
Comet tail DNA frequency histograms:
The coloured bars represent the following treatments,
Red bars: 0 Gy, t=0 min 
Green bars: 0 Gy, t=30 min 
Dark blue bars: 0 Gy, t=120 min
Pink bars: 4 Gy, t=J<»min 
Yellow bars: 4 Gy, t= 0 min 
Pale blue bars: 4 Gy, t=120 min
(Two 4 Gy t=120 min timepoints are missing due to gel loss during the assay).
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